<SEC-DOCUMENT>0001178913-23-002694.txt : 20230804
<SEC-HEADER>0001178913-23-002694.hdr.sgml : 20230804
<ACCEPTANCE-DATETIME>20230804160553
ACCESSION NUMBER:		0001178913-23-002694
CONFORMED SUBMISSION TYPE:	F-3
PUBLIC DOCUMENT COUNT:		9
FILED AS OF DATE:		20230804
DATE AS OF CHANGE:		20230804

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		F-3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-273709
		FILM NUMBER:		231144001

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-3
<SEQUENCE>1
<FILENAME>zk2330099.htm
<DESCRIPTION>F-3
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">As filed with the Securities and Exchange Commission on August 4, 2023<br>
        <br style="line-height: 1.25;">
      </font></div>
    <div style="text-align: right; line-height: 1.25; font-weight: bold;">&#160;Registration No. 333-</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 1pt;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <font style="font-size: 14pt;"><br>
      </font></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">WASHINGTON, D.C. 20549</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM F-3</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REGISTRATION STATEMENT</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">UNDER</div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">THE SECURITIES ACT OF 1933</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">REDHILL BIOPHARMA LTD.</div>
    <div style="text-align: center; line-height: 1.25;">(Exact name of registrant as specified in its charter)</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z5dc6e5bf39414874a7616421bcc76836" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.01%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Israel</div>
          </td>
          <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 49%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Not Applicable</div>
          </td>
        </tr>
        <tr>
          <td style="width: 49.01%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">(State or other jurisdiction of</div>
            <div style="text-align: center; line-height: 1.25;">incorporation or organization)</div>
          </td>
          <td style="width: 2%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 49%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25;">(I.R.S. Employer</div>
            <div style="text-align: center; line-height: 1.25;">Identification Number)</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <hr align="center" style="height: 1px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">21 Ha'arba'a Street</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Tel Aviv 6473921</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Israel</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">+972 (3) 541-3131</div>
    <div style="text-align: center; line-height: 1.25;">(Address and telephone number of registrant&#8217;s principal executive offices)</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <hr align="center" style="height: 1px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">RedHill Biopharma Inc.</font><br>
      <font style="font-weight: bold;">8045 Arco Corporate Drive, Suite 200</font><br>
      <font style="font-weight: bold;">Raleigh, NC&#160; 27617</font><br>
      <font style="font-family: 'Times New Roman',Times,serif;">(<font style="font-weight: bold;">984) 444-7010</font></font> <br>
    </div>
    <div style="text-align: center; line-height: 1.25;">(Name, address, and telephone number of agent for service)</div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <hr align="center" style="height: 1px; width: 20%; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-style: italic; font-weight: bold;">Copies of all communications, including communications sent to agent for service, should be sent to:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z8508847620a54e079d955a91e67deb68" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 49.69%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Rick A. Werner, Esq.</div>
            <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Jayun Koo, Esq.</div>
            <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Haynes and Boone, LLP</div>
            <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">30 Rockefeller Plaza, 26<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor<br>
              New York, New York 10112<br>
              Tel. (212) 659-7300</div>
            <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Fax (212) 884-8234</div>
          </td>
          <td style="width: 50.31%; vertical-align: top;">
            <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Perry Wildes, Adv.</div>
            <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Goldfarb Gross Seligman &amp; Co.</div>
            <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">One Azrieli Center</div>
            <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Tel Aviv 6702100, Israel</div>
            <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">+972 (3) 607-4444</div>
          </td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><font style="font-weight: bold;">Approximate date of commencement of proposed sale to the public</font><font style="font-family: 'Times New Roman',Times,serif;">: From time to time
        after the effective date of this Registration Statement.</font></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. &#9744;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following
      box. &#9746;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act
      registration statement number of the earlier effective registration statement for the same offering. &#9744;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number
      of the earlier effective registration statement for the same offering. &#9744;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission
      pursuant to Rule 462(e) under the Securities Act, check the following box. &#9744;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of
      securities pursuant to Rule 413(b) under the Securities Act, check the following box. &#9744;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"> Emerging growth company &#9744;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended
      transition period for complying with any new or revised financial accounting standards&#8224; provided pursuant to Section 7(a)(2)(B) of the Securities Act.&#160; &#9744;</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a
        further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this Registration Statement shall become effective on such date as
        the Commission, acting pursuant to said Section 8(a), may determine.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;</font></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #FF0000; font-weight: bold;">The information in this prospectus is not complete and may be changed. The selling shareholders named in this prospectus may not sell these securities until the
      Registration Statement filed with the Securities and Exchange Commission, of which this prospectus is a part, is effective. This prospectus is not an offer to sell these securities and the selling shareholders named in this prospectus are not
      soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; color: #FF0000; font-weight: bold;">SUBJECT TO COMPLETION, DATED AUGUST 4, 2023</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROSPECTUS</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;<font style="font-weight: bold;">1,998,221 American Depositary Shares representing 799,288,400 Ordinary Shares</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><img width="160" height="91" src="image00003.jpg"></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold; color: rgb(0, 0, 0);">REDHILL BIOPHARMA LTD.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;</font></div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">This prospectus relates to the resale by the selling shareholders named in this prospectus from time to time of up to an aggregate of <font style="color: rgb(0, 0, 0);">1,998,221 </font>American
      Depositary Shares (&#8220;<font style="color: rgb(0, 0, 0);">Offered ADSs&#8221;), with each American Depositary Share (&#8220;ADS&#8221;) </font>representing 400 of our ordinary shares, par value NIS 0.01 per share (&#8220;Ordinary Shares&#8221;), or&#160;<font style="color: rgb(0, 0, 0);">799,288,400 Ordinary Shares in the aggregate, issued or issuable upon the exercise of warrants (the &#8220;Warrants&#8221;),&#160;that were issued pursuant to (i) a securities purchase agreement, dated as of May 9, 2022, between us and the purchaser named on
        the signature page therein(ii) a warrant reprice and reload agreement, dated as of July 21, 2023, between us and an investor in the July 2023 Offering (as defined herein), and (iii) an engagement letter dated as of July 17, 2023.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">We will not receive any of the proceeds from the sale of the <font style="color: rgb(0, 0, 0);">Offered ADSs</font> by the selling shareholders. Any ADSs subject to resale hereunder will have been
      issued by us and acquired by the selling shareholders prior to any resale of such shares pursuant to this prospectus.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The selling shareholders named in this prospectus and any of their pledgees, assignees and successors-in-interest, may offer or resell the Offered ADSs from time to time through public or private
      transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The selling shareholders will bear all commissions and discounts, if any, attributable to the sale of the Offered ADSs. We will
      bear all costs, expenses and fees in connection with the registration of the Ordinary Shares. For additional information on the methods of sale that may be used by the selling shareholders, see &#8220;Plan of Distribution&#8221; beginning on page 15 of this
      prospectus.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The ADSs are listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;RDHL&#8221;. On August 3, 2023, the last reported sale price of the ADSs was $1.07 per ADS.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Investing in our securities involves a high degree of risk. These risks are discussed in this prospectus under &#8220;Risk Factors&#8221; beginning on page 8<font style="background-color: rgb(255, 255, 0);"></font> and the &#8220;Risk Factors&#8221; in &#8220;Item 3: Key Information-Risk Factors&#8221; of our most recent Annual Report on Form 20-F, which is incorporated by reference in this prospectus, as well as in any other recently filed reports and, if
      any, in any applicable prospectus supplement.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Neither the Securities and Exchange Commission (the &#8220;SEC&#8221;) nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or
      accuracy of this prospectus. Any representation to the contrary is a criminal offense.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2023.</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%LCR%2%%%-->
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="zd9731b17bf9440798272147c6d18c20d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 88.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 11.26%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Page</div>
          </td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#PROSPECTUS">About This Prospectus</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; text-align: center;">1</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#STATEMENTS">Cautionary Statement Regarding Forward-Looking Statements</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: center;">2</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#SUMMARY">Prospectus Summary</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; text-align: center;">4</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#OFFERING">The Offering</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: center;">5</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#FACTORS">Summary of Risk Factors</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: center; background-color: rgb(204, 238, 255);">7</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#RISK">Risk Factors</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: center;">8</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#PROCEEDS">Use of Proceeds</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; text-align: center;">9</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#CAPITALIZATION">Capitalization and Indebtedness</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: center;">10</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#SHAREHOLDERS">Selling Shareholders</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; text-align: center;">11</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#DISTRIBUTION">Plan of Distribution</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: center;">15</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#EXPENSES">Expenses</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: center; background-color: rgb(204, 238, 255);">16</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#MATTERS">Legal Matters</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: center;">16</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#EXPERTS">Experts</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: center; background-color: rgb(204, 238, 255);">17</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#INFORMATION">Where You Can Find Additional Information</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: center;">17</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif; background-color: rgb(204, 238, 255);">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#INCORPORATION">Incorporation of Documents by Reference</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: center; background-color: rgb(204, 238, 255);">18</td>
        </tr>
        <tr>
          <td style="width: 88.74%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><a href="#LIABILITIES">Enforceability of Civil Liabilities</a></div>
          </td>
          <td style="width: 11.26%; vertical-align: top; font-family: 'Times New Roman',Times,serif; text-align: center;">19</td>
        </tr>

    </table>
    <div style="text-align: center; line-height: 1.25;"><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">ii</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
        <div style="font-family: 'Times New Roman',Times,serif; font-weight: 400; text-align: left;">
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;"><br>
            ABOUT THIS PROSPECTUS<a name="PROSPECTUS"><!--Anchor--></a></div>
          <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">The selling shareholders named in this prospectus may resell, from time to time, in one or more offerings, the Offered ADSs. Information about the
            selling shareholders may change over time. When the selling shareholders sell Offered ADSs representing Ordinary Shares under this prospectus, we will, if necessary and required by law, provide a prospectus supplement that will contain specific
            information about the terms of that offering. Any prospectus supplement may also add to, update, modify or replace information contained in this prospectus. If a prospectus supplement is provided and the description of the offering in the
            prospectus supplement varies from the information in this prospectus, you should rely on the information in the prospectus supplement. You should carefully read this prospectus and the accompanying prospectus supplement, if any, along with all
            of the information incorporated by reference herein, before making an investment decision.</div>
          <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">You should rely only on the information contained or incorporated by reference in this prospectus or any applicable prospectus
            supplement. We have not, and the selling shareholders have not, authorized any other person to provide you with different or additional information. If anyone provides you with different or additional information, you should not rely on it.
            This prospectus is not an offer to sell, nor are the selling shareholders seeking an offer to buy, the Offered ADSs in any jurisdiction where the offer or sale is not permitted. No offers or sales of any of the Offered ADSs are to be made in
            any jurisdiction in which such an offer or sale is not permitted. You should assume that the information contained in this prospectus or in any applicable prospectus supplement is accurate only as of the date on the front cover thereof or the
            date of the document incorporated by reference, regardless of the time of delivery of this prospectus or any applicable prospectus supplement or any sales of the Offered ADSs offered hereby or thereby.</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">You should read the entire prospectus and any prospectus supplement and any related issuer free writing prospectus, as well as the documents
            incorporated by reference into this prospectus or any prospectus supplement or any related issuer free writing prospectus, before making an investment decision. Neither the delivery of this prospectus or any prospectus supplement or any issuer
            free writing prospectus nor any sale made hereunder shall under any circumstances imply that the information contained or incorporated by reference herein or in any prospectus supplement or issuer free writing prospectus is correct as of any
            date subsequent to the date hereof or of such prospectus supplement or issuer free writing prospectus, as applicable. You should assume that the information appearing in this prospectus, any prospectus supplement or any document incorporated by
            reference is accurate only as of the date of the applicable documents, regardless of the time of delivery of this prospectus or any sale of securities. Our business, financial condition, results of operations and prospects may have changed
            since that date.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Unless the context otherwise requires, all references to &#8220;RedHill,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; and similar designations refer to RedHill
            Biopharma Ltd. and its wholly-owned subsidiary, RedHill Biopharma Inc. The term &#8220;NIS&#8221; refers to New Israeli Shekels, the lawful currency of the State of Israel, and the terms &#8220;dollar,&#8221; &#8220;US$&#8221; or &#8220;$&#8221; refer to U.S. dollars, the lawful currency of
            the United States (&#8220;U.S.&#8221;). Our functional and presentation currency is the U.S. dollar. Foreign currency transactions in currencies other than the U.S. dollar are translated in this prospectus into U.S. dollars using exchange rates in effect
            at the date of the transactions.</div>
        </div>
        <div>&#160;</div>
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%%%-->
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
        <div style="font-family: 'Times New Roman',Times,serif; font-weight: 400; text-align: left;">
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> <br>
          </div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS<a name="STATEMENTS"><!--Anchor--></a></div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">This prospectus, including the information incorporated by reference herein, may include forward-looking statements. These statements involve known
            and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking
            statements. In some cases, you can identify forward-looking statements by terms, including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would,&#8221;
            and similar expressions intended to identify forward-looking statements. Forward-looking statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. In addition,
            certain sections of this prospectus and the information incorporated by reference herein contain information obtained from independent industry and other sources that we have not independently verified. You should not put undue reliance on any
            forward-looking statements. Unless we are required to do so under U.S. federal securities laws or other applicable laws, we do not intend to update or revise any forward-looking statements.</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Our ability to predict our operating results or the effects of various events on our operating results is inherently uncertain. Therefore, we
            caution you to consider carefully the matters described under the caption &#8220;Risk Factors&#8221; on page 8<font style="background-color: rgb(255, 255, 0);"></font> of this prospectus,<font style="font-weight: bold;">&#160;</font>under the similar headings
            of our most recent Annual Report on Form 20-F incorporated by reference herein, and certain other matters discussed in this prospectus and the information incorporated by reference herein, and other publicly available sources. Such factors and
            many other factors beyond our control could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by the forward-looking
            statements.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements include, but
            are not limited to:</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">the going concern reference in our financial statements and&#160;our ability to obtain additional financing;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25; color: #000000;">our reduced revenues, business size and scope, market share and opportunities in certain markets following the sale of our rights to Movantik<font style="font-family: 'Times New Roman',Times,serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>;</font></div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">estimates of our expenses, future revenues, capital requirements and our needs for additional financing;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">our ability to obtain additional financing;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the commercialization and market acceptance of our commercial products;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our ability to generate sufficient revenues from our commercial products, including obtaining commercial insurance and government reimbursement;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">o<font style="color: rgb(0, 0, 0);">ur ability to advance our therapeutic candidates into clinical trials or to successfully complete our preclinical studies or clinical trials, and to
                      complete the development of such therapeutic candidates and obtain approval for marketing by the Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory authorities</font>;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our reliance on third parties to satisfactorily conduct key portions of our commercial operations, including manufacturing and other supply chain functions, market analysis services,
                    safety monitoring, regulatory reporting and sales data analysis and the risk that those third parties may not perform such functions satisfactorily;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our ability to maintain an appropriate sales and marketing infrastructure;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our ability to establish and maintain corporate collaborations;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">that our current commercial products or commercial products that we may commercialize or promote in the future may be withdrawn from the market by regulatory authorities and our need to
                    comply with continuing laws, regulations and guidelines to maintain clearances and approvals for those products;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our exposure to significant drug product liability claims;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the initiation and completion of any postmarketing studies or trials;</div>
                </td>
              </tr>

          </table>
          <div>&#160; </div>
        </div>
      </div>
    </div>
    <br>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>
      <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
        <div style="font-family: 'Times New Roman',Times,serif;">
          <div> <br>
          </div>
          <div> <br>
          </div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our ability to acquire products approved for marketing in the U.S. that achieve commercial success and to maintain our own marketing and commercialization capabilities;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our estimates of the markets, their size, characteristics and their potential for our commercial products and therapeutic candidates and our ability to serve those markets;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the successful commercialization of products we in-license or acquire;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our inability to enforce claims relating to a breach of a representation and warranty by a counterparty;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the hiring and continued employment of executives, sales personnel, and contractors;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our receipt and timing of regulatory clarity and approvals for our commercial products and therapeutic candidates, and the timing of other regulatory filings and approvals;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the initiation, timing, progress, and results of our research, development, manufacturing, preclinical studies, clinical trials, and other commercial efforts and therapeutic candidate
                    development, as well as the extent and number of additional studies that we may be required to conduct;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our ability to advance our therapeutic candidates into clinical trials or to successfully complete our preclinical studies or clinical trials, including developing a commercial
                    companion diagnostic for the detection of Mycobacterium avium paratuberculosis;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our reliance on third parties to conduct key portions of our clinical trials, including data management services and the risk that those third parties may not perform such functions
                    satisfactorily;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our reliance on third parties to manufacture and supply our therapeutic candidates and their respective active pharmaceutical ingredients with the requisite quality and manufacturing
                    standards in sufficient quantities and within the required timeframes and at an acceptable cost;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the research, manufacturing, clinical development, commercialization, and market acceptance of our therapeutic candidates;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the interpretation of the properties and characteristics of our commercial products or therapeutic candidates and of the results obtained in research, preclinical studies or clinical
                    trials;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the implementation of our business model, strategic plans for our business, commercial products, and therapeutic candidates;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the impact of other companies and technologies that compete with us within our industry;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the scope of protection we are able to establish and maintain for intellectual property rights covering our commercial products and therapeutic candidates, including from existing or
                    future claims of infringement, and our ability to operate our business without infringing or violating the intellectual property rights of others;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">parties from whom we license or acquire our intellectual property defaulting in their obligations toward us;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the failure by a licensor or a partner of ours to meet their respective obligations under our acquisition, in-license or other development or commercialization agreements or renegotiate
                    the obligations under such agreements, or if other events occur that are not within our control, such as bankruptcy of a licensor or a partner;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our reliance on the actions of third parties, including sublicensors and their other sublicensees, to maintain our rights under our in-licenses which are sublicenses;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the effect of a potential occurrence of patients suffering serious adverse events using investigative drugs under our Expanded Access Program;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our ability to implement network systems and controls that are effective at preventing cyber-attacks, malware intrusions, malicious viruses and ransomware threats;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#9679;</div>
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;">&#160;</font></div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our ability to resolve the disputes regarding the alleged events of default under our term loan facility, if not resolved, could harm our financial condition which could materially
                    adversely affect our financial performance;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">our ability to regain or maintain compliance with the Nasdaq&#8217;s listing standards;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the effects of the economic and business environment, including unforeseeable events and the changing market conditions caused by the COVID-19 endemic; and</div>
                </td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
              </tr>
              <tr>
                <td style="width: 2.09%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#9679;</div>
                </td>
                <td style="width: 94.06%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">the impact on our business of the political and security situation in Israel, the U.S. and other places in which we operate.</div>
                </td>
              </tr>

          </table>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">We have included important factors in the cautionary statements included in this prospectus and the documents we incorporate by reference herein,
            particularly in the &#8220;Risk Factors&#8221; sections of these documents, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the
            potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. No forward-looking statement is a guarantee of future performance.</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">You should read this prospectus and the documents that we incorporate by reference herein completely and with the understanding that our actual
            future results may be materially different from what we expect. The forward-looking statements in this prospectus and the documents we incorporate by reference herein represent our views as of the date of this prospectus. We anticipate that
            subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by
            applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus.</div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</div>
        </div>
      </div>
    </div>
    <div> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
        <div style="font-family: 'Times New Roman',Times,serif; font-weight: 400; text-align: left;">
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> <br>
          </div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">PROSPECTUS SUMMARY<a name="SUMMARY"><!--Anchor--></a></div>
          <div style="text-align: center; margin-right: 11.5pt; margin-left: 11.5pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic;">This summary highlights selected information about us and information contained in greater detail elsewhere in this prospectus,
            and in the documents incorporated by reference herein. This summary is not complete and does not contain all of the information that you should consider before investing in the Offered ADSs. You should carefully read and consider this entire
            prospectus and information incorporated by reference into this prospectus, including the financial statements and related notes and &#8220;Risk Factors&#8221; starting on page 8<font style="background-color: rgb(255, 255, 0);"></font> of this prospectus,
            before making an investment decision. If you invest in our securities, you are assuming a high degree of risk.</div>
          <div style="text-align: justify; margin-left: 9.7pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-style: italic;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Our Business&#160;</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">We are a specialty biopharmaceutical company, primarily focused on gastrointestinal (&#8220;GI&#8221;) and infectious diseases. Our primary goal is to become a
            leading specialty biopharmaceutical company.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">We are currently focused primarily on the commercialization in the U.S. of the GI-related products, Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (omeprazole, amoxicillin,
            and rifabutin) and Aemcolo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (rifamycin).</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">In addition, we continue to develop our pipeline of clinical-stage therapeutic candidates, including, among others, opaganib and RHB-107
            (upamostat), as potential treatments for COVID-19, and nuclear radiation protection development program opaganib, with newly published data from eight U.S. government-funded <font style="font-style: italic;">in vivo</font> studies. We look for
            opportunities to leverage our commercial presence and capabilities in the U.S. to support the potential future launch of our therapeutic candidates currently under development, if approved by the FDA, or any FDA-approved products that we may
            acquire the rights to in the future.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Our current pipeline consists of five therapeutic candidates, most of which are in late-stage clinical development. We generate our pipeline of
            therapeutic candidates by identifying, validating and in-licensing or acquiring products that are consistent with our product and corporate strategy and that have the potential to exhibit a favorable probability of therapeutic and commercial
            success. We have one product that we primarily developed internally which has been approved for marketing and, to date, none of our therapeutic candidates has generated meaningful revenues. We have out-licensed one of our commercial products,
            Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, and one of our clinical-stage therapeutic candidates, opaganib, for specific territories outside the U.S. and we plan to commercialize our therapeutic candidates, upon approval, if any, through licensing and other
            commercialization arrangements outside the U.S. with pharmaceutical companies on a global and territorial basis or, in the case of commercialization in the U.S., independently with our dedicated commercial operations or in potential partnership
            with other commercial-stage companies. We also evaluate, on a case-by-case basis, co-development, co-promotion, licensing, acquisitions and similar arrangements.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">July 2023 Offering</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif;">On July 21, 2023, we entered into a securities purchase agreement with an institutional investor for the purchase and sale in a
            registered direct offering of (i) 1,084,923 ADSs and (ii) pre-funded warrants to purchase up to an aggregate of 217,000 ADSs at an exercise price of $0.001 per ADS (the &#8220;July 2023 Pre-funded Warrants&#8221;). The purchase price of each ADS was $1.35,
            and the purchase price of each July 2023 Pre-funded Warrant was $1.349 (equal to the purchase price per ADS minus $0.001). The offering (the &#8220;July 2023 Offering&#8221;) closed on July 25, 2023. All of the July 2023 Pre-funded Warrants have been
            exercised in full for aggregate gross proceeds of $217.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif;">The gross proceeds to us from the July 2023 Offering, together with the proceeds of the concurrent March 2023 Warrant Exercise
            Transaction described below, were approximately $3.8 million, before deducting the placement agent&#8217;s fees and other offering expenses payable by us.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><font style="color: #000000;">As part of the compensation to the placement agent in connection with the July 2023 Offering, pursuant to an
              engagement agreement, dated as of July 17, 2023, by between us and H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;), we issued to Wainwright&#8217;s designees unregistered warrants to purchase up to 78,115 ADSs at an exercise price of $1.6875 per ADS
              and a termination date of July 21, 2028 (the &#8220;July 2023 Placement Agent Warrants&#8221;).</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;</font><font style="color: #000000;">The resale of the ADSs issuable upon exercise of the
              July 2023 Placement Agent Warrants and the Ordinary Shares underlying the ADSs is being registered in this registration statement.</font></div>
        </div>
        <div>&#160;</div>
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-weight: bold;">
      <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
        <div style="font-family: 'Times New Roman',Times,serif; font-weight: 400; text-align: left;">
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> <br>
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">March 2023 Warrant Exercise Transaction</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif;">On July 21, 2023, concurrent with the July 2023 Offering, we entered into a warrant reprice and reload letter (the &#8220;Exercise
            Agreement&#8221;) with an investor in that offering, holding Series A Warrants to purchase up to an aggregate of 1,500,000 ADSs (the &#8220;Series A Warrants&#8221;) and Series B Warrants to purchase up to an aggregate of 1,500,000 ADSs (the &#8220;Series B Warrants&#8221;)
            previously issued in the March 2023 Offering described below, pursuant to which such investor agreed to exercise its Series A Warrants in full at a reduced exercised price of $1.35 per ADS, for gross proceeds of $2,025,000, before deducting the
            placement agent&#8217;s fees and other offering expenses payable by us.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif;">In consideration for the exercise of the Series A Warrants for cash (i) the exercising holder received new unregistered warrants to
            purchase up to an aggregate of 1,500,000 ADSs at an exercise price of $1.80 per ADS, which is exercisable until April 3, 2028 (the &#8220;July 2023 Reload Warrants&#8221;) and (ii) the exercise price of the Series B Warrants to purchase up to an aggregate
            of 1,500,000 ADSs were reduced to $1.80 per ADS.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif;">The exercise of the Series A Warrants, the issuance of the July 2023 Reload Warrants and the reduction in exercise price of the
            Series B Warrants is collectively referred to as the &#8220;March 2023 Warrant Exercise Transaction.&#8221;</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><font style="color: #000000;">The July 2023 Reload Warrants described above were offered in a private placement under Section 4(a)(2) of the
              Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Regulation D promulgated thereunder and, along with the ADSs representing Ordinary Shares underlying the </font><font style="font-family: 'Times New Roman',Times,serif;">July
              2023 Reload Warrants<font style="color: rgb(0, 0, 0);">, were not registered under the Securities Act or applicable state securities laws.</font></font></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif;">As part of the March 2023 Warrant Exercise Transaction, we agreed to file this Registration Statement with the SEC within 15 days
            of the date of the Exercise Agreement to register the resale of the ADSs underlying the July 2023 Reload Warrants.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif;">In connection with the March 2023 Exercise Transaction, we issued to the placement agent&#8217;s designees, warrants to purchase up to an
            aggregate of 90,000 ADSs at an exercise price of $1.6875 per ADS which shall be exercisable until April 3, 2028 (the &#8220;Warrant Exercise Placement Agent Warrants&#8221;).</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif;">The resale of the ADSs issuable upon exercise of the July 2023 Reload Warrants and the Warrant Exercise Placement Agent Warrants
            and the Ordinary Shares underlying the ADSs is being registered in this registration statement.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Amendment of May 2022 Warrants and the December 2022 Warrants</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif;">In connection with the July 2023 Offering, we agreed with the investors in that offering to amend pursuant to a Warrant Amendment
            Agreement (the &#8220;July 2023 Warrant Amendment&#8221;), (i) the warrants to purchase up to an aggregate of 330,106 ADSs at an exercise price of $4.75 per ADS, issued on May 11, 2022, in a private placement completed concurrently with a registered direct
            offering, as subsequently amended pursuant to the March 2023 Warrant Amendment (as defined below) effective as of April 3, 2023 (the&#160; &#8220;May 2022 Warrants&#8221;), and (ii) the warrants (the &#8220;December 2022 Warrants&#8221;) to purchase up to an aggregate of
            971,817 ADSs at an exercise price of $4.6305 per ADS issued on December 6, 2022, in an underwritten offering, so that the amended warrants, in each case, had a reduced exercise price of $1.80 per ADS, effective upon closing of the July 2023
            Offering.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif; font-weight: bold;">March 2023 Offering and Related Warrant Amendment</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif;">On March 30, 2023, we entered into a securities purchase agreement with an institutional investor for the purchase and sale of (i)
            270,000 ADSs, (ii) pre-funded warrants to purchase up to an aggregate of 1,230,000 ADSs (the &#8220;March 2023 Pre-Funded Warrants&#8221;), (iii) Series A Warrants to purchase up to an aggregate of 1,500,000 ADSs, and (iv) Series B Warrants to purchase up
            to an aggregate of 1,500,000 ADSs at a combined offering price of $4.00 per ADS and accompanying Series A Warrant and Series B Warrants (or $3.999 per March 2023 Pre-funded Warrant and accompanying Series A Warrant and Series B Warrant). The
            offering (the &#8220;March 2023 Offering&#8221;) closed on April 3, 2023. The March 2023 Pre-Funded Warrants had an exercise price of $0.001 per ADS, were exercisable immediately and terminated when exercised in full. All of the March 2023 Pre-funded
            Warrants have been exercised. The Series A Warrants had an initial exercise price of $4.75 per ADS, prior to giving effect to the reduction in the exercise price of the Series A Warrant pursuant to the Exercise Agreement described above, were
            exercisable immediately and had a term of five years following issuance. The Series B Warrants had an initial exercise price of $4.00 per ADS, prior to giving effect to the reduction in the exercise price of the Series B Warrant pursuant to the
            Exercise Agreement, are exercisable immediately and have a term of nine months following issuance. The gross proceeds to us from the March 2023 Offering were approximately $6 million, before deducting the placement agent&#8217;s fees and other
            offering expenses payable by us.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; line-height: 1.25; color: #000000; font-family: 'Times New Roman', Times, serif;">In connection with the March 2023 Offering, we amended the May 2022 Warrants pursuant to a Warrant Amendment Agreement, dated March
            30 2023 (the &#8220;March 2023 Warrant Amendment&#8221;), which had an exercise price of $59.20 per ADS and a termination date of November 11, 2027, so that the amended warrants would have a reduced exercise price of $4.75 per ADS and a termination date of
            April 3, 2028, effective upon the closing of the March 2023 Offering (prior to giving effect to the July 2023 Warrant Amendment described above).</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Corporate Information</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</div>
          <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">We were incorporated as a limited liability company under the laws of the State of Israel on August 3, 2009. Our principal executive offices are
            located at 21 Ha&#8217;arba&#8217;a Street, Tel-Aviv, Israel and our telephone number is +972 (3) 541-3131. Our website address is http://www.redhillbio.com. The information on, or that can be accessed through, our website does not constitute part of this
            prospectus. Our registered agent in the U.S. is RedHill Biopharma Inc. (&#8220;Redhill U.S.&#8221;). The address of RedHill Biopharma Inc. is 8045 Arco Corporate Drive, Raleigh, NC 27617, U.S.A.</div>
        </div>
        <div>&#160;</div>
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">5</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
        <div style="font-family: 'Times New Roman',Times,serif; font-weight: 400; text-align: left;">
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> <br>
          </div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">THE OFFERING<a name="OFFERING"><!--Anchor--></a></div>
          <div style="text-align: center; margin-right: 11.5pt; margin-left: 11.5pt; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;</div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">Securities offered by the selling shareholders</div>
                </td>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">Up to <font style="color: rgb(0, 0, 0);">1,998,221 </font>ADSs&#160;representing <font style="color: rgb(0, 0, 0);">799,288,400 </font>Ordinary Shares.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">The ADSs</div>
                </td>
                <td style="width: 50%; vertical-align: top;">
                  <div style="text-align: justify; line-height: 1.25;">Each ADS represents 400 of our Ordinary Shares. The ADSs will be delivered by The Bank of New York Mellon, as depositary (the &#8220;Depositary&#8221;).</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;">&#160;</font></div>
                  <div style="text-align: justify; line-height: 1.25;">The Depositary, as depositary, or its nominee, will be the holder of the Ordinary Shares underlying the ADSs and you will have rights as provided in the Deposit Agreement, dated as of
                    December 26, 2012, among us, the Depositary and all owners and holders from time to time of ADSs issued thereunder (the &#8220;Deposit Agreement&#8221;), a form of which has been filed as Exhibit 1 to the Registration Statement on Form F-6 filed by
                    the Depositary with the SEC on December 6, 2012.</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;">&#160;</font></div>
                  <div style="text-align: justify; line-height: 1.25;">Subject to the terms of the Deposit Agreement and in compliance with the relevant requirements set out in the prospectus, you may turn in the ADSs to the Depositary for cancellation and
                    withdrawal of the Ordinary Shares underlying the ADSs. The Depositary will charge you fees for such cancellations pursuant to the Deposit Agreement.</div>
                  <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;">&#160;</font></div>
                  <div style="text-align: justify; line-height: 1.25;">You should carefully read the Deposit Agreement to better understand the terms of the ADSs.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">Selling shareholders</div>
                </td>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">All of the Offered ADSs are being offered by the selling shareholders named herein. See &#8220;Selling Shareholders&#8221; on page <font style="background-color: rgb(255, 255, 255); color: rgb(0, 0, 0);">11</font> of this prospectus for more information on the selling shareholders.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">Use of proceeds</div>
                </td>
                <td style="width: 50%; vertical-align: top;">
                  <div style="line-height: 1.25;">
                    <div style="text-align: justify; line-height: 1.25;">We will not receive any proceeds from the sale by the selling shareholders of the Offered ADSs <font style="color: rgb(0, 0, 0);">issued or issuable upon exercise of the Warrants</font>.
                      However, we may receive the proceeds from any exercise of the Warrants if the holders exercise the Warrants for cash. The May 2022 Warrants, however, are exercisable on a cashless basis under certain circumstances. <font style="color: rgb(0, 0, 0);">We intend to use the proceeds from the exercise of the Warrants for cash, if any, for working capital, acquisitions, research and development and general corporate purposes. </font>See the section of
                      this prospectus titled &#8220;Use of Proceeds.&#8221;</div>
                    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;">&#160;</font></div>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">Plan of Distribution</div>
                </td>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">The selling shareholders, and any of their pledgees, and successors-in-interest, may offer or sell the Offered ADSs from time to time through public or private transactions at
                    prevailing market prices, at prices related to prevailing market prices or at privately negotiated prices. The selling shareholders may also resell the Offered ADSs to or through underwriters, broker-dealers or agents, who may receive
                    compensation in the form of discounts, concessions or commissions. See &#8220;Plan of Distribution&#8221; beginning on page 15 of this prospectus for additional information on the methods of sale that may be used by the selling shareholders.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">Risk factors</div>
                </td>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">See &#8220;Risk Factors&#8221; beginning on page <font style="background-color: rgb(255, 255, 255);">8</font> and the other information included elsewhere in this prospectus for a discussion of
                    factors you should carefully consider before deciding to invest in the ADSs.</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="line-height: 1.25;">NASDAQ trading symbol for ADSs</div>
                </td>
                <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
                  <div style="text-align: justify; line-height: 1.25;">The ADSs are listed on Nasdaq under the symbol &#8220;RDHL.&#8221;</div>
                </td>
              </tr>

          </table>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#160;&#160; </div>
        </div>
      </div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;SUMMARY OF RISK FACTORS<a name="FACTORS"><!--Anchor--></a></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The following is a summary of some of the principal risks we face. The list below is not exhaustive, and investors should read the &#8220;Risk Factors&#8221; section, including the &#8220;Item 3. Key Information -
      Risk Factors&#8221; in our Annual Report on Form 20-F for the year ended December 31, 2022, in full.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="z79ced70cfd8a4a8ea92712226f16a332" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 24.4pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Our financial statements include a going concern reference. We will need to raise significant additional capital to finance our losses and negative cash flows from operations, and if we were to fail to raise sufficient capital or on
                favorable terms and/or fail to replace Movantik<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> with another commercial product on a timely basis, we may need to cease operations. Management has substantial doubt about our ability to continue as a going concern.<font style="font-weight: bold; font-style: italic;">&#160; </font></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z3b58c4ccf3ec422592f32b6985e2aeb7" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 24.4pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Following our sale of our rights to Movantik<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, our revenue, business&#8217; size and scope, market share and opportunities in certain markets, or our ability to compete in certain markets and therapeutic categories is reduced. Our
                ability to replace Movantik<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> with another commercial product, either internal or external, may not occur, and we may never achieve the levels of revenue we have achieved through Movantik<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z0a80cbc8cc79497fb16f3bb731e7b42d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 24.4pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Our failure to maintain compliance with Nasdaq&#8217;s continued listing requirements could result in the desilting of the ADSs.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="za1f0576904af48eea22292259a186aac" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 20.5pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 22.5pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Certain obligations under the Credit Agreement dated <font style="color: rgb(0, 0, 0);">February 23, 2020 and as amended on June 17, 2022 </font>and the A<font style="color: rgb(0, 0, 0);">sset Purchase Agreement dated February 2, 2023
                  that were</font> entered into with HCR Collateral Management, LLC (&#8220;HCRM&#8221;) and certain of its affiliates in connection with the sale of Movantik<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> in exchange for extinguishment of all debt obligations under the Credit Agreement
                are secured by a lien on Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and Aemcolo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>-related assets. As a result of this security interest, until extinguishment of such security interest, if we were to become insolvent the Talicia<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and Aemcolo<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
                assets would only be available to satisfy claims of our general creditors or to holders of our equity securities to the extent the value of such assets exceeded the amount of our indebtedness and other obligations. In addition, if we lose
                these assets to a foreclosure, we will lose our remaining source of revenue following the sale of Movantik<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, assuming we are not able to replace Movantik<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> with another commercial product. The existence of these
                security interests may also adversely affect our financial flexibility.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="z7eee9d47ee104127be1ec1f0493328d4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18.6pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 24.4pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>Our pursuit of treatments for SARS-CoV-2 (the virus that causes COVID-19) infection in patients entails a high level of uncertainty. We cannot assure you that either opaganib (ABC294640; Yeliva<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>) (&#8220;opaganib&#8221;) or RHB-107 will
                prove to be a safe and effective treatment for COVID-19, or will be approved for marketing or Emergency Use Authorization or be granted with Expanded Access clearance by the FDA or other regulatory authorities. In addition, we cannot assure
                that we will be able to complete the development of opaganib or RHB-107.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" id="zf300f9d67a0549d7b68f86a5e3364522" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 16pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>If we are successful in developing a COVID-19 therapeutic, we may need to devote significant resources to our manufacturing scale-up and large-scale deployment, including for use by the U.S. or other governments. If one of our COVID-19
                therapeutic candidates is approved for marketing or for Emergency Use, we may also need to devote significant resources to further expand our U.S. and non-U.S. sales and marketing activities and increase or maintain personnel to accommodate
                sales in the U.S. and outside the U.S.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zdcb342c45c7c408a80c09aa99e030423" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 16pt; font-family: 'Times New Roman',Times,serif;"><br>
            </td>
            <td style="width: 27pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
              <div>If we or our future development or commercialization partners are unable to obtain or maintain the FDA or other foreign regulatory clearance and approval for our commercial products or therapeutic candidates, we or our commercialization
                partners will be unable to commercialize our current commercial products, products we may commercialize or promote in the future or our therapeutic candidates, upon approval, if any.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">7</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;<a name="RISK"><!--Anchor--></a>RISK FACTORS</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">Investing in our securities involves a high degree of risk. In addition to the other information contained in this prospectus and in the documents we incorporate by reference
      herein, you should carefully consider the risks discussed below and under the heading &#8220;Risk Factors&#8221; in the Annual Report on Form 20-F for the year ended December 31, 2022, before making a decision about investing in our securities. The risks and
      uncertainties discussed below and in the Annual Report on Form 20-F are not the only ones facing us. Additional risks and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business. If any of these
      risks occur, our business, financial condition and operating results could be harmed, the trading price of the ADSs could decline, and you could lose part or all of your investment.</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">Please also read carefully the section above entitled &#8220;Cautionary Statement Regarding Forward-Looking Statements.&#8221;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-weight: bold;">Risks Related to the ADSs</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Our failure to maintain compliance with Nasdaq&#8217;s continued listing requirements could result in the desilting of the ADSs.</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">The ADSs are currently listed for trading on Nasdaq. We must satisfy Nasdaq&#8217;s continued listing requirements, including, among other things, a minimum Market Value of Publicly
        Held Shares (&#8220;MVPHS&#8221;) and a minimum closing bid price of $1.00 per ADS or risk delisting, which would have a material adverse effect on our business.</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">On May 9, 2023, we received a written notification from Nasdaq, indicating that we are not in compliance with the minimum MVPHS set forth in the Nasdaq Listing Rules for
        continued listing on Nasdaq. Nasdaq Listing Rule 5450(b)(3)(C) requires companies to maintain a minimum MVPHS of $15 million, and Listing Rule 5810(c)(3)(D) provides that a failure to meet the MVPHS requirement exists if the deficiency continues
        for a period of 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(D), we have a compliance period of 180 calendar days (or until November 6, 2023) to regain compliance.</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">We will seek to regain compliance with all applicable Nasdaq requirements within the allotted compliance period. If we do not regain compliance within the allotted compliance
        period, including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the ADSs will be subject to delisting.</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">Further, even if we regain compliance with the minimum MVPHS requirement, no assurance can be given that we will be able to comply with the other standards that we are required
        to meet in order to maintain a listing on such exchange, such as the minimum stockholders&#8217; equity or the minimum closing bid price requirements. In the recent past, we did not meet the minimum closing bid price requirement and only regained
        compliance with that requirement in April 2023, after completing a ratio change of the ADSs to our non-traded Ordinary Shares from the previous ratio of one ADS representing ten Ordinary Shares to a new ratio of one ADS representing 400 Ordinary
        Shares. No assurance can be given that the price of the ADSs will not again be in violation of Nasdaq&#8217;s minimum bid price rule in the future. Our failure to meet these requirements may result in our securities being delisted from Nasdaq.</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">A delisting could substantially decrease trading in the ADSs, adversely affect the market liquidity of the ADSs as a result of the loss of market efficiencies associated with
        Nasdaq and the loss of federal preemption of state securities laws, adversely affect our ability to obtain financing on acceptable terms, if at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees
        and fewer business development opportunities. Additionally, the market price of the ADSs may decline further and stockholders may lose some or all of their investment.</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">U.S. holders of ADSs may suffer adverse tax consequences if we were characterized as a passive foreign investment company.</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; color: #000000;">Based on the current composition of our gross income and assets and on reasonable assumptions and projections, we believe we should not be treated as a passive foreign investment
        company (a &#8220;PFIC&#8221;), for U.S. federal income tax purposes for 2023. However, there can be no assurance that this will be the case in 2023 or in future taxable years. If we were characterized as a PFIC, U.S. holders of the ADSs may suffer adverse tax
        consequences such as (i) having gains realized on the sale of the ADSs treated as ordinary income rather than capital gain, not qualifying for the preferential rate otherwise applicable to dividends received in respect of the ADSs by individuals
        who are U.S. holders, and (ii) having interest charges apply to certain distributions by us and upon certain sales of the ADSs.</div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
      </div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;"><font style="color: #000000;">The sale of a substantial amount of the ADSs, including resale of the Offered ADSs issuable upon the exercise of the Warrants by
        the selling shareholders, in the public market</font><font style="font-family: 'Times New Roman',Times,serif;">, or the perception that future sales may occur, <font style="color: rgb(0, 0, 0);">could adversely affect the prevailing market price
          of the ADSs.</font></font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000;">We are registering for resale 799,288,400 Ordinary Shares represented by 1,998,221 ADSs underlying the Warrants. In addition, as of July 31, 2023, we had outstanding warrants to
      purchase 2,126,358,250 Ordinary Shares (represented by 5,315,896 ADSs), outstanding options to purchase 43,702,000 Ordinary Shares (represented by 109,255 ADSs) and 233,831 outstanding Restricted Share Units (&#8220;RSUs&#8221;), each with respect to one ADS.&#160;
      Sales of substantial amounts of ADSs in the public market, or the perception that such sales might occur in the future, including sales of the Offered ADSs, ADSs issuable upon vesting of RSUs and the exercise of options, warrants or other
      equity-based securities, may cause the market price of the ADS to decline. We cannot predict if and when the selling shareholders may sell such shares in the public markets. Furthermore, in the future, we may issue additional ADSs or other equity or
      debt securities convertible into ADSs. Any such issuance could result in substantial dilution to our existing shareholders and could cause the price of the ADSs to decline.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">8</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">USE OF PROCEEDS<a name="PROCEEDS"><!--Anchor--></a> <br>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; color: #000000;">We will not receive any proceeds from the sale by the selling shareholders of the Offered ADSs issued or issuable upon exercise of the Warrants. All net proceeds from the sale of the
      Offered ADSs covered by this prospectus will go to the selling shareholders.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">We may receive proceeds from the exercise of the Warrants to the extent that these Warrants are exercised for cash<font style="color: rgb(0, 0, 0);">.</font> The May 2022 Warrants, however, are
      exercisable on a cashless basis under certain circumstances. If all of the Warrants are exercised for cash in full, the proceeds would be approximately $3.6 million.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">We intend to use the proceeds from the exercise of the Warrants for cash, if any, for working capital, acquisitions, research and development and general corporate purposes.</div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">9</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; color: #000000;">&#160;<a name="CAPITALIZATION"><!--Anchor--></a><font style="font-weight: bold;">CAPITALIZATION AND INDEBTEDNESS</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; color: #000000;">The following table sets forth our total capitalization as of March 31, 2023:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="zf496bebeea504da8934eaa024e9f9ae6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#8226;</div>
          </td>
          <td style="width: 97%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">on an actual basis; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
          <td style="width: 97%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 3%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#8226;</div>
          </td>
          <td style="width: 97%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25; color: rgb(0, 0, 0);">on a pro forma basis, after giving effect to (i) the March 2023 Offering (including the issuance of Series A Warrants and Series B Warrants), giving effect to the
              exercise in full of the March 2023 Pre-funded Warrants to purchase an aggregate of 1,230,000 ADSs for aggregate cash consideration of $1,230.00, after March 31, 2023, and after deducting placement agent fees and offering expenses paid by us
              in connection with the March 2023 Offering, and the March 2023 Warrant Amendment, effective upon closing of the March 2023 Offering, (ii) the sale of 1,084,923 ADSs and July 2023 Pre-funded Warrants in the July 2023 Offering, giving effect to
              the exercise in full of the July 2023 Pre-funded Warrants to purchase an aggregate of 217,000 ADSs for aggregate cash consideration of $217, after deducting placement agent fees and expenses payable by us, (iii) the exercise of the July 2023
              Pre-funded Warrants in full for aggregate gross proceeds of $217, (iv) the July 2023 Warrant Amendment reducing the exercise price of the May 2022 Warrants and December 2022 Warrants to $1.80 per ADS, and (v) the March 2023 Warrant Exercise
              Transaction, and after deducting placement agent fees.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000;">The information set forth in the following table should be read in conjunction with and is qualified in its entirety by reference to the audited and unaudited financial statements and
      notes thereto incorporated by reference in this prospectus.</div>
    <div style="text-align: justify; line-height: 1.25; color: #000000;"> <br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" align="center" style="width: 80%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z518c63c0653e43b58d838d53f3401a77" class="cfttable">

        <tr>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: top; font-family: 'Times New Roman',Times,serif; padding-bottom: 2px;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0); font-style: italic;">(In thousands, except share data)</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="line-height: 1.25; color: rgb(0, 0, 0); font-style: italic; text-align: center;">Actual</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="line-height: 1.25; color: rgb(0, 0, 0); font-style: italic; text-align: center;">Pro Forma</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 76%;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">Total debt<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">$</div>
          </td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">56,830</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">$</div>
          </td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">62,558</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman',Times,serif; width: 76%;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">Ordinary shares, par value NIS 0.01 per share</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">2,845</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">7,599</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 76%;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">Additional paid-in capital</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">382,634</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">378,101</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman',Times,serif; width: 76%;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">Accumulated deficit</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">383,475</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">385,723</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 76%;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">Total shareholders&#8217; equity</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">$</div>
          </td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">2,004</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">$</div>
          </td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">(23</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">)</div>
          </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman',Times,serif; width: 76%;">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: top; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 76%;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">Total capitalization and indebtedness</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">$</div>
          </td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">58,834</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">$</div>
          </td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">62,535</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z6f668affb54a4ae38b7085af06f898b9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 2.5%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">(1)</div>
          </td>
          <td style="width: 97.5%; vertical-align: top;">
            <div style="text-align: justify; line-height: 1.25; color: #000000;">&#160;Includes $48.4 million reported as current liabilities, which mainly consist of allowance for deductions from revenue and accrued expenses and account payable, and $8.4
              million reported as non-current liabilities, which mainly consist of lease liabilities and derivative financial instruments. The warrants granted in the May 2022 financing, December 2022 financing, March 2023 financing and July 2023 financing
              were classified as a financial liability due to a net settlement provision. Therefore, the proceeds of the issuances were classified as derivative financial instruments and increased the total debt accordingly.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; color: #000000;">The above discussion and table are based on 1,082,007,694 Ordinary Shares outstanding as of March 31, 2023. As of March 31, 2023, prior to giving effect to the July 2023 Warrant
      Amendment and the March 2023 Warrant Exercise Transaction, we had (i) 50,511,200 Ordinary Shares issuable upon the exercise of outstanding options to purchase Ordinary Shares at a weighted average exercise price of $0.63 per share (equivalent to
      126,278 ADSs at a weighted average exercise price of $252.54 per ADS), (ii) 823,112,400 Ordinary Shares issuable upon the exercise of outstanding warrants to purchase Ordinary Shares at a weighted average exercise price of $0.03 per share (equivalent
      to 2,057,781 ADSs at a weighted average exercise price of $13.38 per ADS), and (iii) 62,451 outstanding RSUs, each RSU representing one ADS. The number of Ordinary Shares to be outstanding immediately after the offering does not include the ADSs we
      agreed to issue to Kukbo Co. Ltd. for the second tranche of $5 million pursuant to the Subscription Agreement, dated October 25, 2021.&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">10</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">SELLING SHAREHOLDERS<a name="SHAREHOLDERS"><!--Anchor--></a></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>May 2022 Offering</u></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">On May 11, 2022, we issued to <font style="color: rgb(0, 0, 0);">Armistice Capital Master Fund Ltd. (&#8220;Armistice&#8221;)</font>, the May 2022 Warrants to purchase up to 330,106 ADSs representing
      132,042,400 of our Ordinary Shares at an initial exercise price of $59.20 per ADS (reflecting the subsequent change of ratio of the Company&#8217;s ADSs to its non-traded ordinary shares to a new ratio of one (1) ADS representing four hundred (400)
      ordinary shares, effective March 23, 2023) in a private placement completed concurrently with a registered direct offering. All of the May 2022 Warrants remain unexercised.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The May 2022 Warrants are exercisable <font style="color: rgb(0, 0, 0);">at any time after November 11, 2022, and initially until the close of business on November 11, 2027. </font>The holder of
      May 2022 Warrants (together with its affiliates) may not exercise any portion of the May 2022 Warrants to the extent that the holder would own more than 4.99% (or, at the holder&#8217;s option upon initial issuance, 9.99%) of our outstanding Ordinary
      Shares immediately after the exercise. However, upon at least 61 days&#8217; prior notice from the holder to us, a holder with a 4.99% ownership blocker may increase the amount of ownership of outstanding Ordinary Shares after exercising the May 2022
      Warrants up to 9.99% of the number of our Ordinary Shares outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the May 2022 Warrants.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">On March 29, 2023, in connection with the March 2023 Offering, our Board of Directors approved the repricing and extension of the May 2022 Warrants to an exercise price equal to the exercise price of
      the Series A Warrants issued and sold in the March 2023 Offering and to an expiration date of five years following the closing date of the March 2023 Offering. The initial exercise price of the Series A Warrants issued and sold in the March 2023
      Offering was $4.75 per ADS, and the closing date of the March 2023 Offering was April 3, 2023. Accordingly, pursuant to the March 2023 Warrant Amendment, the exercise price of the May 2022 Warrants was reduced to $4.75 per ADS, and the expiration
      date was extended to April 3, 2028.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="color: #000000;">In connection with the July 2023 Offering, </font><font style="font-family: 'Times New Roman',Times,serif;">our Board of Directors approved the further repricing <font style="color: rgb(0, 0, 0);">of the May 2022 Warrants. Pursuant to the July 2023 Warrant Amendment, the exercise price of the May 2022 Warrants was further reduced from $4.75 per ADS to $1.80 per ADS, effective upon closing of the July 2023
          Offering</font>. The expiration date of the May 2022 Warrants remained unchanged.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the terms of the May 2022 Warrants, if at the time of exercise, a registration statement registering the resale of the ADSs underlying the May 2022 Warrants under the Securities Act is
      not then effective or available, the holder may exercise the May 2022 Warrant through a cashless exercise, in whole or in part, in which case the holder would receive upon such exercise the net number of ADSs determined according to the formula set
      forth in the May 2022 Warrants.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The issuance of the May 2022 Warrants to Armistice was exempt from the registration requirements of the Securities Act pursuant to an exemption provided by Section 4(a)(2) thereof and Rule 506 of
      Regulation D promulgated thereunder as a transaction by an issuer not involving a public offering. Pursuant to the securities purchase agreement with Armistice, executed in connection with the private investment by Armistice, we are obligated, among
      other things, to file a registration statement with SEC for purposes of registering the resale of the ADSs issuable upon exercise of the May 2022 Warrants.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="color: #000000;">Pursuant to the securities purchase agreement, we agreed to, among others, use commercially reasonable efforts to cause a registration statement providing for the resale
        by holders of the ADSs issuable upon exercise of the </font><font style="font-family: 'Times New Roman',Times,serif;">May 2022 <font style="color: rgb(0, 0, 0);">Warrants, to become effective as soon as practicable following the closing date, and
          to keep such registration statement effective until such time as no holder owns any </font>May 2022 <font style="color: rgb(0, 0, 0);">Warrants or the ADSs issuable upon exercise thereof.</font></font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;"><u>July 2023 Offering</u></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="color: #000000;">On July 21, 2023, concurrent with the July 2023 Offering, we entered into the Exercise Agreement with Armistice</font><font style="font-family: 'Times New Roman',Times,serif;">, <font style="color: rgb(0, 0, 0);">an investor in the July 2023 Offering, holding Series A Warrants to purchase up to an aggregate of 1,500,000 ADSs and Series B Warrants to purchase up to an aggregate of 1,500,000 ADSs
          previously issued in the March 2023 Offering, pursuant to which Armistice agreed to exercise its Series A Warrants in full at a reduced exercised price of $1.35 per ADS for aggregate gross proceeds of $2,025,000. In consideration for the exercise
          of the Series A Warrants for cash, among other things, Armistice received new unregistered July 2023 Reload Warrants to purchase up to an aggregate of 1,500,000 ADSs at an exercise price of $1.80 per ADS, which are exercisable until April 3,
          2028. See &#8220;Prospectus Summary - July 2023 Offering&#8221; above.</font></font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">11</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><font style="color: #000000;">The issuance of the July 2023 Reload Warrants described above was exempt from the registration requirements of the Securities Act pursuant to an exemption provided by
        Section 4(a)(2) thereof and Rule 506 of Regulation D promulgated thereunder as a transaction by an issuer not involving a public offering. </font><font style="font-family: 'Times New Roman',Times,serif;">Pursuant to the Exercise Agreement with
        Armistice, we are obligated, among other things, to file a registration statement with the SEC for purposes of registering the resale of the ADSs issuable upon exercise of the July 2023 Reload Warrants <font style="color: rgb(0, 0, 0);">as soon as
          practicable (and in any event within fifteen (15) calendar days of the date of Exercise Agreement) and to keep such registration statement effective until such time as Armistice no longer owns any </font>July 2023 Reload Warrants <font style="color: rgb(0, 0, 0);">or the ADSs issuable upon exercise thereof.</font></font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">We are registering the resale by Armistice of the ADSs issuable upon exercise of the July 2023 Reload Warrants in order to permit Armistice to offer such ADSs for resale from time to time pursuant to
      this prospectus. Armistice may also sell, transfer or otherwise dispose of all or a portion of its ADSs in transactions exempt from the registration requirements of the Securities Act, or pursuant to another effective registration statement covering
      those.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Placement Agent Warrants</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">As part of the compensation to Wainwright in connection with the July 2023 Offering and the March 2023 Exercise Transaction, pursuant to an engagement agreement, dated as of July 17, 2023, by between
      us and Wainwright, we issued to Wainwright&#8217;s designees unregistered (i) July 2023 Placement Agent Warrants to purchase up to an aggregate of 78,115 ADSs at an exercise price of $1.6875 per ADS and a termination date of July 21, 2028, and (ii) Warrant
      Exercise Placement Agent Warrants to purchase up to an aggregate of 90,000 ADSs at an exercise price of $1.6875 per ADS which shall be exercisable until April 3, 2028.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The resale of the ADSs issuable upon exercise of the July 2023 Placement Agent Warrants and the Warrant Exercise Placement Agent Warrants and the Ordinary Shares underlying the ADSs is being
      registered in this registration statement.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Relationships with the Selling Shareholders</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Except for ownership of the May 2022 Warrants and the July 2023 Reload Warrants and as described in this prospectus and the documents incorporated by reference into this prospectus, including the
      investment by Armistice in the May 2022 Offering, March 2023 Offering, the March 2023 Warrant Exercise Transaction and the July 2023 Offering, Armistice has not had any material relationship with us within the past three years.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Wainwright and its respective affiliates have engaged in investment banking, advisory and other commercial dealings in the ordinary course of business with us or our affiliates for which they have
      received customary fees and commissions. Wainwright acted as the placement agent in connection with several offerings of our securities in the past three years, and it received compensation for each such offering.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Information About Selling Shareholders Offering</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The <font style="color: rgb(0, 0, 0);">Ordinary Shares represented by the</font> Offered ADSs being offered by the selling shareholders are those issued or&#160;issuable upon exercise of the May 2022
      Warrants, the July 2023 Reload Warrants, the July 2023 Placement Agent Warrants and the <font style="color: rgb(0, 0, 0);">Warrant Exercise Placement Agent Warrants</font>, described above. We are registering the Offered ADSs in order to permit the
      selling shareholders to offer the Offered ADSs for resale from time to time.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Throughout this prospectus, when we refer to the Offered ADSs being registered on behalf of the selling shareholder, we are referring to the Offered ADSs issued or issuable upon cash exercise of the
      May 2022 Warrants, the July 2023 Reload Warrants, the July 2023 Placement Agent Warrants and the Warrant Exercise Placement Agent Warrants, and when we refer to the selling shareholders in this prospectus we are referring to each selling shareholder
      identified below, and, as applicable, permitted transferees or other successors-in-interest of the selling shareholders that may be identified in a supplement to this prospectus or, if required, a post-effective amendment to the registration
      statement of which this prospectus is a part.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">12</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">The table below provides information regarding the beneficial ownership of the Ordinary Shares represented by the Offered ADSs by the selling shareholders<font style="color: rgb(0, 0, 0);">. </font>The



      second column lists the number of Ordinary Shares represented by the Offered ADSs beneficially owned by the selling shareholders, based on their beneficial ownership of the Offered ADSs, as of August 2, 2023,<font style="color: rgb(0, 0, 0);">
        assuming the exercise of the Warrants held by each selling shareholder on that date, </font>without regard to any limitations on the exercise of the Warrants. The fourth column lists <font style="color: rgb(0, 0, 0);">the maximum number of
        Ordinary Shares represented by the Offered ADSs being offered in this prospectus by each selling shareholder</font>, issuable upon exercise of the Warrants, respectively, without regard to any limitations on the exercise of the Warrants.<font style="color: rgb(0, 0, 0);"> The fifth and sixth columns list the number of Ordinary Shares represented by the Offered ADSs owned after the Offering and the percentage of outstanding Ordinary Shares, assuming in both cases the exercise of the
        Warrants held by that selling shareholder, </font>without regard to any limitations on the exercise of the Warrants<font style="color: rgb(0, 0, 0);"> and the sale of all of the Ordinary Shares represented by the Offered ADSs offered by that
        selling shareholder pursuant to this prospectus.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The selling shareholders may sell some, all or none of their Offered ADSs. We do not know when or whether the selling shareholders will exercise their Warrants nor do we know how long the selling
      shareholders will hold their Offered ADSs before selling them, and we currently have no agreements, arrangements or understandings with the selling shareholders regarding the exercise of any Warrants, or the sale or other disposition of any of the
      Offered ADSs. The Offered ADSs covered hereby may be offered from time to time by the selling shareholders.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Unless otherwise indicated, all information contained in the table below and the footnotes thereto is based upon information provided to us by the selling shareholders. The percentage of shares owned
      prior to and after the offering is based on 2,341,812,494 of our Ordinary Shares outstanding as of August 2, 2023. Unless otherwise indicated in the footnotes to this table, we believe that each selling shareholder has sole voting and investment
      power with respect to the Ordinary Shares indicated as beneficially owned. Except as otherwise indicated below, based on the information provided to us by the selling shareholders, and to the best of our knowledge, no selling shareholder is a
      broker-dealer or an affiliate of a broker-dealer.&#160;</div>
    <br>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z4900a83bf5004d4680f41d15b082477f" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; padding-bottom: 2px;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);" colspan="6">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ordinary Shares Beneficially Owned Before Offering</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; padding-bottom: 2px;" colspan="2">&#160;</td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="6">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Ordinary Shares Beneficially Owned After Offering</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;"> </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Selling Shareholders</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Percentage</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Maximum Number of Ordinary Shares Offered<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)</sup></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Number</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Percentage</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; text-align: center;">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">Armistice Capital, LLC(2)</div>
            </div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; text-align: right;" colspan="2">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">
              <div style="line-height: 1.25;">1,856,042,400</div>
            </div>
          </td>
          <td nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: top;" colspan="1" class="cftfncell"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(3)</sup></td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: middle; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="text-align: center; line-height: 1.25;">
              <div style="text-align: right; line-height: 1.25;">46.03</div>
            </div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1" class="cftfncell">%** <br>
          </td>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;"><font style="color: #000000;">732,042,400</font></div>
          </td>
          <td nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: top;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup>&#160;</font></div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; text-align: right;" colspan="2">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">1,056,754,000</div>
            </div>
          </td>
          <td nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: top;" colspan="1" class="cftfncell"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></td>
          <td style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;" colspan="1" class="cftguttercell">&#160;</td>
          <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; text-align: right;" colspan="2">
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;">27.88</div>
            </div>
          </td>
          <td nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom;" colspan="1" class="cftfncell">%** </td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman',Times,serif; width: 40%;">
            <div style="text-align: center; line-height: 1.25;">Michael Vasinkevich<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">66,206,800</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(7)</sup>&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: #000000;">2.83</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25; color: #000000;">%</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">43,121,600</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(8)</sup>&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;"><font style="color: #000000;">23,085,200</font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(9)</sup>&#160;</font></div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: middle; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 40%;">
            <div style="text-align: center; line-height: 1.25;">Noam Rubinstein<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">22,714,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(10)</sup>&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;"></font></div>
            <div style="line-height: 1.25;">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">14,794,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(11)</sup>&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;"><font style="color: #000000;">7,920,000</font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(12)</sup>&#160;</font></div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman',Times,serif; width: 40%;">
            <div style="text-align: center; line-height: 1.25;">Aileen Gibbons<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">9,808,400</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(13)</sup>&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;"></font></div>
            <div style="line-height: 1.25; color: #000000;">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">6,388,400</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(14)</sup>&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;"><font style="color: #000000;">3,420,000</font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(15)</sup>&#160;</font></div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: middle; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 40%;">
            <div style="text-align: center; line-height: 1.25;">Craig Schwabe<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">3,484,800</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(16)</sup>&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;"></font></div>
            <div style="line-height: 1.25; color: #000000;">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">2,269,600</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(17)</sup>&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;"><font style="color: #000000;">1,215,200</font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(18)</sup>&#160;</font></div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: middle; font-family: 'Times New Roman',Times,serif; width: 40%;">
            <div style="text-align: center; line-height: 1.25;">Charles Worthman<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(6)</sup></div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">1,032,400</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(19)</sup>&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><font style="line-height: 1.25;"></font></div>
            <div style="line-height: 1.25; color: #000000;">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">672,400</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(20)</sup>&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;"><font style="color: #000000;">360,000</font></div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">
            <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif;"><sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(21)</sup>&#160;</font></div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">*</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">* Less than 1%. &#160;</div>
    <div style="text-align: justify; line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-right: 5.2pt; margin-left: 5.3pt; line-height: 1.25;">** The May 2022 Warrants, the July 2023 Reload Warrants and the Series B Warrants held by Armistice are subject to a 4.99% blocker according to which the holder of the May 2022
        Warrants, the July 2023 Reload Warrants and the Series B Warrants (together with its affiliates) may not exercise any portion of the warrants to the extent that the holder would own more than 4.99% (or, at the holder&#8217;s option upon initial issuance,
        9.99%) of our outstanding Ordinary Shares immediately after the exercise. However, upon at least 61 days&#8217; prior notice from the holder to us, a holder with a 4.99% ownership blocker may increase the amount of ownership of outstanding Ordinary
        Shares after exercising the warrants up to 9.99% of the number of our Ordinary Shares outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants (the
        &#8220;Blocker&#8221;). Assumes that 895,000 ADSs held in abeyance pursuant to the exercise of the Series A Warrants in the March 2023 Warrant Exercise Transaction have been issued for the purposes of calculating beneficial ownership percentages.</div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">13</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%14%%%-->
    <div style="text-align: justify; line-height: 1.25;">(1) Number of Ordinary Shares includes Ordinary Shares represented by ADSs. Each ADS represents four hundred (400) Ordinary Shares.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div>
        <div style="text-align: justify;">(2) The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the &#8220;Master Fund&#8221;), and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC
          (&#8220;Armistice Capital&#8221;), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital.&#160; The warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the
          selling shareholder from exercising that portion of the warrants that would result in the selling shareholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The
          address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022.</div>
      </div>
      <div style="line-height: 1.25; text-align: justify;">&#160;</div>
      <div>
        <div style="text-align: justify;">(3) Represents 1,856,042,400 Ordinary Shares represented by 4,640,106 ADSs issued or issuable upon (i) exercise of the May 2022 Warrants issued in a private placement consummated concurrently to our May 2022
          Offering, (ii) exercise of the July 2023 Reload Warrants issued in a private placement consummated concurrently to our July 2023 Offering, (iii) the Series B Warrants issued in our March 2023 Offering, (iv) 895,000 ADSs held in abeyance pursuant
          to the exercise of the Series A Warrants in the March 2023 Warrant Exercise Transaction, and (v) 415,000 ADSs, without regard to any limitations on the exercise of such warrants. The exercise of the foregoing warrants is subject to the Blocker.
          Consequently, as of the date set forth above, Armistice may not necessarily be able to exercise all of these warrants due to the Blocker. The number of Ordinary Shares set forth in the above table does not reflect the application of this
          limitation.</div>
      </div>
      <div style="line-height: 1.25; text-align: justify;">&#160;</div>
      <div>
        <div style="text-align: justify;">(4) Represents 732,042,400 Ordinary Shares represented by 1,830,106 ADSs issuable upon exercise of the May 2022 Warrants and the July 2023 Reload Warrants, without regard to any limitations on the exercise of such
          warrants. The exercise of the foregoing warrants is subject to the Blocker.</div>
      </div>
      <div style="line-height: 1.25; text-align: justify;">&#160;</div>
      <div>
        <div style="text-align: justify;">(5) Represents 1,124,000,000 Ordinary Shares represented by 2,810,000 ADSs issued or issuable upon (i) exercise of the Series B Warrants issued in our March 2023 Offering, (ii) 895,000 ADSs held in abeyance
          pursuant exercise of the Series A Warrants in the March 2023 Warrant Exercise Transaction, and (v) 415,000 ADSs without regard to any limitations on the exercise of such warrants. The exercise of the foregoing warrants is subject to the Blocker.
          Consequently, as of the date set forth above, Armistice may not necessarily be able to exercise all of these warrants due to the Blocker. The number of ordinary shares set forth in the above table does not reflect the application of this
          limitation.</div>
      </div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(6) The selling shareholders were issued compensation warrants as a designee of Wainwright in connection with each of the March 2023 Offering, the March 2023 Warrant Exercise Transaction and the July
      2023 Offering. Each selling stockholder has sole voting and dispositive power over the securities held. The business address is c/o H.C. Wainwright &amp; Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022. Each selling stockholder may not
      exercise the July 2023 Placement Agent Warrants, the <font style="color: rgb(0, 0, 0);">Warrant Exercise Placement Agent Warrants and the warrants issued to Wainwright or its designees in connection with the March 2023 Offering</font> (the &#8220;March
      2023 Placement Agent Warrants&#8221;) to the extent such exercise would cause each selling shareholders, together with his affiliates and attribution parties, to beneficially own a number of Ordinary Shares which would exceed 4.99% of our then outstanding
      Ordinary Shares following such exercise, or, upon notice to us, 9.99% of our then outstanding Ordinary Shares following such exercise, excluding for purposes of such determination shares of Ordinary Shares issuable upon exercise of such securities
      which have not been so exercised.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(7)<font style="color: rgb(0, 0, 0);"> Represents 66,206,800 </font>Ordinary Shares<font style="color: rgb(0, 0, 0);"> represented 165,517 ADSs issuable upon exercise of the March 2023</font>
      Placement Agent Warrant<font style="color: rgb(0, 0, 0);">s, the </font>July 2023 Placement Agent Warrants and the <font style="color: rgb(0, 0, 0);">Warrant Exercise Placement Agent Warrants, </font>without regard to any limitations on the
      exercise of such warrants.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><font class="BRPFPageNumber" style="font-weight: normal; font-style: normal;">14</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">(8)<font style="color: rgb(0, 0, 0);"> Represents 43,121,600 </font>Ordinary Shares<font style="color: rgb(0, 0, 0);"> represented 107,804 ADSs issuable upon exercise of the </font>July 2023
      Placement Agent Warrants and the <font style="color: rgb(0, 0, 0);">Warrant Exercise Placement Agent Warrants, </font>without regard to any limitations on the exercise of such warrants.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(9)<font style="color: rgb(0, 0, 0);"> Represents 23,084,800 </font>Ordinary Shares<font style="color: rgb(0, 0, 0);"> represented by 57,712 ADSs issuable upon exercise of the March 2023 Placement
        Agent Warrants, </font>without regard to any limitations on the exercise of such warrants<font style="color: rgb(0, 0, 0);">.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(10)<font style="color: rgb(0, 0, 0);"> Represents 22,714,000 </font>Ordinary Shares<font style="color: rgb(0, 0, 0);"> represented by 56,785 ADSs issuable upon exercise of the March 2023</font>
      Placement Agent Warrant<font style="color: rgb(0, 0, 0);">s, the July 2023 Placement Agent Warrants and the Warrant Exercise Placement Agent Warrants, </font>without regard to any limitations on the exercise of such warrants.</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(11)<font style="color: rgb(0, 0, 0);"> Represents 14,794,000 </font>Ordinary Shares<font style="color: rgb(0, 0, 0);"> represented by 36,985 ADSs issuable upon exercise of the </font>July 2023
      Placement Agent Warrants and the <font style="color: rgb(0, 0, 0);">Warrant Exercise Placement Agent Warrants, </font>without regard to any limitations on the exercise of such warrants.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(12)<font style="color: rgb(0, 0, 0);"> Represents 7,920,000 </font>Ordinary Shares<font style="color: rgb(0, 0, 0);"> represented by 19,800 ADSs issuable upon exercise of the March 2023 Placement
        Agent Warrants, </font>without regard to any limitations on the exercise of such warrants<font style="color: rgb(0, 0, 0);">.</font></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(13)<font style="color: rgb(0, 0, 0);"> Represents 9,808,400 Ordinary Shares represented by 24,521 ADSs issuable upon exercise of the March 2023 Placement Agent Warrants, the July 2023 Placement
        Agent Warrants and the Warrant Exercise Placement Agent Warrants, without regard to any limitations on the exercise of such warrants</font>.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(14)<font style="color: rgb(0, 0, 0);"> Represents 6,388,400 Ordinary Shares represented by 15,971 ADSs issuable upon exercise of the July 2023 Placement Agent Warrants and the Warrant Exercise
        Placement Agent Warrants, without regard to any limitations on the exercise of such warrants</font>.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(15)<font style="color: rgb(0, 0, 0);"> Represents 3,420,000 </font>Ordinary Shares<font style="color: rgb(0, 0, 0);"> represented by 8,550 ADSs issuable upon exercise of the March 2023 Placement
        Agent Warrants, </font>without regard to any limitations on the exercise of such warrants<font style="color: rgb(0, 0, 0);">.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(16)<font style="color: rgb(0, 0, 0);"> Represents 3,484,800 Ordinary Shares represented 8,712 ADSs issuable upon exercise of the March 2023 Placement Agent Warrants, the July 2023 Placement Agent
        Warrants and the Warrant Exercise Placement Agent Warrants, without regard to any limitations on the exercise of such warrants</font>.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(17)<font style="color: rgb(0, 0, 0);"> Represents 2,269,600 Ordinary Shares represented 5,674 ADSs issuable upon exercise of the July 2023 Placement Agent Warrants and the Warrant Exercise Placement
        Agent Warrants, without regard to any limitations on the exercise of such warrants</font>.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(18)<font style="color: rgb(0, 0, 0);"> Represents 1,215,200 Ordinary Shares represented by 3,038 ADSs issuable upon exercise of the March 2023 Placement Agent Warrants, without regard to any
        limitations on the exercise of such warrants.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(19)<font style="color: rgb(0, 0, 0);"> Represents 1,032,400 Ordinary Shares represented 2,581 ADSs issuable upon exercise of the March 2023 Placement Agent Warrants, the July 2023 Placement Agent
        Warrants and the Warrant Exercise Placement Agent Warrants, without regard to any limitations on the exercise of such warrants</font>.</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(20)<font style="color: rgb(0, 0, 0);"> Represents 672,400 Ordinary Shares represented by 1,681 ADSs issuable upon exercise of the July 2023 Placement Agent Warrants and the Warrant Exercise
        Placement Agent Warrants, without regard to any limitations on the exercise of such warrants</font>.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">(21)<font style="color: rgb(0, 0, 0);"> Represents 360,000 Ordinary Shares represented by 900 ADSs issuable upon exercise of the March 2023 Placement Agent Warrants, without regard to any limitations
        on the exercise of such Warrants.</font></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">15</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PLAN OF <a name="DISTRIBUTION"><!--Anchor--></a>DISTRIBUTION</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The selling shareholders of the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of the securities covered hereby on the principal
      trading market or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. The selling shareholders may use any one or more of the following
      methods when selling securities:</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="z6672462bf4e04214aab37aae95c99737" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">block trades in which the broker-dealer will attempt to sell the securities as an agent but may position and resell a portion of the block as principal to facilitate the transaction;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">an exchange distribution in accordance with the rules of the applicable exchange;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">privately negotiated transactions;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">settlement of short sales made after the effective date of the registration statement;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">in transactions through broker-dealers that agree with the selling shareholders to sell a specified number of such securities at a stipulated price per security;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">a combination of any such methods of sale; or</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 92%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">any other method permitted pursuant to applicable law.</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The selling shareholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Broker-dealers engaged by the selling shareholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the selling shareholders (or,
      if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary
      brokerage commission in compliance with FINRA Rule 2121, and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">In connection with the sale of the securities or interests therein, the selling shareholders may enter into hedging transactions with broker-dealers or other financial institutions, which may, in
      turn, engage in short sales of the securities in the course of hedging the positions it assumes. The selling shareholders may also sell securities short and deliver these securities to close out its short positions, or loan or pledge the securities
      to broker-dealers that in turn may sell these securities. The selling shareholders may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
      delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect
      such transaction).</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The selling shareholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with
      such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. The selling
      shareholders have informed the Company that they do not have any written or oral agreement or understanding, directly or indirectly, with any person to distribute the securities.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">16</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">We are required to pay certain fees and expenses incurred by us incident to the registration of the securities. We have agreed to indemnify the selling shareholders against certain losses, claims,
      damages and liabilities, including liabilities under the Securities Act.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">We agreed to keep this prospectus effective until the selling shareholders do not own any Warrants or do not own any Ordinary Shares represented by the Offered ADSs issuable upon exercise of the
      Warrants. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they
      have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Under applicable rules and regulations under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), any person engaged in the distribution of the resale securities may not
      simultaneously engage in market-making activities with respect to the Offered ADSs for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the selling shareholders will be subject
      to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Offered ADSs by the selling shareholders or any other person. We will make copies
      of this prospectus available to the selling shareholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="EXPENSES"><!--Anchor--></a>EXPENSES</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">The following table sets forth the estimated costs and expenses payable by the registrant expected to be incurred in connection with the issuance and distribution of the Offered ADSs being registered
      hereby. All of such expenses are estimates, except for the SEC registration fee.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;" id="z03ad8764631f4f8f966c57db6a0e1026" class="cfttable">

        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; padding-bottom: 2px;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Amount</div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">to be Paid</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 88%;">
            <div style="line-height: 1.25;">SEC registration fee</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">255.44</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; width: 88%;">
            <div style="line-height: 1.25;">Legal fees and expenses</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">10,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 88%;">
            <div style="line-height: 1.25;">Accountants&#8217; fees and expenses</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">5,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman',Times,serif; width: 88%; padding-bottom: 2px;">
            <div style="line-height: 1.25;">Miscellaneous</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftcurrcell">&#160;</td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">5,000</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>
        <tr>
          <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; width: 88%; padding-bottom: 4px;">
            <div style="line-height: 1.25;">Total</div>
          </td>
          <td valign="bottom" style="font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
            <div style="line-height: 1.25;">$</div>
          </td>
          <td valign="bottom" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
            <div style="line-height: 1.25;">20,255.44</div>
          </td>
          <td valign="bottom" nowrap="nowrap" style="background-color: rgb(204, 238, 255); font-family: 'Times New Roman',Times,serif; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">Each of the amounts set forth above, other than the registration fee, is an estimate.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">LEGAL MATTERS<a name="MATTERS"><!--Anchor--></a></div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Certain legal matters with respect to Israeli law and with respect to the validity of the offered securities under Israeli law will be passed upon for us by Goldfarb Gross Seligman &amp; Co. Certain
      legal matters with respect to U.S. federal securities law and New York law will be passed upon for us by Haynes and Boone, LLP.</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">17</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="EXPERTS"><!--Anchor--></a>EXPERTS</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The financial statements and management&#8217;s assessment of the effectiveness of internal control over financial reporting (which is included in Management&#8217;s Annual Report on Internal Control over
      Financial Reporting) incorporated in this prospectus by reference to the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2022, have been so incorporated in reliance on the report of Kesselman &amp; Kesselman, Certified Public
      Accountants (Isr.) (which contains an adverse opinion on the effectiveness of the Company&#8217;s internal control over financial reporting and includes an explanatory paragraph regarding the existence of substantial doubt about the Company&#8217;s ability to
      continue as a going concern as described in Note 1a(3) to the financial statements), a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm, given on the authority of said firm as experts in
      auditing and accounting.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">WHERE YOU CAN FIND ADDITIONAL INFORMATION<a name="INFORMATION"><!--Anchor--></a></div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">We are subject to the informational requirements of the Securities Exchange Act of 1934, as amended, and in accordance therewith file annual and special reports with, and furnish other information
      to, the SEC. The SEC maintains a website that contains reports, information statements and other information regarding registrants that file electronically with the SEC. The address of the SEC&#8217;s website is www.sec.gov.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">We make available free of charge on or through our website at <font style="font-style: italic;">www.redhillbio.com</font>, our Annual Reports on Form&#160; &#160;&#160; 20-F, Reports on Form 6-K and amendments to
      those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable after we electronically file such material with or otherwise furnish it to the SEC.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">We have filed with the SEC a registration statement under the Securities Act of 1933, as amended, relating to the offering of these securities. The registration statement, including the attached
      exhibits, contains additional relevant information about us and the securities. This prospectus does not contain all of the information set forth in the registration statement. You can obtain a copy of the registration statement for free at
      www.sec.gov. The registration statement and the documents referred to below under &#8220;Incorporation of Documents by Reference&#8221; are also available on our website, <font style="font-style: italic;">www.redhillbio.com</font>.&#160;We will provide you without
      charge, upon your written or oral request, a copy of any of the documents incorporated by reference in this prospectus, other than exhibits to such documents which are not specifically incorporated by reference into such documents. Please direct your
      written or telephone requests to RedHill Biopharma Ltd., 21 Ha'arba'a Street, Tel Aviv 6473921, Israel, Attn: Razi Ingber, telephone number +972 (3) 541-3131.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">We have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">18</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="INCORPORATION"><!--Anchor--></a>INCORPORATION OF DOCUMENTS BY REFERENCE</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The SEC allows us to &#8220;incorporate by reference&#8221; the information we have filed with it, which means that we can disclose important information to you by referring you to those documents. The
      information we incorporate by reference is an important part of this prospectus, and later information that we file with the SEC will automatically update and supersede this information. We specifically are incorporating by reference the following
      documents filed with the SEC:</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="zc8c28848af8941c282066e0be0cda5ee" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 92.31%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">our Annual Report on <a href="https://www.sec.gov/Archives/edgar/data/1553846/000155837023007149/0001558370-23-007149-index.htm">Form 20-F</a> for the year ended December 31, 2022, filed
              with the SEC on April 28, 2023;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 92.31%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 92.31%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">the description of our Ordinary Shares contained in our Registration Statement on <a href="https://www.sec.gov/Archives/edgar/data/1553846/000114420412069612/0001144204-12-069612-index.htm">Form



                20-F</a> filed with the SEC on December 26, 2012; and</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 92.31%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 3.85%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">&#9679;</div>
          </td>
          <td style="width: 92.31%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: justify; line-height: 1.25;">our Reports on Form 6-K,&#160; furnished with the SEC on <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323000009/0001178913-23-000009-index.htm">January 3, 2023</a><font style="color: rgb(0, 0, 255);">, <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323000240/0001178913-23-000240-index.htm">January 24, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323000252/0001178913-23-000252-index.htm">January 25, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323000284/0001178913-23-000284-index.htm">January




                  26, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323000372/0001178913-23-000372-index.htm">February 6, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323000646/0001178913-23-000646-index.htm">February 15, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323000657/0001178913-23-000657-index.htm">February




                  16, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323000774/0001178913-23-000774-index.htm">February 28, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323000848/0001178913-23-000848-index.htm">March 6, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323000884/0001178913-23-000884-index.htm">March
                  9, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323000925/0001178913-23-000925-index.htm">March 13, 2023</a>, </font><a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323001555/0001178913-23-001555-index.htm">April<font style="color: rgb(0, 0, 255);"> 28, 2023</font></a> (solely with respect to &#8220;Financial results for the quarter ended
              December 31, 2022&#8221;, &#8220;Financial results for the year ended December 31, 2022&#8221; and &#8220;Liquidity and Capital Resources&#8221;), <font style="color: rgb(0, 0, 255);"><a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323001582/0001178913-23-001582-index.htm">May 1, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323001688/0001178913-23-001688-index.htm">May 4,
                  2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323001742/0001178913-23-001742-index.htm">May 9, 2023</a>, <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323001908/0001178913-23-001908-index.htm">May 16, 2023</a> <font style="color: rgb(0, 0, 0);">and</font> <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323001979/0001178913-23-001979-index.htm">May 22, 2023</a>,&#160;</font><a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323002196/0001178913-23-002196-index.htm">June



                12, 2023</a><font style="color: rgb(0, 0, 0);">, </font><a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323002322/0001178913-23-002322-index.htm">June 29, 2023</a><font style="color: rgb(0, 0, 0);">, </font><a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323002381/0001178913-23-002381-index.htm">July 6, 2023</a><font style="color: rgb(0, 0, 0);">, </font><a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323002511/0001178913-23-002511-index.htm">July 21, 2023</a><font style="color: rgb(0, 0, 0);"> (</font>two reports<font style="color: rgb(0, 0, 0);">), <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323002551/0001178913-23-002551-index.htm">July 25, 2023</a> (two reports), <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323002630/0001178913-23-002630-index.htm">July 31, 2023</a> and <a href="https://www.sec.gov/Archives/edgar/data/1553846/000117891323002652/0001178913-23-002652-index.htm">August




                  1, 2023</a>.</font></div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;">In addition, any reports on Form 6-K submitted to the SEC by the registrant pursuant to the Exchange Act after the date of the initial registration statement and prior to effectiveness of the
      registration statement that we specifically identify in such forms as being incorporated by reference into the registration statement of which this prospectus forms a part and all subsequent annual reports on Form 20-F filed after the effective date
      of this registration statement and prior to the termination of this offering and any reports on Form 6-K subsequently submitted to the SEC or portions thereof that we specifically identify in such forms as being incorporated by reference into the
      registration statement of which this prospectus forms a part, shall be considered to be incorporated into this prospectus by reference and shall be considered a part of this prospectus from the date of filing or submission of such documents.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Any statement contained herein or in any document incorporated or deemed to be incorporated by reference shall be deemed to be modified or superseded for purposes of the registration statement of
      which this prospectus forms a part to the extent that a statement contained in any other subsequently filed document which also is or is deemed to be incorporated by reference modifies or supersedes such statement. Any such statement so modified or
      superseded shall not be deemed to constitute a part of the registration statement of which this prospectus forms a part, except as so modified or superseded.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">You should rely only on the information incorporated by reference or provided in this prospectus. We have not authorized anyone else to provide you with different information. You should not assume
      that the information in this prospectus is accurate as of any date other than the date of this prospectus or the date of the documents incorporated by reference in this prospectus.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">We will provide you without charge, upon your written or oral request, a copy of any of the documents incorporated by reference in this prospectus, other than exhibits to such documents which are not
      specifically incorporated by reference into such documents. Please direct your written or telephone requests to RedHill Biopharma Ltd., 21 Ha'arba'a Street, Tel Aviv 6473921, Israel, Attn: Razi Ingber, telephone number +972 (3) 541-3131. You may also
      obtain information about us by visiting our website at <font style="font-style: italic;">www.redhillbio.com</font>. Except for the specific incorporated documents listed above, no information available on or through our website shall be deemed to be
      incorporated in this prospectus or the registration statement of which it forms a part.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">19</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">ENFORCEABILITY OF CIVIL LIABILITIES<a name="LIABILITIES"><!--Anchor--></a></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this prospectus, a majority of whom reside
      outside the United States, may be difficult to obtain within the United States. Furthermore, because many of our assets and a majority of our directors and officers are located outside the United States, any judgment obtained in the United States
      against us or any of our directors and officers may not be collectible within the United States.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">It may be difficult to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws because
      Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the
      content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Subject to specified time limitations and legal procedures, Israeli courts may enforce a United States judgment in a civil matter which, subject to certain exceptions, is non-appealable, including
      judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z6fb655f59ed64b829f7340aebc84a919" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>the judgments are obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international law currently prevailing in Israel;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zb54e15e95161425d9c30921f3380fc49" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>the prevailing law of the foreign state in which the judgments were rendered allows the enforcement of judgments of Israeli courts (however, the Israeli courts may waive this requirement following a request by the attorney general);</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z89ed3b96502443f283a0cef74d90c212" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z11f2549f49d941f8b73db59dcd52d672" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>the judgments are not contrary to public policy, and the enforcement of the civil liabilities set forth in the judgment does not impair the security or sovereignty of the State of Israel;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zf528b22576f440e79486431355d3c6a4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>the judgments were not obtained by fraud and do not conflict with any other valid judgment in the same matter between the same parties;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zc0a28cc5614844edb5dad1b1d0fd1b88" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z14805867eb724fc1841aafe5df5d01a2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>the obligations under the judgment are enforceable according to the laws of the State of Israel and according to the law of the foreign state in which the relief was granted.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zed5c281308e24016806c57633122009a" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div>We have irrevocably appointed RedHill Biopharma Inc. as our agent to receive service of process in any action against us in any United States federal or state court arising out of this offering or any purchase or sale of securities in
              connection with this offering.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zaff27abefd924408a5922434a39761e4" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli
              court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment, but the judgment debtor may make
              payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli
              regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">20</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">1,998,221 American Depositary Shares representing 799,288,400 Ordinary Shares</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><img width="160" height="91" src="image00003.jpg"></div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold; color: rgb(0, 0, 0);">REDHILL BIOPHARMA LTD.</font><font style="font-family: 'Times New Roman',Times,serif;">&#160;</font></div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROSPECTUS</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">21</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">PART II</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">INFORMATION NOT REQUIRED IN PROSPECTUS</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Item 8. Indemnification of Directors and Officers.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Exemption, Insurance and Indemnification of Directors and Officers</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Exemption of Officers and Directors</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Under the Israeli Companies Law, a company may not exempt an officer or director from liability with respect to a breach of his duty of loyalty but may exempt in advance an officer or director from
      liability to the company, in whole or in part, with respect to a breach of his duty of care, except in connection with a prohibited distribution made by the company, if so provided in its articles of association. Our articles of association provide
      for this exemption from liability for our directors and officers.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Directors&#8217; and Officers&#8217; Insurance</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The Israeli Companies Law and our articles of association provide that, subject to the provisions of the Israeli Companies Law, we may obtain insurance for our directors and officers for any
      liability stemming from any act performed by an officer or director in his capacity as an officer or director, as the case may be with respect to any of the following:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z2f63230a1e1441158e2a6c4b56edd521" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>a breach of such officer&#8217;s or director&#8217;s duty of care to us or to another person;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zf0a56abcd5974f569d5a199b7e409e6f" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>a breach of such officer&#8217;s or director&#8217;s duty of loyalty to us, provided that such officer or director acted in good faith and had reasonable cause to assume that his act would not prejudice our interests;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zbb04ec03c74f4cba8e470547952818a5" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>a financial liability imposed upon such officer or director in favor of another person;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z5052934f048d49f6b512298580530f35" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>financial liability imposed on the officer or director for payment to persons or entities harmed as a result of violations in administrative proceedings as described in Section 52(54)(a)(1)(a) of the Israeli Securities Law (&#8220;Party Harmed
              by the Breach&#8221;);</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z7f42dcf5f932490daf3245daab883d31" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>expenses incurred by such officer or director in connection with an administrative proceeding conducted in this matter, including reasonable litigation expenses, including legal fees; or</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z00d90ce658fe468cba10251d92f96459" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>a breach of any duty or any other obligation, to the extent insurance may be permitted by law.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the Compensation Policy, we may obtain a directors&#8217; and officers&#8217; liability insurance policy, which would apply to our or our subsidiaries&#8217; directors and officers, as they may be, from
      time to time, subject to the following terms and conditions: (a) the total insurance coverage under the insurance policy may not exceed $100 million; and (b) the purchase of such policy shall be approved by the Compensation Committee (and, if
      required by law, by the Board of Directors) which shall determine that such policy reflects the current market conditions, and it shall not materially affect the Company's profitability, assets or liabilities. In addition, pursuant to our
      Compensation Policy, should we sell our operations (in whole or in part) or in case of merger, spin-off or any other significant business combination involving us or part or all of our assets, we may obtain a director&#8217;s and officers&#8217; liability
      insurance policy (run-off) for our directors and officers in office with regard to the relevant operations, subject to the following terms and conditions: (a) the insurance term may not exceed seven years; (b) the coverage amount may not exceed $100
      million; and (c) the purchase of such policy shall be approved by the Compensation Committee (and, if required by law, by the Board of Directors) which shall determine that such policy reflects the current market conditions, and it shall not
      materially affect the Company&#8217;s profitability, assets or liabilities. The Compensation Policy is in effect for three years from the 2022 annual general meeting.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the foregoing approvals, we carry directors&#8217; and officers&#8217; liability insurance. This insurance is renewed on an annual basis.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%II - %%-->
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Indemnification of Officers and Directors</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The Israeli Companies Law provides that a company may indemnify an officer or director for payments or expenses associated with acts performed in his capacity as an officer or director of the
      company, provided the company&#8217;s articles of association include the following provisions with respect to indemnification:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z6521379da73f4497b0262948dca1ad38" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>a provision authorizing the company to indemnify an officer or director for future events with respect to a monetary liability imposed on him in favor of another person pursuant to a judgment (including a judgment given in a settlement or
              an arbitrator&#8217;s award approved by the court), so long as such indemnification is limited to types of events which, in the board of directors&#8217; opinion, are foreseeable at the time of granting the indemnity undertaking given the company&#8217;s
              actual business, and in such amount or standard as the board of directors deems reasonable under the circumstances. Such undertaking must specify the events that, in the board of directors&#8217; opinion, are foreseeable in view of the company&#8217;s
              actual business at the time of the undertaking and the amount or the standards that the board of directors deemed reasonable at the time;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z23b4ab9e5c6549c18ee50e7d61139044" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>a provision authorizing the company to indemnify an officer or director for future events with respect to reasonable litigation expenses, including counsel fees, incurred by an officer or director in which he is ordered to pay by a court,
              in proceedings that the company institutes against him or instituted on behalf of the company or by another person, or in a criminal charge of which he was acquitted, or a criminal charge in which he was convicted of a criminal offense that
              does not require proof of criminal intent;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z47dbf50cb650457cb6fa9378ee4af4ed" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>a provision authorizing the company to indemnify an officer or director for future events with respect to reasonable litigation fees, including attorney&#8217;s fees, incurred by an officer or director due to an investigation or proceeding filed
              against him by an authority that is authorized to conduct such investigation or proceeding, and that resulted without filing an indictment against him and without imposing on him financial obligation in lieu of a criminal proceeding, or that
              resulted without filing an indictment against him but with imposing on him a financial obligation as an alternative to a criminal proceeding in respect of an offense that does not require the proof of criminal intent or in connection with a
              monetary sanction;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z36d501da49f1444bae49710a8755830c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>a provision authorizing the company to indemnify an officer or director for future events with respect to a Party Harmed by the Breach;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z00e37036ef5547b99ca5ca1bee4310e2" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>a provision authorizing the company to indemnify an officer or director for future events with respect to expenses incurred by such officer or director in connection with an administrative proceeding, including reasonable litigation
              expenses, including legal fees; and</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="ze6c24598db8d462aac5642b84accfddd" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>a provision authorizing the company to indemnify an officer or director retroactively.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Limitations on Insurance, Exemption and Indemnification</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The Israeli Companies Law and our articles of association provide that a company may not exempt or indemnify a director or an officer nor enter into an insurance contract, which would provide
      coverage for any monetary liability incurred as a result of any of the following:</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z964d7784adb244cdb5acdae8267606eb" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>a breach by the officer or director of his duty of loyalty, except for insurance and indemnification where the officer or director acted in good faith and had a reasonable basis to believe that the act would not prejudice the company;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">II - 2</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <table cellspacing="0" cellpadding="0" id="z1874129fb54847b095fd7ef8b2f42303" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>a breach by the officer or director of his duty of care if the breach was done intentionally or recklessly, except if the breach was solely as a result of negligence;</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z816d20fa1681445e8af888e4d9b1fe51" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>any act or omission done with the intent to derive an illegal personal benefit; or</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z4a7a9931e8b74f56a8f6e8ee126d4651" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 18pt; font-family: 'Times New Roman',Times,serif;"><br>
          </td>
          <td style="width: 18pt; vertical-align: top;">&#8226;</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-family: 'Times New Roman',Times,serif;">
            <div>any fine, civil fine, monetary sanctions, or forfeit imposed on the officer or director.</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">In addition, under the Israeli Companies Law, exemption of, indemnification of, and procurement of insurance coverage for, our directors and officers must be approved by our audit committee and board
      of directors and, in specified circumstances, by our shareholders.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Letters of Indemnification</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">We may provide a commitment to indemnify in advance any director or officer of ours in the course of such person&#8217;s position as our director or officer, all subject to the letter of indemnification,
      as approved by our shareholders from time to time and in accordance with our articles of association. We may provide retroactive indemnification to any officer to the extent allowed by the Israeli Companies Law. As approved by our shareholders, the
      amount of the advance indemnity is limited to the higher of 25% of our then shareholders&#8217; equity, per our most recent annual financial statements, or $10 million.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">As part of the indemnification letters, we exempted our directors and officers, in advance, to the extent permitted by law, from any liability for any damage incurred by them, either directly or
      indirectly, due to the breach of an officer&#8217;s or director&#8217;s duty of care vis- &#224;-vis us, within his acts in his capacity as an officer or director. The letter provides that so long as not permitted by law, we do not exempt an officer or director in
      advance from his liability to us for a breach of the duty of care upon distribution, to the extent applicable to the officer or director, if any. The letter also exempts an officer or director from any liability for any damage incurred by him, either
      directly or indirectly, due to the breach of the officer or director&#8217;s duty of care vis- &#224;-vis us, by his acts in his capacity as an officer or director prior to the letter of exemption and indemnification becoming effective.</div>
    <div style="line-height: 1.25;">&#160;&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">II - 3</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Item 9. Exhibits.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The following exhibits are filed with this Registration Statement.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The agreements included or incorporated by reference as exhibits to this registration statement contain representations and warranties by each of the parties to the applicable agreement. These
      representations and warranties were made solely for the benefit of the other parties to the applicable agreement and (i) were not intended to be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the
      parties if those statements prove to be inaccurate; (ii) may have been qualified in such agreement by disclosures that were made to the other party in connection with the negotiation of the applicable agreement; (iii) may apply contract standards of
      &#8220;materiality&#8221; that are different from &#8220;materiality&#8221; under the applicable securities laws; and (iv) were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The undersigned registrant acknowledges that, notwithstanding the inclusion of the foregoing cautionary statements, it is responsible for considering whether additional specific disclosures of
      material information regarding material contractual provisions are required to make the statements in this registration statement not misleading.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zd82303f0f87d48c899e52f1ca6d26b5b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 13.1%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; font-weight: bold;"><u>Exhibit Number</u></div>
          </td>
          <td style="width: 86.9%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;"><u>Description of Document</u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.1%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 86.9%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 13.1%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">5.1</a></div>
          </td>
          <td style="width: 86.9%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">Opinion of Goldfarb Gross Seligman &amp; Co., Israeli legal counsel to the Registrant, re legality
                (including consent).</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.1%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;"><a href="exhibit_5-2.htm">5.2</a></div>
          </td>
          <td style="width: 86.9%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;"><a href="exhibit_5-2.htm">Opinion of Haynes and Boone, LLP, U.S. legal counsel to the registrant.</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.1%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;"><a href="exhibit_23-1.htm">23.1</a></div>
          </td>
          <td style="width: 86.9%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;"><a href="exhibit_23-1.htm">Consent of Kesselman &amp; Kesselman, Certified Public Accountant (Isr.), a member of
                PricewaterhouseCoopers International Limited, independent registered public accounting firm for the Registrant.</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.1%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">23.2</a></div>
          </td>
          <td style="width: 86.9%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;"><a href="exhibit_5-1.htm">Consent of Goldfarb Gross Seligman &amp; Co. (included in Exhibit 5.1).</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.1%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;"><a href="exhibit_5-2.htm">23.3</a></div>
          </td>
          <td style="width: 86.9%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;"><a href="exhibit_5-2.htm">Consent of Haynes and Boone, LLP (included in Exhibit 5.2).</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.1%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;"><a href="#POWER">24.1</a></div>
          </td>
          <td style="width: 86.9%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;"><a href="#POWER">Powers of Attorney (included in the signature page to Registration Statement)</a></div>
          </td>
        </tr>
        <tr>
          <td style="width: 13.1%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;"><a href="exhibit_107.htm">107</a></div>
          </td>
          <td style="width: 86.19%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;"><a href="exhibit_107.htm">Filing Fees</a></div>
          </td>
          <td style="width: 0.71%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Item 10. Undertakings.</div>
    <div style="text-align: justify; text-indent: -4.5pt; margin-left: 4.5pt; line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25;">The undersigned Registrant hereby undertakes:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(a)(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(i) to include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(ii) to reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which,
      individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of
      securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the
      aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(iii) to include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information
      in the registration statement;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;"><font style="font-style: italic;">provided</font><font style="font-family: 'Times New Roman',Times,serif;">, <font style="font-style: italic;">however</font>, that paragraphs
        (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section
        13 or 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.</font></div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">II - 4</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 31.5pt; line-height: 1.25;">(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement
      relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
    <div style="text-align: justify; text-indent: 31.5pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 31.5pt; line-height: 1.25;">(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 31.5pt; line-height: 1.25;">(4) to file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A of Form 20-F at the start of any delayed offering or
      throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3) of the Act need not be furnished, <font style="font-style: italic;">provided</font> that the registrant includes in the prospectus, by
      means of a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information in the prospectus is at least as current as the date of those financial
      statements. Notwithstanding the foregoing, with respect to registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Act or Item 8.A of Form
      20-F if such financial statements and information are contained in periodic reports filed with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by
      reference in the Form F-3.&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; text-indent: 31.5pt; line-height: 1.25;">(5) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(i) If the registrant is relying on Rule 430B (&#167;230.430B of this chapter):</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt; line-height: 1.25;">(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed
      prospectus was deemed part of and included in the registration statement; and</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; margin-left: 36pt; line-height: 1.25;">(B) Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to
      an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the
      earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any
      person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such
      securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or
      deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was
      made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date.</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">(6) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the
      undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
      are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</div>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">II - 5</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on
      behalf of the undersigned registrant; and</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; text-indent: 72pt; line-height: 1.25;">(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability of the registrant under the Securities Act of 1933, each filing of the registrant&#8217;s annual report
      pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan&#8217;s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated
      by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
    <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
      provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event
      that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or
      proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a
      court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">II - 6</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> &#160; SIGNATURES</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has
      duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Tel Aviv, Israel, on August 4, 2023.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="zcbe57b72fff34488a202023c5186f5bc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">REDHILL BIOPHARMA, LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 46.14%; vertical-align: top; border-bottom: 2px solid black; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Dror Ben-Asher</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Name:</div>
          </td>
          <td style="width: 46.14%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Dror Ben-Asher</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Title:</div>
          </td>
          <td style="width: 46.14%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Executive Officer and Director</div>
          </td>
        </tr>

    </table>
    <div style="text-align: justify; line-height: 1.25;">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="POWER"><!--Anchor--></a>POWER OF ATTORNEY</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">KNOW ALL PERSONS BY THESE PRESENTS, each director and officer whose signature appears below constitutes and appoints, Dror Ben-Asher or Razi Ingber, or either of these, his true and lawful
      attorney-in-fact and agent, with full power of substitution and re-substitution, to sign in any and all capacities any and all amendments or post-effective amendments to this registration statement on Form F-3, and to sign any and all additional
      registration statements relating to the same offering of securities of the Registration Statement that are filed pursuant to Rule 462(b) of the Securities Act, and to file the same with all exhibits thereto and other documents in connection therewith
      with the Securities and Exchange Commission, granting such attorney-in-fact and agent full power and authority to do all such other acts and execute all such other documents as he may deem necessary or desirable in connection with the foregoing, as
      fully as the undersigned may or could do in person, hereby ratifying and confirming all that such attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</div>
    <div style="text-align: center; line-height: 1.25;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z8015bbe8ff9943f6958366d98599da1e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td nowrap="nowrap" style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Signature</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Title</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 21%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">Date</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Dror Ben-Asher</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Chief Executive Officer and Director</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">August 4, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Dror Ben-Asher</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">(Principal Executive Officer)</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Razi Ingber</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Chief Financial Officer</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">August 4, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Razi Ingber</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">(Principal Financial Officer and Principal Accounting Officer)</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Ofer Tsimchi</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Chairman of the Board of Directors</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">August 4, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Ofer Tsimchi</div>
          </td>
          <td style="width: 47%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Shmuel Cabilly</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 21%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">August 4, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Shmuel Cabilly</div>
          </td>
          <td style="width: 47%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">&#160;</td>
          <td style="width: 23%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 47%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">&#160;</td>
          <td style="width: 23%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Dr. Kenneth Reed</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">August 4, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Dr. Kenneth Reed</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 47%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 23%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;" colspan="2">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Eric Swenden</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">August 4, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Eric Swenden</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Alla Felder</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Director</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">August 4, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Alla Felder</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; font-style: italic;">/s/ Rick Scruggs</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Director and Chief Commercial Officer</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">August 4, 2023</div>
          </td>
        </tr>
        <tr>
          <td style="width: 30%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">Rick Scruggs</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 45%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 2%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td nowrap="nowrap" style="width: 21%; vertical-align: bottom; font-family: 'Times New Roman',Times,serif;">
            <div style="text-align: center; line-height: 1.25;">&#160;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: center; line-height: 1.25; color: #000000; font-weight: bold;">Signature of authorized representative in the United States</div>
      <div style="text-align: center; line-height: 1.25; color: #000000;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-indent: 35.45pt; line-height: 1.25;"><font style="color: #000000;">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant&#8217;s duly authorized representative has signed this Registration Statement on Form
          F-3 on this 4th day of&#160;</font><font style="font-family: 'Times New Roman',Times,serif;">August<font style="color: rgb(0, 0, 0);"> 2023.</font></font></div>
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" id="ze5db9069a5fb44f1a946979c9de057e0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25; color: #000000; font-weight: bold;">REDHILL BIOPHARMA INC.</div>
            <div style="line-height: 1.25; color: #000000;">Authorized U.S. Representative</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
          <td style="width: 50%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle; font-family: 'Times New Roman',Times,serif;">
            <div style="line-height: 1.25; color: rgb(0, 0, 0);">&#160;</div>
          </td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25; color: #000000;">By:&#160;<u><font style="font-style: italic;">/s/ Rick Scruggs</font></u></div>
            <div style="line-height: 1.25; color: #000000;">Name: Rick Scruggs</div>
            <div style="line-height: 1.25; color: #000000;">Title: President &amp; Chief Commercial Officer</div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>exhibit_5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="margin-left: 5.95pt; line-height: 1.25;">
      <div style="font-family: 'Times New Roman',Times,serif;">
        <hr align="center" style="border-width: 4px medium 1px; border-style: solid none; border-color: black -moz-use-text-color; -moz-border-top-colors: none; -moz-border-right-colors: none; -moz-border-bottom-colors: none; -moz-border-left-colors: none; border-image: none; height: 10px; color: rgb(255, 255, 255); background-color: rgb(255, 255, 255); text-align: center; margin-left: auto; margin-right: auto;"></div>
      <div>
        <div>
          <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u>Exhibit 5.1</u></div>
        </div>
        <br>
      </div>
      <div style="text-align: center;"><img width="713" height="107" src="image0.jpg"></div>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Tel-Aviv, August 4, 2023</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">RedHill Biopharma Ltd. </div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">21 Ha'arba'a St.</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Tel Aviv 6473921 <u></u></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;"><u>Israel</u></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Re: <u>Registration on Form F-3</u></div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Ladies and Gentlemen:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; We have acted as Israeli counsel to RedHill Biopharma Ltd., an Israeli company organized under the laws of the State of Israel (the
      &#8220;Company&#8221;), in connection with the preparation and filing of a Registration Statement on Form F-3 (the &#8220;Registration Statement&#8221;) under the Securities Act of 1933, as amended (the &#8220;Act&#8221;), to be filed with the Securities and Exchange Commission. The
      Registration Statement relates to the proposed resale by the selling shareholders named in the Registration Statement of up to an aggregate of 1,998,221 American Depositary Shares (the "ADSs") each representing 400 ordinary shares, par value NIS 0.01
      per share, of the Company (the &#8220;Ordinary Shares&#8221;), issuable upon exercise of warrants to purchase ADSs (&#8220;Warrants&#8221;) issued by the Company to the selling shareholders as described in the Registration Statement and the prospectus contained therein. The
      ADSs may be sold from time to time as set forth in the Registration Statement and the prospectus contained therein.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; In connection with this opinion, we have examined and relied upon the Registration Statement, the Company&#8217;s Amended and Restated Articles
      of Association, and such statutes, regulations, corporate records, documents, certificates and such other instruments that we have deemed relevant and necessary for the basis of our opinions hereinafter expressed. In such examination, we have
      assumed: (i) the authenticity of original documents and the genuineness of all signatures; (ii) the conformity to the originals of all documents submitted to us as copies; (iii) the truth, accuracy and completeness of the information, representations
      and warranties contained in the corporate records, documents, certificates and instruments we have reviewed; (iv) the due execution and delivery of all documents where due execution and delivery are a prerequisite to the effectiveness thereof; and
      (v) the legal capacity of all natural persons.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; We are members of the Israel Bar, and we express no opinion as to any matter relating to the laws of any jurisdiction other than the laws
      of the State of Israel and have not, for the purpose of giving this opinion, made any investigation of the laws of any other jurisdiction than the State of Israel. The opinions set forth herein are made as of the date hereof. We assume no obligation
      to revise or supplement any of these opinions to reflect any changes of law or fact that may occur after the date hereof. This opinion is expressly limited to the matters set forth above, and we render no opinion, whether by implication or otherwise,
      as to any other matters.</div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; On the basis of the foregoing, and in reliance thereon, we are of the opinion that the ordinary shares underlying the ADSs being
      registered pursuant to the Registration Statement have been duly authorized by the Company and, when issued upon exercise of the Warrants in</div>
    <br>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; accordance with their terms and payment of the exercise price for the ADSs thereunder, will be validly issued, fully paid and non-assessable.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not admit that
      we are &#8220;experts&#8221; within the meaning of such term as used in the Securities Act, or the rules and regulations of the Commission issued thereunder with respect to any part of the Registration Statement, including this opinion as an exhibit or
      otherwise.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <table cellspacing="0" cellpadding="0" border="0" id="z8f08d01259024ea18878b5e0e36e31ea" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; color: rgb(0, 0, 0); width: 100%;">

          <tr>
            <td style="width: 50%;">
              <div>&#160;</div>
            </td>
            <td style="width: 50%;">
              <div>
                <div style="text-align: left; line-height: 1.25;">Very truly yours,</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: left; line-height: 1.25; font-style: italic;">/s/ Goldfarb Gross Seligman &amp; Co.</div>
              </div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;">&#160;</div>
    <div style="line-height: 1.25; text-align: center;"><img width="643" border="0" height="77" src="image00002.jpg"> </div>
    <br>
    <hr align="center" style="border-width: 1px medium 4px; border-style: solid none; border-color: black -moz-use-text-color; -moz-border-top-colors: none; -moz-border-right-colors: none; -moz-border-bottom-colors: none; -moz-border-left-colors: none; border-image: none; height: 10px; color: rgb(255, 255, 255); background-color: rgb(255, 255, 255); text-align: center; margin-left: auto; margin-right: auto;">
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.2
<SEQUENCE>3
<FILENAME>exhibit_5-2.htm
<DESCRIPTION>EXHIBIT 5.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;"><u>Exhibit 5.2</u></div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25;">Haynes and Boone, LLP</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">August 4, 2023</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">RedHill Biopharma Ltd.</div>
      <div style="line-height: 1.25;">21 Ha'arba'a Street</div>
      <div style="line-height: 1.25;">Tel Aviv, 64739</div>
      <div style="line-height: 1.25;">Israel</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Ladies and Gentlemen:</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We have acted as special U.S. counsel to RedHill Biopharma Ltd., a company limited by shares organized under the
        laws of the State of Israel (the &#8220;<font style="font-weight: bold; font-style: italic;">Company</font>&#8221;), in connection with the offering by certain selling stockholders of up to an
        aggregate of 1,998,221 American Depositary Shares (the &#8220;<font style="font-weight: bold; font-style: italic;">ADSs</font>&#8221;), each ADS representing four hundred (400) ordinary shares of
        the Company, NIS 0.01 par value per share (the &#8220;<font style="font-weight: bold; font-style: italic;">Ordinary Shares</font>&#8221;), issuable upon the exercise of (i) warrants to purchase up
        to 330,106 ADSs, issued on May 11, 2022; (ii) warrants to purchase up to 1,500,000 ADSs, issued on July 25, 2023; (iii) warrants to purchase up to 90,000 ADS, issued on July 25, 2023; and (iv) warrants to purchase up to 78,115 ADS, issued on July
        25, 2023 (collectively, the &#8220;<font style="font-weight: bold; font-style: italic;">Warrants</font>&#8221;), pursuant to the registration statement on Form F-3 (the &#8220;<font style="font-weight: bold; font-style: italic;">Registration Statement</font>&#8221;) filed with the Securities and Exchange Commission (the &#8220;<font style="font-weight: bold; font-style: italic;">Commission</font>&#8221;) under the Securities Act of 1933, as amended (the &#8220;<font style="font-weight: bold; font-style: italic;">Securities
          Act</font>&#8221;), on August 4, 2023. The ADSs will be issued pursuant to a Deposit Agreement dated as of December 26, 2012 (the &#8220;<font style="font-weight: bold; font-style: italic;">Deposit
          Agreement</font>&#8221;) among the Company, The Bank of New York Mellon, as depositary (the &#8220;<font style="font-weight: bold; font-style: italic;">Depositary</font>&#8221;), and all Owners and
        Holders (each as defined therein) from time to time of ADSs of the Company issued thereunder.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In connection with this opinion, we have examined such corporate records, documents, instruments, certificates of
        public officials and of the Company, including the Warrants, and such questions of law as we have deemed necessary for the purpose of rendering the opinions set forth herein.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">In such examination, we have assumed the genuineness of all signatures and the authenticity of all items submitted
        to us as originals and the conformity with originals of all items submitted to us as copies.&#160;&#160; We have also assumed that the Warrants have been duly authorized and executed by the Company and delivered against payment in full of the consideration
        payable therefor.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Based on the foregoing, and subject to the further assumptions and qualifications set forth below, it is our
        opinion that the ADSs, when issued in accordance with the terms of the Warrants and the Deposit Agreement against the deposit of duly authorized, validly issued, fully paid and non-assessable Ordinary Shares, such ADSs will be duly and validly
        issued under the Deposit Agreement and will entitle the holders thereof to the rights specified therein.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Please note that we are opining only as to the matters expressly set forth herein, that no opinion should be
        inferred as to any other matter. We are opining herein as to the laws of the State of New York as in effect on the date hereof, and we express no opinion with respect to any other laws, rules or regulations. This opinion is based upon currently
        existing laws, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth
        herein. In rendering the foregoing opinions, we have relied, for matters involving Israeli law, solely on the opinion of Goldfarb Gross Seligman &amp; Co., Israeli counsel to the Company.</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This opinion is being rendered solely in connection with the registration of the offering and sale of the ADSs,
        pursuant to the registration requirements of the Securities Act.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">We hereby consent to the use of this opinion as Exhibit 5.2 to the Registration Statement, and to the reference to
        us under the caption &#8220;Legal Matters&#8221; in the base prospectus included in the Registration Statement. In giving such consent, we do not hereby admit that we are acting within the category of persons whose consent is required under Section 7 of the
        Securities Act or the rules or regulations of the Commission thereunder. This opinion is given as of the date hereof and we assume no obligation to update or supplement such opinion to reflect any facts or circumstances that may hereafter come to
        our attention or any changes that may hereafter occur.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <table cellspacing="0" cellpadding="0" border="0" id="z4f0c32721e3c4f0ea674eb25647fb12d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

            <tr>
              <td style="width: 50.00%;">
                <div>&#160;</div>
              </td>
              <td style="width: 50%;">
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Very truly yours,</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic;">/s/ Haynes and Boone, LLP</div>
                <div style="line-height: 1.25;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Haynes and Boone, LLP</div>
              </td>
            </tr>

        </table>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>exhibit_23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
      <div style="text-align: right;"><font style="font-weight: bold;"><u> Exhibit 23.1</u></font></div>
      <div style="text-align: right;"><br>
      </div>
      <img src="image00001.jpg"></div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">&#160;<font style="font-weight: bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div>
    <div style="line-height: 1.25;"><font style="font-weight: bold;"> <br>
      </font></div>
    <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">We hereby consent to the incorporation by reference in this Registration Statement on Form F-3 of RedHill Biopharma Ltd. of our
      report dated April 28, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in RedHill Biopharma Ltd.&#8217;s Annual Report on Form 20-F for the year ended December 31, 2022. We also
      consent to the reference to us under the heading &#8220;Experts&#8221; in such Registration Statement.</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">/s/ Kesselman &amp; Kesselman</div>
    <div style="line-height: 1.25;">Certified Public Accountants (Isr.)</div>
    <div style="line-height: 1.25;">A member firm of PricewaterhouseCoopers International Limited</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;">Tel-Aviv, Israel</div>
    <div style="line-height: 1.25;">August 4, 2023</div>
    <div style="line-height: 1.25;"> <br>
    </div>
    <div style="line-height: 1.25;"><br>
      <hr noshade="noshade" align="center" style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 1px; color: #000000; text-align: center;"></div>
    <div style="line-height: 1.25; font-style: italic;">Kesselman &amp; Kesselman, Derech Menachem Begin 146 Tel Aviv-Yafo 6492103 Israel,</div>
    <div style="line-height: 1.25; font-style: italic;">P.O Box 7187 Tel-Aviv 6107120 Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il</div>
    <div style="line-height: 1.25; font-style: italic;"> <br>
    </div>
    <div style="line-height: 1.25; font-style: italic;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>5
<FILENAME>exhibit_107.htm
<DESCRIPTION>FILING FEES TABLE
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 23.7.1.5162
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">
      <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
    <div style="text-align: right; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><u> Exhibit 107</u><br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">CALCULATION OF FILING FEE TABLE</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">Form F-3</div>
    <div style="text-align: center; line-height: 1.25;">(Form Type)</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-weight: bold;">REDHILL BIOPHARMA LTD.</div>
    <div style="text-align: center; line-height: 1.25;">(Exact Name of Registrant as Specified in its Charter)</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: center; line-height: 1.25;"><u>Table 1: Newly Registered and Carry Forward Securities</u></div>
    <div style="line-height: 1.25">&#160;</div>
    <table cellspacing="0" cellpadding="1" border="0" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);" id="z453deb3dce4a421aa361a207713ab162">

        <tr>
          <td style="width: 8%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Security Type</div>
          </td>
          <td style="width: 8%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Security Class Title<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(2)(3)</sup></div>
          </td>
          <td style="width: 7.81%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Fee Calculation Rule</div>
          </td>
          <td style="width: 9.4%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Amount Registered<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(1)(3)</sup></div>
          </td>
          <td style="width: 8%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Proposed Maximum Offering Price Per Unit<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div>
          </td>
          <td style="width: 8%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Maximum Aggregate Offering Price<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(4)</sup></div>
          </td>
          <td style="width: 8.26%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Fee Rate</div>
          </td>
          <td style="width: 8.22%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Amount of Registration Fee<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">(5)</sup></div>
          </td>
          <td style="width: 6.39%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Carry Forward Form Type</div>
          </td>
          <td style="width: 7%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Carry Forward File Number</div>
          </td>
          <td style="width: 6.39%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Carry Forward Initial effective date</div>
          </td>
          <td style="width: 7.74%; vertical-align: bottom; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward</div>
          </td>
        </tr>
        <tr>
          <td colspan="9" style="vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Newly Registered Securities</div>
          </td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.74%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Fees to Be Paid</div>
          </td>
          <td style="width: 8%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Equity</div>
          </td>
          <td style="width: 8%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Ordinary Shares, par value NIS 0.01 per share</div>
          </td>
          <td style="width: 7.81%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">457(c)</div>
          </td>
          <td style="width: 9.4%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">799,288,400</div>
          </td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">$0.00289</div>
          </td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">$2,317,936.36</div>
          </td>
          <td style="width: 8.26%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; text-align: center;">0.0001102</div>
          </td>
          <td style="width: 8.22%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">$255.44</div>
          </td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.74%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Fees Previously Paid</div>
          </td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.81%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 9.4%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.26%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.22%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.74%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td colspan="9" style="vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Carry Forward Securities</div>
          </td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.74%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Carry Forward Securities</div>
          </td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#8212;</div>
          </td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#8212;</div>
          </td>
          <td style="width: 7.81%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#8212;</div>
          </td>
          <td style="width: 9.4%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#8212;</div>
          </td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#8212;</div>
          </td>
          <td style="width: 8.26%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.22%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.39%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#8212;</div>
          </td>
          <td style="width: 7%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#8212;</div>
          </td>
          <td style="width: 6.39%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#8212;</div>
          </td>
          <td style="width: 7.74%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">&#8212;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td colspan="4" style="vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.26%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.22%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.74%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td colspan="4" style="vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Total Offering Amounts</div>
          </td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">$2,317,936.36</div>
          </td>
          <td style="width: 8.26%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.22%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">$255.44</div>
          </td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.74%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td colspan="4" style="vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Total Fees Previously Paid</div>
          </td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.26%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.22%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">$0.00</div>
          </td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.74%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td colspan="4" style="vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Total Fee Offsets</div>
          </td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.26%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.22%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">$0.00</div>
          </td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.74%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);">&#160;</td>
        </tr>
        <tr>
          <td style="width: 8%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td colspan="4" style="vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">Net Fee Due</div>
          </td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.26%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 8.22%; vertical-align: middle; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">
            <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">$255.44</div>
          </td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 6.39%; vertical-align: top; border-top: 1px solid rgb(0, 0, 0); border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
          <td style="width: 7.74%; vertical-align: top; border-width: 1px; border-style: solid; border-color: rgb(0, 0, 0);">&#160;</td>
        </tr>

    </table>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25">
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd49335e00cef4678a122c1a62b31efa6">

          <tr>
            <td style="width: 18pt; vertical-align: top;">(1)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the American Depositary Shares (&#8220;ADSs&#8221;) representing ordinary shares offered hereby also include an indeterminate number of additional ordinary
                shares and ADSs as may from time to time become issuable by reason of stock splits, stock dividends, recapitalizations or other transactions. In addition, up to 1,998,221 ADSs, representing 799,288,400 ordinary shares, may be sold from time
                to time pursuant to this registration statement by the selling shareholders named herein.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zaaa5835211b84d0d874e27edbc4c6b28">

          <tr>
            <td style="width: 18pt; vertical-align: top;">(2)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>ADSs evidenced by American depositary receipts issuable upon deposit of the ordinary shares being registered hereby have been registered pursuant to a separate registration statement on Form F-6 (File No. 333-185302). Each ADS represents
                four hundred (400) ordinary shares.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zffeb79751817469692be0db1fcf5de2d">

          <tr>
            <td style="width: 18pt; vertical-align: top;">(3)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Represents ordinary shares represented by ADSs registered for resale by the selling shareholders described herein. Pursuant to Rule 416(a) under the Securities Act, this registration statement shall also cover an indeterminate amount and
                number of ordinary shares as may be issued upon conversion, exchange, exercise or settlement of any other securities that provide for such conversion, exchange, exercise or settlement.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z16f6e89e52354a74af1d8abea2d880cf">

          <tr>
            <td style="width: 18pt; vertical-align: top;">(4)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Estimated solely for the purpose of computing the amount of the registration fee for the ADSs being registered in accordance with Rule 457(c) under the Securities Act based upon a proposed maximum aggregate offering price per unit of
                $1.16 per ADS (equivalent to $0.00289 per ordinary share), the average of the high and low prices of the ADSs of the registrant as reported on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) on August 2, 2023, which such date is within five business
                days of the filing of this registration statement.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0c17074e4ff64cf48ef18b294b0438e5">

          <tr>
            <td style="width: 18pt; vertical-align: top;">(5)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant does not have any fee offsets.</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
      <br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0V!W\# 2(  A$! Q$!_\0
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MZ4T_2F@$I#TZTM(>F<4Q#?QIISSS3OPIA^E(0V@]>M+2'KTJD,;2'-+2'Z4
M)^-!Z=:/PH/3I0 W\:.?6C\*/?% "'.,YZ4G]*4^N*3^E,D3\:***8A#UZTA
M^OUI3UZ4A^G6@8W\?\]Z.?6C\*/PH$'/K33UZTOX"D/7I0 E)2T4#$IOXTZF
M_A0@0<^M-IWX4VF2Q#GUI.?6E;Z4G?H* $Y]::?K2_A2'Z4T <^M-_&E_"D]
M\4P$.<]:3GUI3UZ4G/I0 $GU]Z3\:4_2D_"@3$YQUH_&CMT%'X4"&GKUIIZ4
MX]>E-/3I30P_&D[4OX4G:@ IIZ]:=3>_2@0ASC[PIM..<=!3:8P[]:3MU[4O
M?I2=NG:D ASGKS2'., ^U*>O2@Y Z>U- -_&BC\**8A.?6D/U]J7\*0_2@0F
M3US[TW\:=^%-H&(<^HI#G'6E.?04AZ=* $IISGK3OPIIZ]*:$&3_ 'A36^N:
M=@_W133]*8!^--_&G4W\* $.?6D_&E/TI*:$P_&F]^M._"FGKTIB$.<=:;2G
M..@I*!B<^OO2'I2]^E(>E A.?7_(IOXT[\*;^%( Y]:/QH_"C\*: 0YQUIM.
M/3I3:8F)SGK2'I2]^E(>E !SGK3:=WZ4V@!#GUQ1S_>%!^F:,'^Z*: 9^-=-
MX4!\FZ;/&\#^M<S^%=3X4!-I<#'68?\ H-!,]CGM3.=6O"#UG?\ F:J58O\
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M5X9@,_,V$%=Y#$+:WAMP>(E"?U_K5T]3.;)"<\D'D4M-SQ][M3JU,6%%%%(
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MSS3CUZTT].M Q/P-%'X_Y-'XT )QZ&FGK3L^]-/7K0(****!B=J93^U-_&A
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M,_Z+<\])A_(4$SV.:O/^/ZXS_P ]6Q^9J ^GX5/>?\?UQS_RU;'YFH#Z9]J
MZ!^!IE/_ !IG3OS0!B]^W/\ 6D]^.F:/PH]\>]?&'U0O(/;@_P J3MCCIBCO
MTH_#M0 O)/;G^M)^73-'?I1^% "\@]N#_*D[=NF*/PHQQT[4 +^77^=)VSQZ
MT?A1^% "\CTX_I2?ETQ1^%';IVH 7\O_ -=)S[4?A1VZ4 R>RA-U=PP\8=N?
MH*[8C)XQQ\OX5SGARW#W,MP5^5$V+]>:Z,=.E85'=V-$'Y4O]*3\**R&'Y4?
MY_.C';%% !^5'^?RH_"B@ ]N*.O^?6C'M10 ?EZTOY4GX4OX4NH%S2(!<ZM
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MQH[]:8!QD]:3CWI3UZT?C0 G'O3J3\:=^- !111^- !111^- !WH_.BES[T
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ML+ ?WN])_9_O5O*CBEWKCI0!4&G!OXJ7^S0/XN:N!U)_6C*T 4?[+']ZE&E
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MPK/QP1CG%;_AJ$'[5<%><>6I^O6JCN3/8Z'G&3C-'Y4O?FDP*V3T.<6BBBD
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MHI;"8W<9.#U^E=)X6A @FNL?-(P1/H*YIV*QL0>@-=QIR+::3;J,#9&9"?\
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MJ]K"!-9NL?Q,K?FH/]:H_@::*6P*AD=$ 'S,%_,BNQUR7[)HTX3@G$:_F?\
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M9$;?3+:/C[@)^IYJY6\=CFEN'XT444Q!1110 ?C1110 4444 %%%% !1110
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M#D?>[4T>E.&?;I5(0_\ &E[=:2EYQVS5(3'4\4VG"FA,****H04AZ4M(>G%
M#?Q[TT].M._*FGIVJB1I^M,;ZT\_A3&_"F,C_&D/WNM.IIZ\8H$QA^M1_C4A
M]*CIDC>_6F$\]:?W[8IASGM30"?C4;=>3]:DY]JC;D_7BF#(VZ=>>M-I[<C/
MXTRJ ;Z\TP]^:?ZTTY]J8#<^]-/7K3ORIIZ]J"6-/7K3#UX-/.<]J8>M" :<
M9ZU$>G6I3U[5$>GTJB6-II/OZTZFG/J.] AAZ=::>O6GFFGKV]:H9'VZTT_6
MG]NU,/X4T E(>G6EI#T[4Q#?QIA^M/--.?:D(90>O6EI#U[52&-I#]:6D.:
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M_.CCW[TQ"'Z4G]*4_C24"$_"BBBF(0]>E(?IUH/7O2'&,<\T#$_"C\*./?\
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M\_ZK'Y$UC'KWIK82V-GPRI_M*X8#_EAC]4_^O^=5=?PVN7  X 0#V^05?\+
M&:Z;GA%'YM_]:LS6FW:W='G.Y0/^^5H8=2AWZ4AI>.V:0T##_@--I>,]Z;3
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M\: #O2_A2=Z/SH 7\*?3/Q-/IB"BBB@04444 % ^E% H 7MTH YZ4E+WZFF
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MU?R>F3Z4[/H3S[4 S._L#3?^>+_G2?V!IO\ SR?\ZT]WN?RI@SZFFB;LS_[
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M[9Q]*+BN9/\ PC.DX_U+_G6OHVD65I!*L"E0T@8Y/?%,)R._Y5>T\$I)]?\
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MFI.O:HVX.,=.:8,8W Q^%,I[<#&*95 -_*FGOR*=^%,([8I@)SZBFGKVIW_
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M0M%'X44AA1110 44?A10 4444 %%'X44 %%%% !1110 4444 %%%% !1110
M4444 (>AI1^%(>AXI1TZ4 +_ )_*EY]J3\*7\* #\J.?:C\*/PIH Y]J.<]J
M/PH[]*8 <Y[4<^U!Z]*/PH$'/M3J;^%._"@8444?A0 444?A0 4OY4E+^% !
MS[<4^F?A3Z8@HHHH$%%%% !0**!UZ4 +^5'.>WI1^% Z]*8"_P"?\*7\J2C'
M;%(!:7GVS2?A1^%4,<.E.&?:FCITI1]* '4[GVIOX4[\*"0&<&G=^W6FCZ4N
M.>E4 ?X4]<X[=:8/7'O3QTZ4Q,4=>U._K_6F]3TIWX4"#MVI_/M3/PIWX52
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M'KVI:0]>G>@0ASCM3:<>GW>U-IC#OVZTG;\*7\*3KVI (<YH.0./I0>O2D/
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M0_WA46<\YQGG%>=)<KLSLB[H*6D'UI:D84444 %%%% !1110 4444 %)2T4
M%%%% !1110 4444 %%%% "'I2C&,<TAZ=:4=.M !^?\ GK3N.O-)^-+GWH /
MSHX]Z/QH_&F@#\Z3C/>E_&COUI@!Z]Z./4T=^M'XT"$X]33J3\:=0,***/QH
M **** #O2\>])2_C0 =?7TIU-_'K3J"1:***8!1110 4"B@?6@!>/>@=>]'X
MT \YS[TP%H]N:*.?6D OY_\ ZZ..O-'XT9[Y]ZH8X<"E&/>D'3K_ )%*/K0
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M 0X]^*2E/UH_&@3')]WO3#^-/3[O6F'ZT"&]^]-/2G'KUIIZ=::&%)2_C24
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M@=>@]:3\*4#)Z4P%I>?2DH_"D O^?\*7\!2?A1@>AJACATIP^@IHZ=*4?0T
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M9DE'WG)R"*&Q/8\\N_"FL/>3R+''M,C$<^IJ$^$]9/\ RSC_ #KOY3B:09.
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M2]^M'Y4#.>H]*8"T9[YHI?Q%( _'_(H_$T?C1SZC-4,<.1UI1]:0=*<,^HH
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MN_2F]N].XSWIH!P^F?>G#./N]J:/UI0>.AZ52$/_  IW;IUIM.[=^:I"8_\
M"G"F4X4T)BT4450@I#TI:0]#0 W\*:?I2_G2&J)&GZ4QOI3S^-,;'O3&,IIZ
M]*6D.,]Z!,C;/3%,_"GM3*9(WOT_&F'KTIYZ]\TP_C30"?A4;<GIUXJ3\ZC;
MKQ^%,&,;GG'>F4YO;UIM4 WUXIA[\4ZFG'/6F F/:FGKTIW'O33C/?F@EC3G
M/3WJ-ASTJ0GGO49'/?BF@&_A49Z=/>I".<<U'V[^M,EB4PCV]:=3#CGKWH$-
M/3IFD/7I2FFG&>]4,9SCI33]*=VIIQ[TT E(>F<4M-/3O3$)CVIA^GK3Z8<>
M_>D(;0>O2B@XSWJD,;2'Z4M(: $_"@].E%(?QH 3'M1^'O1^=''OWIB$/TI/
MZ4I_&DH$)^%%%%,0AZ]*0].G6E/7O33C&.>:!B?A1^%'Y_\ ZZ* $Q[4AZTO
M'O2'K0(2BBB@8E-_"G4RA +SZ4VE_.DIDB'Z4GX4K8]Z3C/>@!OX4A^E+Q[T
MAIH!/PI/PI>/>CBF T]>E)SZ4IZ]Z3WYH 0_2C\*#CWXI*!,D3[O2HS]*>F-
MO>F'\:!#3UZ4T].GO3N,]Z:>E-##\*2EI.U "4G?I2TAZ]^M A#G'W:;3CC'
M0]*;3&'X4G;IVI?SI.OX_P!:0"'KTH.0.E!Z]Z0G S30"?A11@>_I13$)^%3
M6F?ML/'\8J'\ZFM/^/V$\_?% BSJ_6#CL:S*T]6QF#KT-9E Q#]*0].E*<>]
M(>G>@!/PIIZ]*=33U[TT(,?[(II^F*7CT-(?QI@'X4W\*6D_.@!#UZ4F..G:
ME[YYYI#T]Z!,Z+PS%^[N[@#EV6/\,<_TJIXHNA+>I9@?);K\Q]3U_K6QX:B5
M-%C)X\UV)_/_  45R5Q.;JXEF;DRN7/X\TK:B(3G&&'S4GX4IQCO258Q/PI#
MTZ4O'O2&@0G/I5_1?^0S:X'\1_E5#\ZO:+C^V;7K]X_RI"9<\3_\?-J0/^61
M_G6&>O3O6YXGXN;7'_/$_P ZPCU[]:%L$=CH_"WW+KC^)/Y&L74_^0K=\?\
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M&._%,D>O..*>/IBF+VIX_&@D=VZ4[OTIO;O3N,]ZI .'TS[TX#CICC%-'6E
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M%&?KZT4R6)^%36@_TV'C^,<U#^=36G_'[".?OB@99U?_ )8<=C69^%:6K_\
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ME1T_SZ5Y>QZ ?C1_G\Z/;\** #\?>BBEZ?Y]* $_&EI/;\*.V>QI,:-'P_J
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M&#K][)QO2URI]F?!'Y5V?B]PG@[523\_D!1]"Z#^1KD?AD!_:.I,1C]RJ_\
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M-1JRY5BY5ASMJ0#8 $&2HVA?[U-":'C&,[ACUIP/)&>E-_U>=T8$8'/TIPZ
MD?,1S]*:W):LQXZ=:=WZCK31G'2G=^@JD(</K3@?<=*:/7&?>G <=!5(0[M3
MO7FD[=.E+^'2J0F/I124HZ4T)BT4450@I#2TAH ;^---._"FGZ51(T_6F-]1
M3S]*8P]J8QG:FG.[K3NU-/WNE F,8]ZC_&I#ZXJ/\*9(W\:8>O44_OG%,/7I
M30"?B*C;@]>G-2=>WO4;<'&.G-,&,;@8S[4RGMP,4RJ ;^--/?D4[\*81U&*
M8"<^HIIZ]:=^ IIZXQ[4$L0GFL/Q6<>%]19N56-2P]0'4G],UMGD]*P_%O\
MR*>J<?\ +$?^A"JA\2)EL>5:8#_:^F@GYA=1*3]'7_"O:G<Y.,=:\6TS_D-:
M?Q_R]Q_^AK7L[Y&>*Z<3>Z,J/43>1Z4QF//2G'KTIA]<5S:FUD-W-CM2;B6'
M2E/3I3?XP,4XWN(\BU3=_:]\1R?M+\?C_P#6KT+PT2?#5B>GRMQ_P-C_ %KS
MS4\+K%^2^U3<L=P/3DUZ#X7.[PMIS8SF-N?7YVKJJN\48TU:3+6L?\@/4?\
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M.>.*3%25H&\^WY4F3[4?A1^%";#0-Q]N]-+-W(I::?IFG=AH&3ZBC+>HI/\
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MKP6[ML]B.U@[=^E'?_/X49XZT4AAQ[T4?C10 =N_2C_/^%'XT4 ''O11^-%
M"-]PY!Z5] 6)W6,!]8U/_CHKY^?F-N>JFO?]+_Y!5F?^F"?^@BO0P&[.+&="
MW7G4RXGF7TD8?D37HM>?ZBGEZG=1@])F_7#5MBUHF8T'K8@HHHK@.D**** "
MBC\:* "BBB@ HH_&B@ HHHH **/QHH **** "BBB@ I*6D[DY[8_.@#ROQ_(
M9?%DD8/,4$<8]B0&_P#9J[7P7:FV\'V '#SAIF/KN;C],'\:\Z\83[_%.JR
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M0H /89_PJQHVLP>(-'CU&WC9$=G0 ]?E(_\ KUQOQ7&=,TK_ *^)/_016O\
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M7//?<:TK2S33[.*SB_U460GXDFK1^M-^IJ^:ZL"CK<HZP/\ B1ZC_P!>DO\
MZ :\I;E>,UZMK'_(#U'_ *])O_0#7E)Z=:Z*'P&%7<]<3&Q>OW1_*CCWH3[B
M?[H_E0>YS7/)ZFEQOYT?G2Y]Z0GGK1N,Y#QMC_B6\'_EM_[3JAX3_P"0Z.O^
MI?\ I6AXUZZ;SVF_]IU0\)_\AT<_\L7_ *5T1TIF4U^\.X[UY]XB_P"1@OA_
MM#_T%:]!S[UY]XA_Y&"]&?XE_P#05J:&Y538Z;PMC^PEP#_K7_G6SGV-8WA7
M_D KS_RV?^=;6?>HF_>8XK00].AI*4].M)4C&^V#1@4OXT4P&\>AI#BG'KUI
MI^M 6# ]Z0XQWH_&C\:+@)CZTAQFE_&FGKUH .,=Z0XI:0T7%82N,\18_MN;
M_=7^5=H>F:XOQ%@:W-S_  K_ "K6C\1,]C7\+X_LR7@_Z\_^@K5S5^-&N_\
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MD?PK_*M:.YG/8U_"^?[,EZ?Z\_\ H*U>U8?\2FZ_ZXM5'PO_ ,@R7C_EN?\
MT%:T-10OIEVH'S&%@/RI2^,:V.3T<XUBTZ?ZS^AKL\GTKSZ&1XG62,[9%^96
M]*M?VKJ'_/P:UG&[(3L=N0,<4F*XC^U+_P#Y[FC^U+__ )[FIY"N8[4YR>*3
M# 9QTKC/[4O_ /GN:FMM;NX)UEG<R1+]Y?6CE%S'5G.<<4R5=T,B^JD?I3N"
M RG<&&1^-*.O3UK-[E=#A[4'SH1Q_K!_,5VV>>17#[L'*C;M;CZBK']I7Q/,
MYK:4;HSB]3M$)VXQ438R:Y#^TK[&/M!I/[1O?^>YJ>4?,=AQZ4TDXZ<5R/\
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M?PRP#ZUV^Y@.!D$9%(6)[4$W9Q/_  A>L9_U]M^='_"$:Q_S\6WYUVV3_=I
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M?YU\X>/L?\)IXA!Y'VI\CVX./\^M?3$A(F?G!W<'VIPW8JCT1FZ]&LWAO5E
M)9[.<*/4>6P%>&_"K!^(FED$Y>*8-_N^4_\ 45]!&-9HFB(X=/+'L#Q_6OGK
MX2ON\>:._1FAFY_[9L?_ *U.6DDPI_#(^BE^X,]2*?QGO3>@ ST&*=WZULC
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MO;OYOX8Q^9;_  K+U8%=8O!G/[W=^8!_K0'4I<>](:4]>M(>E,8G&>]-I_\
MP*FTP$./?I2<9[TI^M-8L%..3TQ[T^@'6>#[,?9Y]093NE/DQ9[8ZFND<QJ@
M>681QJ<[B<9/I4.GVRV.FV]LS;1%%EC[D9+?K7#ZYJS:K<O$,I:H0$0'^(#&
M?QJ+&>[.FG\6Z7;2%2LI(.#@5'_PFFD_W)ORKAR6)_>-N/3-&!5),=CN/^$T
MTK^Y-^5(?&FDXY2;\JX? ]J0XQTIBL8G.>W/]:3W]LT?A1^%?&'U@O(/;_\
M52>W'2COTH[=.U "]^W-?0GP;MA!\/;>4#_CXN)Y#^#E/_9*^>_PKZ-^$@*_
M#/201U>X/X>?(171AOB9SXE^ZCMZ\H^)DC?\)-;1_P (M%_5W_\ B17J]>0?
M$&X\WQA*F,^1!&OX\M_)JO&/]T8X=?O#EO7@4?T_I1^%'>O(Z'IASTX]*/\
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M?I3&Y[4QC.U-.=W:E]\4AZ]*!,8WK4=2-CTJ/\*9(WWXIAZ]J>>N<4P]>E-
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M6I)_<KU]*:]A:AO]2OY5:7?N^]1(&#<L*.<+%/[#;?\ /%?RK.UFUAAL%>(
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MIH!/Q/6HVZC/XU)T[U&W)^M,&1MTYZ]:;3FY&?QIM4 SUII[\FG^O-,/?FF
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MK""Z0@K(N<U8/UKF>YO%Z"5Y[XA_Y&&]'^TO_H*UZ%^->>^(?^1@O>?XE_\
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MU,$X!ZTAI<YYSUI#TIC$X]33:?WZBFT -./4]*Z'P?$6U*[D!X6%1_WTP_\
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MA-,TV ?>>Y:3'LJ ?^SBIOAO$8_#UPY!Q)=MC\%4?T-4M@Z'+_$;_D:)N/\
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M ,\/_:E6_B:?^)-IO/\ R],?_'#53X79V:Q_VP_]J5;^)O\ R!M-_P"OIO\
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MKE,+1A:.0.8ZL^,?^F I#XPS_P NXKE<+1A:/9AS'5?\)>/^> I/^$O_ .F
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M!.BCEE9_D_+)JD4MCDTC5>@+@?,Q)^]QTKM/AK8K<>(I[XC*V4)"'U>3.!^
MKC4=I&VQ1.\N24C4?-N'J/QKV?P?HAT/P_'%.!]KNF^T3,O08 VC]:>JU!O2
MQO8 "@=ABEHHJ"!,<]*\]^)UC+OT_4%C+6T*-'*P_A);BO0ZAN[:"]LIK.Y3
M?%,-K#'0=S]133U&F> $ G,J!@&R![8^[^-,VKG<5R >!Z^U;WB#PM>:!J31
M)%)/ 23!(HR F?E+?A6*HFD8I%$6?L .M4[E)W+>D::^L:W9Z;$F%FESM]%_
MB_2O>U 7Y%^XBB-?HO'\A7#_  ]\,M90R:O>@K<W"^7&#_!D')]J[C((!P>
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MZT^<7*C%VT8 Y/0<UM'P^<?>/3-2V^A(I#2-P.31SARHL:%&UIIGW/FE;?\
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MJ>8!@3KD?4#%9 Z#Z<UY-6/+-H[8.\;CJ***S+"BBB@ HHHH **** "BBB@
MIK;5"E5\P]E]>>OX4ZD^Z01QCI3!%+4-$TK5'#WD"RL.LG3(J:RLK;3H?(T]
M!;1*<XQG?DU-VQ@8]*7GT%.Y5QN.3MX&>GI3NM'Y4M(E@"3R9 F!\V1]X>E9
MG_",:&+LW0M%6Z#%R?4YK2//4 T<DYXS3N5<,[N3QP>!V]Z4=.M(<^U*/PI,
M3' X'WA^5'?KZTW_ /53^?;O28T)WZ\ Y^I]/YUFR>'M%EO1J$EFIN =V/[Q
MK2HQWJKV0!NW'!(7. G'J?N_AFE+@J2<;CWQ]?\ "DQTZ<'(H[]!02Q0?F.X
M\]/QZ_TI6)Z%AZ]*:<Y[4<^U @_&G@D9X#(ZX((_.F<^U.&>E S.L_#NC:=>
M?:;.W5;A@<2_7K6AT#$\L!E?=NX_2CL, >U+_3)HN%Q26/)8$9( QZ8_QH4L
MI!5N!G/'X?UI*.: %;!<8/ X/U.?\*,^])2_E0 H) P&Z<@?I2B0G)VC!#*R
MX]#@?H33?RXIW/M3"YF6WAO1K*^^W6]NJ7BDLK^I(Z5I@#E2?E8!F/H/_P!=
M'X"EZ]>].]R0HHHI % )'S ;B.=OJ.XHH'7CB@:!U6>(PR$>21A@1V[+^%48
M?#VC6TZSP62B13\I_P _C5[''ZTX$Y[4P;#AMQ(V \;?[H]:,]\T=>O<4OY4
MA!EAC:<-T!]*4@2QF%P/)(P,C[H__7FDY_QI1G&./2J&5K'2K#37/V.!8V/!
MDQG<?7^M7 X(.5VJW7Z^M(.@Z>U*,G@XH%<5)&5ONY4#'X\?XTN]F_AP .?K
M_D4G:G<_K_*@+B@GD ]>!]32@D]3P1M_'K31G%.[]L9JA !DXW8_VO[OO_GU
MI0Q4DCEF.2:-N$8M]T<<=32[<+P1C/'TZ_UH%J/@YD6/9M5G!<^^>!^->&^&
MW_M'XDV5PA_U^HM/^;%OZU[;+<K9V[W<Y AB1IC_ ,!R>?RKQ+X;1%_&>EXZ
MQPS2-['RF4?J0::+CLV>Y(Q9MY^ZPY'U_P#UT\EL8W#'TIH&!@=,?I3CGVID
M+1 ,>OX4]6/(WCD8''0TQ:<.W XIBBR0L6RV[Y>P_P _6A>O6D[=J49'IZ4R
M6/!P O'&!TI<E<,ISCJ/;O30>0:=SCMTIC93U+1[#5[86VI0BXMQ(KA3_"PS
M_C3]+TBPT2V:UTZ!8H69G*#^-CC/YXJUVYIXSN'3(Z&K1+8J/E3D@D#KC[PQ
MD'\<_I3OOY&[KQFF@>F,8Q^%+SD=*&B;D@;DAR#GV]J49QEGRQYS2?@*%SCM
M30Y/0>#@9#8QS_6G[AN8<="0<?A_6F=<#MT_"G#Z"@E;#SP:=WZTVG<Y[5HA
M#AZ9Q[4X9Q][M313AG';I30NH[\:=VZTG:EYQVS5(3'TX4VG4T)A1115""D/
M3K2TAZ<4 -_&FGIUIWY4TU1(T_6F-]:>?PIC9]J8R.D/7K3J:>O:@3&-Z9J/
M\:D.>E1TR1O?K3#UZT_OCC%,.<]J: 3\:C;DC)ZU)R/2HVY/;GBF#(VZ=?>F
MT]N1FF50#?7FF'OS3_7I3#GGI3 3/O33UZ_Y%.Y]J:<Y[4$L:>O6F$<]>M/.
M<]JC;(/:@0UBH.77<.N*:Q<<[^:?W[5'5*\A6$WR= U,+,<_/UIQS^E,.23T
MJN5CY4(6;^_3&+]0]*?PI#3YF'*AN%"?*NT$XJ,_6GG)%-/X4[W$,+,#E>Q&
M?Q.*0L>[\"G@X_K3"!CH*28FA.>YIA^M/YII_"@0R@]>M+2'KVJD,;SC=NY(
M^8TAZ9#\KS2\TUOYT)M(5K",VYASR"<T8&#GO1^ H[53Z" +M&WS,XI,_-C?
MWHP3Z4;?I0Y:A9"DX_CIN[_;H(QZ4GX#M1S,+(,?[=(?]_K1@^U)@^U+F860
M9_VZ0GC[]!'/:D/X4^8.5!D_\]*3VW^U'/H*/P%+F$T!/^W2;F'1J.G84AZU
M2D*P;F]:0LWK12$FCF'8,M_>IIP.57GO2Y/M3<FDY-A8.G&ZDR0<K][L*=S[
M4WD<BFA"8QRK8[D>E)N8]&I?ICFC\J+L&AI9CQNI/G_O4<^U(<TTV"0O./O<
M]:8,YPS<T[GVIOO3NQV$/!ZTGXTISGM2<^U A".2 W/6@9 &6H8GKQ29/M1=
MBL'/]ZCG^]0<X[4G6B["PN3_ 'J:5SU;Y:#G/;K3><47%8"3^7 I/QI>1U[4
M=J8QM(>O6G4T]>U A#T^]3:<<X[4VF,,^])^-+^76D[?A2 0]>M!Z8!]J#G/
M:@Y X^E- -S[^]%'Y44Q"?C4UI_Q^PC/\8J'GVJ:TS]MAZ??% BSJ_\ RPY[
M$UF?C6GJ^<P=.AK,H&(?]ZD[=:7GVI.<=J $_&FGKUIU-.<]J:$)G_:I#]<T
M[GVI&_"F W\:3\:6D_*@!#]:N:1_R&+3G_EIC]#5,YSGC-7-(S_;%I_O_P!#
M0'0U/%7WK/G^_P#SKG._6NC\5?>M#Q_'_.N<[]J([$H:>GWJ3\:<<X[4VJ&)
M^/O2'IUI><]J0]*!"?C3?;-.Y]J;^5( _'_)HS[T?E1^5- (>G6FTXYQVIM,
M3$)QPW.><>U,V@G@%1Z9I_.<\4G- 6(F09^\>GK1Y8]3^=2<^U-YH)L,V#^\
M?SKN-$!7P?&0YXBFX_X&]<4?PKMM&)_X0]>G^IF_]"DI-"D<($&P88]/6DV_
M[1_.G+G:.G2EZU1;2(BHS]X_G1M']X_G3SUZ#K2=NU K(;M']X_G2;1GJ?SI
M_P"5,YQVH#E1B?A1^%''J:/YXKXP^I#OTH_"CZ$T4 &/:OISX<.)/AYH; Y
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M_3H3_MB@1:U?_EAQV(K,K3U;K#UXR/ZUF?Y_.@8A_P!VD/3I2G'J>:0XQWH
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MCC/KCO0*3#MC-/\ QIG.*?\ @*I&8#ZT\=N:8/I3QQCB@74=[9H_&CFC\!3
M<.U/[?>%-':G<XZ"J$QPZ4X'YOO"F]J</O=!0(<*.] H[U:!C^?6E'3K2<^E
M*.F,>U,D>O;)IX/J13%YQ3Q[@4T2.&<=:=WZTT=.G:G=^@ZTT X?7'M3@>.2
M.E-'KBG >PZ52$/'3K2]NM-[=*=^'2J0F/\ QI1TI*44T)BT4450@I#2TAH
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MAO\ ^R-6M'^(C*M_#9]#US7CV'SO!U]_L&.3\G!-=+67XAMS=>'=2@ R7MI
MH]]IQ^N*[:BO%HX8NTDSPO\ $<T?U_K2#D<#Z4M>"U8]CH'OQZT?Y_*C\**
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MS[T@#\Z./>C\?\BC\::&(<8[TW_/^%./3K3:9+$X]Z0TO?K2'I0 G'O3:?\
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M_P! ->$CH.*G'[H>$V8OMQ1_G\Z,>U%<!VA^5'3_ #Z4?A10 ?E2TGX4OX4
M)[\5ZO\ #0?\4Q*?6Z?^2UY1^%>L?#92/"S$C[UU+CZ# _I79@E^\.7%? =A
M7&^)?^0S]8D_FU=E7&^)>=9&!TC4?J37;B?@.2C\9E4445YIUA11^%% !111
M0 4444 (:._;&*#].E)@9'':@:W,;PW_ ,><^?\ GN?Y"MKG':L7PW_QYW&1
MUG/\A6T.G2A!+<Q-?CN+F2SMH3@2%@<52TB&?2=:CL;AP3,F.O&ZNGVIO4LF
M6&=M8VM;5U72I1'B5I]F?Q _K4ME11;U@D:/<R+]Y$##\"#_ $J33G+:3;-G
MI N3^&/Z4^^0/IUX,9_=D8_"L^QE,?A17_B2"3)^FXC^=#8MR+PS*\]G<L[9
M/F;A]"-P_05-:DOXKO6<_+&@( Z8P/\ &H/#RK')=1+_ ,\H&'XKC^M2Z6V_
M6=8?;G]XJ#Z98?\ LHIICDM6;/;G'O5357\O1KMFZ&/:?Q(']:MGJ>/6J&M?
M\@2Z&.R_^AK3>PEN+HJLFC6O3+)D_B<C],59OHWFTZZA&/FA=4^I4X_7%,TT
M;=*M!C_EBI_2K,HS#)QCY3_*CH/[1F^'26T>/I@2L!]-Q(_0BN9OQ,=3N&(;
M?YK&,=R,D\?AFNC\-'&C*<<K(QIEZ$_X2S3"(Q_JF(7^]P]3T'U%LUD3PG)N
M#><('&#UR>G\ZYF,7'GGRE;<'428_P!X?_$O7H&Y7*L4P >5]JQ-#8?VAK3-
M%D>?A1Z?,].6MA1TN7=;)71[IDZJOR_]]"ETIB=*M2?O&($TW6N=%N\CG8,C
M_@0S2Z5_R"+3C_EB*?VK$]#-\37<BQ0VD)^:4;G ZX)P/U!JOHMA<6>LQ^82
M%,)DP.G/%6?+6X\8R2,-RVJ#Y/P_Q-= 0N WEX8#;GVI)W')6*>IW)M--GG'
MW@FU?J>!7)&TOK&&WU9F_P!: 0/3///X5O>)"SV]I;IR9[@+C_/N15[68XI=
M)O80G C8Q#TQQ_*DWJ'0MHY>%)!CYXU;\QFN9U:"XUG7Y;2)@%A7UX!'-;FC
MN9=(M78<M$!^1Q5+0XU.KZTS\G[1M/LH=@/Y4[[#LM2?0/-&C1^?]\2,H'L#
MQ_*M/\J:H7[P3:.Z^A/6G?A5D',?$/\ Y$34>G+1_P#H:UU"YVKT^Z/Y5R_Q
M#&? NH8'>/\ ]#6NH7HO'\(_E5= Z#JP?$&?M.ECCFX(_P#0:WJYSQ4QC^Q.
MOWED)'U^6HD[((J[.D8,>N!SWH"DD8QS7!?V_J990\ID&X#&/UKO(\NJ'I\O
M]*$[H;5F<1<VMSK=]?7,3$1VY8]>JY. /?%=;IPD&D6P?[WE9;UK-\*X_LJ8
MLN<W!)]SC-;:@!00.5 7%$=5<)Z.QYV4N!*R@/YBD@COC</\:[K0=YT>Q,PQ
M((PI!]<U10Q_\)Q(WE#;]C^[[@+6UT/W=HVX4>E$>H2V1Q-QIFH:Q>7\Y;:L
M#L1[@=,?E6[X6NI;G2FCDP7BE"_F,BMJ(Q(=JP_*C;G/KDX_K6'X>7[/J.K6
MH7 24,!^=-[C3]T/%N3HT*C&7G5?S4USMXMUJS3ZHNX0(^(@.N#R/YUT7BWC
M18\#'[X<_P# 36II]I%!I,%D8AS%L;_> -3:\A7]U$.@7LEYHL$DA4RIF%OP
MQ_C5'7<_V[H?3_6G_P!"6F^$E*0W]L_6"8?U!_\ 0:=KO_(=T/C_ ):'_P!"
M6G>ZU"VIT0Y4CVYK \'ESH\[.Y?_ $D@%CDXV+_C6\O0\=JP?!O&C38'_+RP
M_P#'$JOM(FVC&>+IIBEKIL/,EP^6V^@('\Z/#.FW6D:A?6<S;T6-2#GC=FI;
ML!?'6G #?_HYDQ_M'?C^5;Z[2H*)AB &/KZ_J:<-QST1@^,MS:3 JX^:Z _0
MURNHW%Q?WDFJ .(A)NA/^R3QG\6KJ?&1QHT?&#]H&#[X-7Y;"W3PVUB(AE+8
MDM_M $_T%3*_,QK9,MZ9<BYTNVGSDNG/U& ?UK,\67[VNF+;P_ZZ>4(,?[."
M?_0A1X0RWAJ(L<[&D4?F*9J$7VGQKI=NR[HXX//<>^6'_LHJN;W43:TF85A9
M7?A37[%9WW1W) 8YX&3@5Z%@EMO<D#\SBN9\:@G1([G9B2*9<-Z9W8_D*Z62
M41EY0.%!;],T1W826B//M5%SXE\136\#$1Q A/J,@_K1X?N)[GQ/I:W'#P!H
M"#UR [?R85M^!X,V-U?,F99YB4/MW_G44ULMO\1K:14V^>HE"^A*LI_E4.^Y
M2MJCL?RI1^'6F]NE+^%=1@0W^!I5Y_U[2?\ H#?_ %JS/!O_ "*EF!CAI?\
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MZ,?UKG.<]JZ'Q4<?8RPQD,/Y5SF]?7WZ4+8$*0<=J3!I"R8ZGTI-R_WOTIW
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M[M-1S^);9[>2$KEB"N<>V/Z5)KT"W.HZ1 _221U/XE*</#=J/3_]='470MZ
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MXOFB D\SSG]-V:)[IBB]&F8?@.T:"YU1'),D0CB<^K$LQ_G767UI%J-E);S
MF-R-WX8KGO!+-/'K%V3Q/>$C\MQ_]#KJU8\X/M54X\T F_>//7TX>$?%NFR0
M2NUG<$*V\]=S$'/TR*[W43_Q*K\'/%O+_+-<M\1%!\/V\X/SI=!1^*$_^RUV
M,\8N%E@8\,K#\QC^M.$>7F0IO9G/^!"#X/L@3]UY4_\ 'V-5[K!^*FG^VGG_
M -JT?#E_-\**&/\ R].H^A4'_P!FI+@JWQ3L"3TL"&]N)/\ $47]V(/XI'8]
MZ=QGO3 3CD\T_OUK=&(X=:4#CJ>E(/3./:G#./O=JI"ZCN*=V[T@Z=:7MUJD
M)CJ<*2G4T)A1115""D/0TM(>E #/SZTAIWXTT_6J)&G\:8WXT\_6F-]:8R.D
M/7O3J:>O6@3&-BHZD/IFH_QJB1IZTP]>]/[]>*8>O6A )^?6HVZC/XU)^-1M
MR>O7K3!D;=/>FT]N1U]Z95 ,II[]:?Z\TP]^:8"<>]-/XT[/N*:>O7_(H)8T
MCGJ:8<9[\T\YSP:8>O6F@&G&>]1'I4IZ]:B/3K3)8VF''OWJ3\:83UY]:!##
M33U[TX].M(>O6J&1\8II_&G=NM-)]Z: 2FGIWIU(>G6F(:<4P]^M/_&F,< G
M/K2$-_.D/!J4)(YW!@<D_+Z>E-,,V?NTKA8C_.N>\98_L: -T^VP?^A5T;HT
M:CY@RMP,=JYWQC_R![?G_E\A_G1?09OR?ZU@>S'^=-/3O3G^^><\TUCM4MGI
M5]!(P_%LRQ^&;E-S@SO%" O<%US^F:B\)Q"UM=1TP,?] OI81GK@DX/Z5)K^
M7U/0++>-KWAE8?[,2AC_ %ING'R/&>N0@[A=0P7*X[8&W^IJ&]2K:&CJ\1N-
M$U")0"TEM(H!]U(_K67%=J?AXLZG:!INT'W5=O\ .N@9/.4Q$\."OY\?UKAH
M)-_PPCAE_BD2UQ]9LM_Z#3D)&MX8F"^"(""1]GBD0$_[.<?RJWX7B$/A73%(
MP[0"1OJY+?R85D"0V'A?Q1%N_=VMU=11#T5\8_\ 0JZ:Q@^S:;:09YB@2+_O
ME0O]*< 9+D9[USOBF);J718'Z37Y7Z H371$^]<_XF=([O07D8"-=1&[V&*)
M_"*.XY_"&E[B"7!!P<#WK8AB6VMHH(B=L,:HGT P/Y4L=S!<LWV:97P23C^[
MG_\ 73LY P>".*(; ]S"\. +<:\/75)?\*NZ[M_X1[5-V2/LLF1_P&J7AS_C
MXU[G_F*2U=UT_P#%/:D<_P#+M)_Z":%\(/XC,T_PYIT^E6<C@@2P1N3CUC!_
MG2>'K2*QUGQ!;0LQC2>+:#VR'K9TF)CHNG;G&QK2(J/0^6/ZUF:0=WB+Q&,Y
M*SPJ3Z_*U2G[R'):%CQ"%;PY?!LX\DAO^^A4'AB=G\.VXD),EL6A8?3D?H:E
M\2G'AC4FST@8_P JATA#;^(-9T_.-SI<C_@8VM_2J<K3!(SM4<R>/=.C4Y6
MH@]FP6/Z$5T_7GGFN1AQ-JEO?*W_ !]:Y(L9_P"F:H0M=5<3K;6LMPPW)$A<
MCU &<4Z?5A(D('<FDXSU-<F/B#;8W&R9MW/7\*#\0K4<_P!GO],TO:-Z$V.J
M_.D-16EU]ML8+H<+-&&4>AJ4_6M4(3CWI*=^-(>G6F(:<9[TGMS2GKUI/QH
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M*I-C?\]11L;_ )Z"@"'[):Y_X](O^^:#:6N/^/2+_OFIMC?\]!2E6_YZ"JU
MK_9;7_GSB_[YH^S6>W'V.+_OFI]K?\]!2>6<9\P4"=R#[):?\^D7_?-:UI#
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MYC]*]FKT\%!J+?<X,5-.5ET,SQ#_ ,BWJO\ UYS?^@&O"1R!7O6M1F;0]1B
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M&G\4+-I#Q>2WGRQE"_;D8S6]H]NUMH]K&PP=F2/>DG[PVO=*:;1XUDW8RUJ
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MK06GF.HZEB2 *:?)!"^*3:&?$1P-!M(%_P!9)<JX'T1@?_0A7;+S+DX&6Y_
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M*8<9Z&F@$Z=A4;<GZ\5)^%1MUX^@I@QC<C-,IS?3O3:H!OK3#WX%.II[\&F
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MZTW4I)O,2&\0L%_BZ<?C6;6I6ECT(DJ1@#KQ7$PX6-=,*@JGB1E _P!C[_\
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ML G.,]ZE%Y.H(W'/;FH<>QIN!UP<CFD38L_;KGU_6F'4+K=U/7UJ#M02<]*
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M6PN,=12?A2TG;O56!;"X-&.Q%'/K2=:;0D*/I2X]J3C-+^=#&%._"FTX?C2
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MN[(]##4]+L]#^&NLA+:;1'ZPCS;<$]5/4?@?YUZ+7S_8W\VEWUO?6_\ KXI
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M,5Q'_"T=#S_K&_[YH_X6CH7_ #T;_OFE]58>W1V^/:@=*XG_ (6CH7_/1O\
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MS?\ X7AX=_YZ-_WS3?\ A=WAS^^W7^[1RL+GHS4SCTKSH_&WPY_?/3^[2?\
M"[/#G]]O^^::0KGHG?I3#CT/>O/#\:_#N/OG_OFD_P"%U>'/[Y_[YIV%=GH7
MX<4QL<<5Y\?C1X>(/S'_ +YIA^,WAX_Q'I_=HL%ST%NW'2F\8Z&O/S\9O#^?
MO'_OFD_X7+X?Z;C_ -\U5@N=\0.]-(Z\5P3?&/P]_>/_ 'S3?^%Q>'_[[?\
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M_P"%DZ+_ ,]&_P"^:3_A9.B_\]&_[YJKH5F=@>G2C'M7'?\ "R=%_P">C?\
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M?E1P.JC\J/PHYHL%P^7^Z/RI/E]!2T?A3$ V_P!T?E1]%'Y4?A1DT!=A\O\
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M1^- !111^- !11^-'XT %%%'XT %%'XT?C0 44?C1^- !11^-'XT %%%'XT
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M -='Y44?A0 4<^U%'X4 'O1^5'X4?A0 4?E11^% !1^5%'X4 %'^?SHH_"@
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M4 %%'X44 'Y44?A10 <GTHH_"B@ _*BC\** #DGM1[T?A1[T 'Y<4>U'X44
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MBM.A#$8_*!CH>?T_PHS[<5K>&]$;Q+XAL]%BD$$MTQ'F'IPK'^E>E_\ #/\
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M@Y[8=1C_ ,>I2ERQ;'%7=CG<8&/\_P">*/RKH_&O@^;P1K4.ESW(G>6V%QN
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M<CM1WKJ/&W@6?P'>V=K/="X:ZB:12!]W:0/ZUR_X41ES*X2CRR"C\J*/PIB
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MYH8VV,13= .2F%;+GVKR8#;D$?=XJH3YT34ARBT8).!C)Z4?A2'&#Z59"%.
MI:0':0",=@!_B!06RLC$KA3B3V)]*ZSP#X)O?&.JS6Z/Y5E -TTA'!8$#9]2
MI/Y5[A/\&O",ME,L-B8YF1@C%ONMV/YUA*KRNQT0IIH^8>1M'8Y(/XTZM_Q;
MX4O/!^K-IUSEE/S1S8XFX!)'TW8K Q[5I3=U<QFK,***/PJR0YHH_"C\* "B
MCCTH_"@ YHH_"B@ HHX]*/PH **/PH_"@ HH_"C\* "BC\*,4 'Y44?A1^%
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MS;\(Z.^N>,M)TM03YURHE_W!R_\ XZ&KZKUSQ!IGA+1OM]Z_EVX*HJ+UQP
M/:O!/@5 MQ\1G>09^S:;+)$?JZ+_ .S-4_QTUN>\\:VFE12[8]/MP7'8R2 ,
M<_\  =M<U7WIV.FG:,;GM^M6]KXO\$7T$&R:'4+)A&>N&*$J?J#@U\?#+*&Y
M''S ]0>,_KG\J^@OV?\ 5Y+OPYJ6E2,S?89HV0L<_*Z_XJU>(>(K9[7Q/J]N
MPV^3>RH%QVWL?_9A3HZ2L35LXW,S-'XT4?C708!1QCOG!_/''ZXH]J<)!$/,
M/.TAC^'(_44GL"W/9_@'X8+W=]XCND!2+-K:$^N3O(_0?B:]V>6*)=TCJF>
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MGP]_U^+_ "-:2?N7,TO?/KQN@(]:^)]4LQINKZA8KG;:W4L SZ*Y%?8YO_\
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MCG8?A1^%%% !1110 ?A1^%%% !^%%'X44 'X4?A110 ?A11^%% !^%'X444
M'X44?A10 ?A1^%%% !^%%'X44 'X4?A110 44?A10 ?A1^%%% !^%%'X44 '
MX4?A110 ?A11^%% !^%%%% !^%%'X44 'X4?A110 ?A11^%% !^%'X44?A0
M?A1110 ?A1^%%% !^%%'X44 'X4444 'X4444 'X44?A10 ?A11^%% !^%'O
M1^%% !^%%%% !WZ4>]'?H:* #\**** #\**/PHH /PHHHH /PHH_"B@ _"BB
MB@ _"BC\** #\**** #\*/>C\** #\**** #\*/>C\** #\**** #\**/PHH
M /PHHHH /PHH_"B@ _"BBB@ _"BC\** #\**** #\*/?%%''IQ0 ?C11W[<4
M>U !^-%'-'O0 >O-?2'P%MI8/ 5Q-*N$N=0EDB/JH6-/_0D8?A7S?WZBOJ+X
M0NMK\(-+GEX5!<RL?;SY#_*L*[T2-J.]SYMU^Z^W>)M6NR^1->S2 ^Q=C6?3
M(B3"A)R2,D_4"G]JU2LD9/=F]X(NFL_'F@2J-V-0A49_VFV?^S5Z]^T&D$FC
M:*WFJ)DO&0*#S\R'_ 5X/;SR6MS%<1'$L,BO&?1E.1^HJ]K?B'4/$VJ3:EJ$
MK&28A@F?E7"A1@?05#@Y33-(R2@S,)W+DG&1S[5]1>$Y3H/P/M+N(?/!I,EV
M >,L5:3'YFOER0X1_H:^H/$V+;X!SX^3&BQ+QQU11_6IK]$51ZL^7T 6),'H
M,4ZCGVZFC^M;)6,+W-+PW>C3?%6BWSMMCM[^"1S_ +(<9_3->]?'^WDE\"6D
MZ)N^S:C&[>RE)%_FRU\Y,<*6STPWY<U]/_%TC4/A%?W,7W6%O./IYB'^1K&K
M\<6;TG[K1\P=NOIS7TQHO_)N3?\ 8 G_ /1;U\T?EU%?2^C?\FYL/^I?G_\
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MIKV%$)Z9,@'\]M:/X69P7O(]X_:! /@:P.>5U-"/^_<@_K7SI^-?1'[06?\
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MZ_X_KC_KJ_\ Z%47/J.]:+1&<G=GK?[/Q?\ X2S5E!^1M/!/U\P ?UKF?BX
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M\:** #\:*** #\:.W6BCF@ _&BBBAZ @_&BDYQU%+S0 ?C11THH /QHHZT4
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M%<\*C;L;RII*YX!/@1R8;(YP?6OJ/XV[O^%77^W_ )[V^?\ OZM?+DY)BD)
M!(Y KZE^->3\+-3"]?-M_P#T<E.K\2)I;,^7!TZTO2C.>>.>:*Z3G$/3KW%?
M2<V?^&;H]W7^Q(__ $$5\UMP"3T YKZ:UU/L7[/#1MU71(4X]2BC^9K"MNC>
MELSYF[ Y]*^F-%_Y-R8_]0"?_P!%O7S1S[=17TOHW_)N3'_J7Y__ $4]%?9!
M1ZGS.I^4<TOXTB_='2E]JW6QB'XUUGPP_P"2G>'_ /KX;_T6]<G76?##_DIW
MA[_KX;_T6]3/X65#XD>B?M%'GPSSWNO_ &E7A_XU[A^T5U\,].MU_P"TJ\/J
M*/P%5?C#\>XKZ1^ 7_)/9_\ L(R_^@I7S=_3FOI'X!\?#V?_ +",O_H*5-?X
M1T?B/GO63_Q/]4Q_S^3?^AM7N/[/7_(O:WVS?+_Z+6O"=0D$NJWTJ\J]S*P_
M%S7NW[/0SX>UO_K^7_T6M%;X$.E\;/81(@)!D7/UH,L?:1?SKY2\6>+->MO&
M>N6\=]*L<.H3QHH;H%<@?RK'7QCX@5@W]H3'!!QOK)4F:.JD4-67;KNI_+@_
M;)LGU^<U<\)VZW?C'0K5DWK-J5LKK_L^8I;] *R6)9BQ<LS'<Q/=CUKLOA/:
MFY^)^B *&\MY)6ST $;?KD"NF:486,(N\ST/]HB\=;+P]8@_NY9IIV^J*JC_
M -&FO(/"=RMGXRT.Y:38L.HV[NW^QY@#?H:]%_:!NGE\4:/:Y&V*R9\>A=^?
M_0%KR+.&4D[0K!B1UQG)_E64/X9<W^\1] ?M!V0?P]H]_G$D-\T*_P"Z\;,?
MUB%> ?C7TI\:1%J'PJ^VJK?)/;W$?'3<<<_\!<U\V;2!V]/Z_P!:=#X15EJ=
M?\*C_P 72T#G_EM)_P"B9*^KWACD^^BL1TR,U\H?"K_DJ6@?]=I/_1,E?0/B
M_P")&C^"]0@LM1$IDFB\U=@[9(_I6=;XS2E\)U?V6,2*P1  #D;167X@UNU\
M.:1?:G=,(TB ;D_?.  /Q/%8OA+XF:+XQU273]/$HFBA,QWC^$,J_P V%>2_
M'75-0/CA-/9V%G':1R)&#\LG+'G\16<4V[&DFDKGF^KZG)K6LWNJ3$[[R8S%
M3_#DG _ <53_ !I6.2> ,GM[TE=T596.-N[N?87@4@?#SPT2< :3:_\ HI:W
M?.B_YZI_WU7#0S26_P  8YH7*21^%PZ,.JD6N0:^:/[>US_H+W?_ '\-<48.
M5['9*2CN?9<Z17<,D!=61U*LH/4'(/\ .OF_XL_#]/"VIPZE8DKI=]+L*?\
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MTO8SMN(55+F/TD"*6P/3)/Y5R3BXLZHR4D?+6M:9<:)KE]IMQGS;.9H<D??
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M-:UI[Z5K^I:<0?\ 1+F2$$]2%; /X\?G7JW[/=J)-<UZ\.-T5M#$/H[N3_Z
M*ZJC]PPA'WSSCQGI-OH'C'4M)M6#16K(H([DQH3^N:POQKH/'3N_Q!\1-)C(
MU&8?@&P/TKG^GI5P^%$3^(/QKW_]GG_D7M;_ .OU?_1:UX!7O_[/)_XI_7/^
MOU3_ .0UK.O\!='XCQSQL,>/O$6>^I7'_HPUA_C6]XYS_P + \1?]A*?_P!"
M-8/Y5I#X3.6X?C1^-'-'\0'3)P#^1_K5"0V0_NFR?X37TM\8?^20'G^.U_\
M0EKYIE!\H].0?\_K7TW\5HC=?!F:1.B);2GZ!D_QK"M\2-J7PL^9OQH_&CGV
MZ45N8AGCK7U$/^3>?^Y5_P#;6OEWK@#')P/QKZB'_)O/_<J_^VM<]?9&]#J?
M+OX\T?C2=1FEKH,&'XT?C110 ?C1^-%% !^-'XT44 'XT?C1S10 ?C1^-%%
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M'^-'XUI:YH-_X<UB;2]055GA"$D=&R >/SJSX9\)ZIXMOIK/3%7?#&9'9^@
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MS7BGC!_,\=>(V+9SJMT,^PD8#^5<\-:C-YZ4T8WX4OX4G?'-+6[E<Q:!5);
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M%<X;Y3Z\_P Z^<-0M9++4[NSF4+-!.\,BKT#*Q! ]LBG3ES/4F:LBOD[9.<
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MY^%UGJ]W;9O-48S1Q'[SQ[MJ_D@0_C7AL>T; Y.W@,>^.A-=+XH\2R>(=/\
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MU !^-'M1^'2B@ _&BC\*/>@ Z=Z^C/@#<M+X$NXF;B#4I4"^@*QM_,FOG/\
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MUOA3_P E1\/\_P#+:3_T3)75_M!_\C?I/_7@?_1AKE/A3_R5+P_Q_P MI/\
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M?)\?>'-QR1J4 7Z;@?ZUZ]^T+_R -$]KUA_Y#->1^ 89)?B)X=5!EA?Q,/\
M=!+$_DM>J_M#70%AX>M"/FDFFE_[Y55_]GK&6M5&T=*;/"*/QH_"C\*W,#<\
M(^'9_%/B&'2X#@L#(SXX15Y)/Z#\:E\<Z3!X?\<ZMI5HGEVMO(OEJ>P,:X_]
M"KJO@7*J?$"6)L#S[&1 ?HZ/C\E-.^.FG?9/B EX%^6^LXW)_P!M-RG] E8\
MW[RQLE^[N>94C9V$*1NYQ^G^-+37SY;8X(YS] 3_ $K:]C%;GTKX@&[]G%,G
M/_$DM3D_[L=?-G8\U]*^.+>32/V?FLI!^]M].L[9Q[[HD-?-78\5A0V9M6W1
M](Z1_P FWM_V!9OY-7S:/NCFOI/2/^3;V_[ LW\FKYL'"@8I4>H5N@M'XT4?
MA708D<^?(?\ W3_*OJ#XY?\ ),KG_KY@_P#0Q7R_/_J']U/\J^H/CE_R3*Y_
MZ^8/_0Q7/5^-&]+X6?,?:C\:.U'X5T'.':O4?@%_R4.\_P"P7-_Z-AKRZO4?
M@%_R4.\_[!<W_HV&LZOPLTI?$@^/W_)0[3_L%1?^C9J\YTF[6PUO3KV092VN
MX9F'LKAC_*O1_C[_ ,E#M/\ L%1?^C9J\KD&Z)QZJ:FGK J?QGTW\<+);KX:
M7=R1DV5S#/CZMY9_20U\SM]X@GD$@_45]7ZNA\5_"*=V4-)?Z.)@HY_>&,./
M_'A7R:A+JK?Q$#/UJ:'4JL.!(((/(KW#]G>V0GQ#=X^<?9X@?;#'_"O#QDX4
M=3Q7T;\ +,P>!;RZ9 &NM0D*MZJJHH_4-5UY>[8FCK*YY5\8?^2JZU](/_1*
M5F_#K_DI'A[G_E]7^1K2^,/_ "576O80?^B4K-^'0_XN1X>_Z_5_D:?_ "[^
M0G_$._\ VA_^0UX?_P"O>?\ ]"2H/V?+P1^)]8LS_P MK-)1_P  ?!_]&5/^
MT/\ \AKP_P#]>\__ *$E<]\$KPVWQ+M8\#_2K2:W/X 2?^R5FE>B:-_O#IK*
MPV?M17"11$Q)NNG]BUL,G_OIA7/_ !TO5NOB/Y*-_P >EA#$XST8L[_R=:];
MBTT#X\W-\D>%/AU-[8ZN;@@?^.Q@5X-\3KK[9\3O$$VT#;<+%_WPBI_[+4TM
M9H=32+/3?V=_^07K_P#U\1?^@&O&O$__ ".&O<_\Q.Y_]&-7LO[._P#R"]?_
M .OB+_T UXUXG!_X3#7?^PE<_P#HQJN/\1D3_AHT/A[ +KXB^'XF&4%]'(?]
MY,LO\J]4^.VOZEI4FA6MA,8RZS2R$?Q$;%'_ *$:X+X.6[7/Q0THA R1)-*_
MMMC8 _G(!6S\?+EI?'.G0!_DBTQ7 ]&>1\_HHI5%>K8J+Y:=S@QXP\0_\_3^
MG4UW'PE\5:S=?$6QL[NZ+6]S'*DBGOB,E?U KS#+'^(UTWPZNDL_B3X?E9R,
MWBQM]7&Q?U85I*"4&1&3<CM?V@K;9XHT>[Q@RV3QY_W7S_[/7D1Z'FO=OVAX
M&-GX>N=G"RS1LWN54@?^.G\J\)/0T4/@)J_$?1>M?\FT1?\ 8*MO_0DKYU_&
MOHK6O^3:(O\ L%6W\TKYU_"IH[,JKT.X^$.J-IGQ)TT&0+'=B2V;/^VN0/\
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MXT4?A1^% !^-%'X44 'OFD;A&Y[4OX4C?<8^U)[ MSZ!T!C/XPTG2C(%2_\
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MJDN9MD-V21Z1\</^2GS<X_T.'_V:N<\$^)9/"7B--41/,4P20,F.6W+D8^C
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M5OZ5SO@KQ)?:A\8M(UBZGD8WMXRLNXX ="BC'T-:7PE1G\&?$%5^\VB@ ?\
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M?_7ZO_HM:UK_  F='XF>.>-/^1\\1<=-3N/_ $8U8=;OC3_D?/$7/_,3N/\
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M^%"3_P#/])7/3GR-F]2'-8\;)&,_=P><^]?4_P )-#F\/_#^SBN4*SW+_:I
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M'_9\_P"1-U7_ +";?^BHJ^>/QKZ'_9\_Y$W5?^PFW_HJ*MJ_PF-'XCY\N?\
MC^NC_P!-Y/\ T(TQ96A/F)P\?SCZCD?J*?<X^W77/_+=_P#T(U'P1U]S].*U
MWC8ANTCZG\>#_A)?@]?7,)&V73X[\9_NKME/YJI'XU\KCID@C/\ A_\ 7%?4
M?PPDCUOX2Z=9S'S4-O+92Y] S*%_[Y(KY>=)(G:&8%98F,;KZ,O!_45A1=FT
M:U5HF7=#O1IGB'2]0R5%K=Q3,?97!/\ ,U]/?%30&\0^ =0MX%W7$"_:X0.[
M1\D#ZKN'XU\HE1(&4G@@@_CC_"OK#X:ZZ_B7P#I5W.VZ98C!<$]2Z':2?J.?
MQI5M+-!2V:/E.9!$X[KT)]3_ )Y_$5N>#="/B+Q9ING &2.299)L?P1+RQ/U
M.!7;^-?A!K<?B6:30;?[1839F )P(V+'Y1[!0HKNO@_\/)_"MG=:AJD834KH
M"+9U\M%)/'UX_*G*LN70:IZE[XSWT=M\,[N'.U[V>&WBP<?QAORPAKYBQ@#J
M>,U[!\?=:>76M.T>$YALXC,X!_Y:."$_)5)_X%7CYX. <A?E!]<<55!6B36W
M/?\ X ZF)_#FJ:7TDL[A90?]F0-@?FC'\17F?Q7T4:#\0]1C5-EO=D7<7'&&
MR6 _X$36Y\#-66P\;RZ?*^U=0M649_BE7YE'_?&[\Z]/^*G@@>,-%#VL8.J6
MP+0_]-%'\.?3+9_"LV^6H:)<T#YA(5>^X@<X]Z]F_9_TR07NLZLR'8D<=E&V
M.I)W-^7%<0OPK\82R/&FF#<CY;YOTKZ1\+>&;?PEH-MIMLP81EFED/&]CC+'
MWP*=6HI:(4(.+NSY]^,]TMS\3[]0<B""&+_QP/\ ^SUO_ "[,?B/5K!2 D]H
MLY4]2R/M_DWZUYOXHU%-7\6:QJ4<IDCN+R5HF/>,.0G_ ([M_*M7X;ZNVA_$
M#1[L/B*6<6TN3P4ERO/T(S^%5*/[M(S4OWAU?QTT$VOBJWUJ!<0:C$%E/_39
M  !^*[?R->5E03\OUV]Z^N?&'A*#Q;H$^ES'RV+K+#*!RC*P((_#(KYV;X6^
M,C/Y2Z8!+C=G=_GWJ:=6RLRZE.[NC5^".E/>?$.&]*YAL+=YF;LKN#& ??YC
M^5;/[0-]YOB#1M/*G=;6LDQ;MB1E4#\X6/XUZ1\+O!@\(>&F2Y'^GWCI+<^J
MD* %^@.3^->'_%O5?[5^).IF-]T%L4MD/NJ\C\'W_G2B^:I<)+EA8XC\*/PH
MH_&NHYSIOAW??V9\0M#NBVU1<K$W/429C/Z-G\*]E^.&@-J?A>TU**,M/ITN
M9& _Y9-]X_@54_G7SJLCQ?O(G*RH0R,/X2.0?T_6OLC3+NV\3>%+2YFC5K?4
M+)7D3MAU&Y?U(KEJZ2N=%+6-CXUQTYZC(]QZ_I6GX?TPZWXBT[2E4LUW<K#M
M'4*2-[?3:&KL/$'PA\1Z=K$T.G6OVFR5ML,I/)!4''X'-=Q\(OAK?>'M3N-<
MUR()>QJT-NF<X# ?-_Z$/QJY54T*-)IW-WXWWP@^&L\.,?:[F"(#Z/YG_LE?
M,YX^E>V_M!:RC/HNBHWSIONY5] ?D3_V?\J\2..Y_P XIT/A)J_%8^DM(_Y-
MN;C_ )@L_P#)Z^;%'R@D=J^HO!NF#6_@=I^EM*8EN[!H2XZ@,2#7*_\ #/=K
M_P!!>7\JRA4Y&S2=/G2/"=M&.#V.>!ZU[M_PSW:_]!>7\JY_QK\(+;PGX0OM
M<349)GM?*"H1_>E1?ZUK[=-VL1[%H\EG/[B3C^$_RKZ@^../^%9761G_ $F#
M_P!&"OE^;_42<_PG^5?8OC;PO'XP\-R:1).T*O(DF]?]DYJ*SM),JEK%GQ]C
MB@\=B:]V_P"&>[7_ *"\OY4?\,]VH_YB\OY53Q"[$^P?<\*P/7G/Y=/Y\UZC
M\ O^2AWG_8*E_P#1L-<O\0O",?@CQ'%I44[3K+9QW)=ASDNZX_\ ':ZCX!?\
ME#O/^P5+_P"C8:)RO3N$8VFD)\?O^2AVG_8)B_\ 1LU>7?+W!*]Q[5ZE\?O^
M2A6G_8*B_P#1LU>6YQTYQT'K54O@1-7XSZG^$FHPZE\,]+!<,UMNM903T96(
MQ^1'YU\Y^,-$/A[QCJFE;2D,,Q,!/_/(_</Y8%>I_L_ZI&(M:T1F&_>M[$I[
MG&UOY1G\:Z#XL?#Z;Q1;P:GI<(;4H#Y;Q]/-0E<9^@'ZUC%\DS9KG@?.#MY4
M;.!G;R#7UEX M/\ A'O!?AS2)5\N>2T,K1GKN(WN/P+BO)/ 7PDU2?78+CQ!
M;"+3X$\W:3D2L&'RG]?RKU:^U))/B_H>EI)EH=+N9Y%]-[1A?_06HJ24@I1Y
M3POXP_\ )5=9^D'_ *)2LWX=?\E)\.\?\OB_R-:7QAY^*NL_2 ?^04K-^'7_
M "4GP[S_ ,OB_P C6W_+OY&7_+P[[]H?_D->'^/^7>?_ -"2N%^&EPUK\2=
MF1@A^U>6V>X=2GZ@UW7[0_\ R&O#_P#U[S_^A)7E>A7D>G>(]*OY&VQ6M[#,
MY_V4=23^0-3#6G8J?QGV+]B7^VC?<;C;B$^O#;OZU\@^*[O[?XOUJ[R&\R^G
M(8=& <@'\@*^Q)IH[:*:XD;;'$A=SZ #)_05\1(Y>)22=Q&2?4GD_P ZC#_$
MV.MLCWO]G?\ Y!GB#_KYB_\ 0#7C7B?_ )'#7>/^8E<_^C&KV7]G?_D&:_\
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M,H/IM<$U2_&D8!T96/!4_GBJ>Q$=&?6'Q,T,^(_A[J5O;+OG2,74 '.YD^;
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M7PTUS5/$GQEL-0O[EFE:&4R*&.U@(BHX_$57\.Q>3^SMXCN Q7S]1ABE8?W
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M$YJ*KCLB'N.CB:>:. #/F.J8'4Y(']:^B_CM(+3X=6EJ@_=3:A# W^Z%=O\
MV05\ZQ,\<T<D;;'1U8/_ '<5IZIXGUK7;:.VU"_DN84E$H1NS $?^S&LIQ;D
MC2$DHLR>OIS1[T4>^*V,CMOA%/\ 9_BCHQR!YAEB8_6)L?RKM/VB+8"]\/7(
M'+QW$1/T,9 _4UX[:WMUIMU%>V3%+B DHXZJ2.OZU:U3Q'J^NQ1QZK>O<&!B
M45OX<]3^E8RB_:)FJ:Y+&]\*>?BEX?.?^6TO'_;&2NL_:"S_ ,)9I#=C8L/_
M !\UY997T^EW<=]:2F"YA!,,B]<L"N/R-2ZIK>I:[-'/J5VURT2%%9OX0>:;
MB_:7!/W+%&NN^%^IC2OB5H<K<QS3&U8#_IHK*O\ X\P_*N1_"I+:XFLKN&\@
M.V:VD65".S*P.:TDKQ:,XNSN>Z?M"::SZ=H>J#;Y<,TELWKF0*R_A^Z;\Z\'
MK6U3Q/K>MV_V34M1DN(8Y X1O[W(!_(UD_A44DU'4NJTY:'V'X$_Y)[X:_[!
M5K_Z*6N@R*^.+?QQXFLK:*TM]6EC@@18XT'15 P!^0J7_A8/BOOK4U<WLY7.
MCVD3[!)&17SY\:O&\&KSVWA_3YA):P.)[IT/#GC:!]/FS7!+\0/%;.@_MJ;:
M3\Q]!7.8&6*L6W'EC_%C_P#75PI/FU(G-6T'NY8Y./7\>I_4FFT?A1^%=1S,
M*56*JX&/F'/Y$?R8TE'X4 CZ ^!?BB.\\.S>'+B7_2+"3]P">6B?)P/]T[OT
MKV$=L]17Q=H>K7F@:W:ZK8$K- =SJ#]Z-<%A^/->[:;\<-)N/#5U>7H%OJD8
MD,5K_?(7*\^YXKBG"S.R$KHO_&_6H['P0^FI,%N;Z:--H/(0$L2?;* ?C7,-
MD?LK %=IVC(/K]MYKRWQ9XHO?%NNW.I7@**5 BASD(H'(_/!JM)XBUE]&&BM
M=N=+''EYX/S!_P"9JXTWHR)25V9E?0W[/O'@[5/^PHW_ *)BKYY_"M;2/%&N
MZ# T.EWCPP>9YLB*>K$ ?R45K53<3*F[,SKD?Z9<9(R99/P^<BH@>ON1GZ<Y
M_I0Q9Y&9A^\8DO\ 4[?ZYH_"M$K:$2W/H+]G_4EG\,ZEIASNLKSS0>VV1>GY
MHWYBO(/B!IS:5\0M?M&QDWLDXQTVRXD4?@& K.TO7M6T#S3IMZ]JLX!EV=]H
M^7_T*JU_J%YJMX]]?2&:XEQND;J=HV_R6L80:DV:RDG!(JG/0=\9KU_X&^+(
M[#4KGP]>2!8KV026Q)X$F I'X_+7D.*DM[B2VGAN8',<\+++"P[,,?R(S^%7
M./-&Q--V9]N1MO16]0,BJVHWUOIEG/?74JQPP)N8D\#_ #Q7D7@?XU6;V:VG
MB/%L\%M$%FZF9L8)_3/XUQ/Q"^)UUXM#Z=9H8;!96!8'_CX4,N ?R)KE4&W8
MZ>9)'*>*-?E\1>(]0U0Y"SR?NE;JL8 50??:J_K6,3TQT __ %_K24OKQ79&
M/*K''*5V6K'4;C3-1L]0LVVW%I*LJ'UVG./S+"OL+P[K%KKNCVE_:',4L"/[
MJ2/NGW'>OC+)7)QTY%=OX)^(NJ>"/.@2,WEI+PD9. LG5C6-:%]4;4I]&?5@
M5020 ">M<'\5/%(\+>#K@0R 7M[^XMQGG+?>;Z ?S%9.J_&O1+?0!<:>XN=1
MPF;?I@G&[GVKP[Q?XLN_%^KM>W3'R4.Z"(GB/<J[@/Q6LH0;9K*22,#Y0HV]
M ,?ETIREAPK;21M##J#U!_.F]LXH[=,>M==DU8Y$W>Y];_#_ ,60^+_"ME>;
MQ]L$2K=IW5QP3]"5)%=4 I.\ 9(ZU\A^#?&>H>"=7^TVL7FV[KB6+.!)P0I_
M#->WVGQI\.MX;2ZFG$>H>06-MCHX'W:XY1:=CL4DSLO%&O6OA?0KS4[AL"./
MY%[N_) 'O7Q[//)=74US,VZ:>1I9#ZLQ)-=7XX^(-]XWFB\\&VMXE3%L#D%Q
MN(;\FQ7( >U;4(6NV8U97T0448H_"N@P 8(.>XP?I@C_  KW_P"!GBN.\T>3
MP]=R8NK-B]N"?OQO\Q ^C!OPQ7@'X5<TW5;W1=0M[^P8K<0/]\'MW7\L_G65
M6/,C2E*S/M7"DD'!P<U!=2Q6Z//,X2.)"SN3PJ@$DG\J\M\,_&[2+^"X;6\:
M?,'7RU'.]<=:XKQ[\7)_$$-SI%@IAL_-8B93_KX<,I!^H/Z5RJ+V.GF2.1\?
M^(?^$F\:W^I(?]'R(8<_W$R/YDG\:YG&[@D#)QGTZTN".",8X(]*:W0[A\N#
MGZX.*[(*T;'))WE<^L_A;_R3#P_T_P"/;_V8UV617QQ;^-/$>FVT=E::E+!;
MPKMCC4\ 5+_PL'Q7_P!!J:N5TY-G2IQL?8.17!_&;_DE&L].6MO_ $HCKYZ_
MX6%XJ_Z#4U5M0\7^(]7T^2TO]0DFLI" ZD_>*G>/U44_9M,/:19AS9\B3W4B
MON8]#@\U\.[2P*@<MQGT]ZZ)_B'XJ9MRZS, ><>E:UHMM-&=*25[GV!D49KX
M^_X6%XK_ .@U-1_PL'Q7_P!!J:L?92-/:1.R^/9_XN!:C(P=*A_/SIL4WX!<
M?$.\R1D:7,#^$L->=ZKK%_KES'=:C.T\Z1>5'(W4@%B/U>ETK5M2T6[EN=+E
M:&Z>/RF=3T!()'YH*UY'[.QGS+GN>A_'W_DH5H?^H5%_Z-FKR\$JP92-RG(S
MZBKFJZSJ.N7,=UJDS37,<0AW-_=#,1_Z%5+\*UIJT4C*H[R9T7@WQ$/"_C&Q
MU5-WV=3Y4X'>,\?RV_E7UU;3Q7<0F@D5X74,C*>"#WKXCQN5AV(PWTKU3X<_
M%6;PW#:Z1JX\RP>7Y+HG)CCV@ 8^JG\ZQK0UNC:E+2S/HJ5HH(VED(2-$)8G
MH .37@?@+6I/$?QZU#5@Q\N:WF6('^%$VJOYCFE^(_Q=758)M$T!MUM/&I>[
M!P0,G>OY5Y/IFJZAHM\MWID[17!C\E6'<=/Y &HA!M,J4M3K?C#S\5=:]Q!_
MZ)2LWX=9/Q)\/=_],4_H:P;^_O-4O9+V_E,UU*!O<]3@ #] *;:WD^G74=[:
MR&*XA)>-UZ@XXKIM[EC"_OW/7OVAL_VSX?/;[//_ .A)7C,HW0LN><'^O^(K
M2U;7=4UUXGU6[>X>'<(]W\()Y_D/RK./ .1QCFE3BU&S'*7O:'UKXIUA)OA1
MJFK*CJMSI#2JO\2^9'Q^6ZODO&SY01M7@'U]ZVI_%?B:;2I--EOY'LC#Y;1D
M\>6/EQ6+DD],#^$>@J:47&XZDDT>\_L\ C2]?8]#<Q ?]\&O&_%((\8:\#P1
MJ=R,?]M#3=+\2:OH,4L>G7SVL<K!V"=R!BJ-Q<27=P]S,=\TSM)(YZLS,32C
M%J;8.2Y$?07[/]NJ>#-1N0I#S:BRDGN%1,?S-> 7]T+_ %*ZO5SBYG>;G_:8
MG^1%7M/\6:[HEF+33-0DAAW&0QKT!/7^59 &  !QT%53BU)L)27*D+2,,HPR
M.E+1C/&,YXQ6K,D?3D0.M? '$PW%]!)('=EB./U45\PY+ L2,G!/MD9K:M_&
M.OVVEC38]2ECM%C,2Q#IM.:QSC&"N/7WK&E!JYK4E>Q]$ZT2O[-,6Y2#_95M
MQ_P)*^=JUI?%7B"?2%T>>]=K ((O+)XV#H/_ !VLG\*JE&R8JCO8/Q%>K_ +
M5)+?QC?Z<6'DWMIOV_[4;?+^A;]*\GQ[5:T_4;S2+Q;RPN&M[J,% Z]<-14C
MS1L*F[2N>K_M"_\ (QZ&>WV27_T,5X_5[5-<U/798Y=3NWN6A4JC-_"#U_6J
M/X4Z::C9A4:<M H))0@'#D\'TZ'^8%&*3OTJVKHF+L[GUQ\/?$\7BSPC87P8
M?:EB"72=UD'RG\RI-="=.L_M'VG[-%Y^<^9L&<^N:^2O!GC+4O!>I_;;4&6U
M8D3V^<!FVD _K7H+_M!WR+EM%7&<?>KAE!IG6I)H].^(7C"'PAX=N)ED4WTR
ME+6//.\Y /T!Q7C/P@\>MX?U8:-J,_\ Q+;MW=7<_<E;;R3Z84_B:Y+Q9XIO
M?%6NR:C?Y2-B1#'G(A7"\C\:P".IV9X/'IQ6D:?NF<IZH^D_CE*LOPQ\V+$D
M;W4+ CH0<X-?-O )P<C-;]QXQUB?PS/X>OI6N(C)#)"S'[BQ G'\ORKGP-O'
MI6E*+2U,ZKN%(>00>_2E_"C'MUK9F9[!\#/%45AJ-WH%Y*%2[D$MJ2>-X^1A
M^.5KW^,YS_G_ #S7Q';S36]Q#=6SF.:%UDA8=G!_H0#7O/@CXUV$MB;?Q#BT
M:"&-4DZF9N0Q_,9_&N2I!IW.JG*Z/7KRY@L+6>\N9 D,2EW9CP!7QOX@UB3Q
M!XAU#5IB=]W.7 /9> H_ 9KN/'?Q3O?%$+:?;1^19B5E)4_\? XPI_"O->O;
MDU=&&MV35EI9!2@_.I8G (.5Z\?_ %J3\* =I#;<XYQZXKH>UCG6Y]:?#KQ5
M'XK\+V]PSC[; BQW*=PV.OT."177=>17Q_X.\7ZAX+UEKVU)FB8;+B'. ^U2
M$/ZFO99_C?I2>%H;R "35G52]I_=)Z\UPR@TSL4E8T?C'XN7P_X7FTZVE"ZA
MJ*&)0#RB'(9OR! ]Z^9^F,8X.1^=:WB7Q!>>*-9GU.^)+NQ\I"?]6I=B$'TK
M)_"NFC&RN857<[/X2C_BZ6A>HDE'_D%_\#7I_P"T'\WA71CV^W_^TGKP;3KZ
M]TO48;VP<QW4(;RV![D%?Y,:MZIXGUS7;=+35;MYTBD\Q0Q[X*_UJ9Q;J7'%
MI0,O\J*/PH_"MS **/PHH&%%'X4?A0 44?A10 44?A1^% !11^%% !11^%'X
M4 %%'X44 %%'X4?A0 44?A10 4<T?A1^% !11^%% !11^%'X4 %%'X44 %%'
MX4?A0 44?A10 44?A1^% !^5%'X48H **/PH_"@ HH_"C% !11^%'X4""BC\
M**!A11^%% ![<4C<J1D#(/\ C2_A1QR&7(XR?3YAS0]@1VOQ-Q))X5!R-WA>
MQR/^_E=M\4]6^U_!_P 'F4[[BZ\B=F'3*P$/^KG\J\<O-0N=1:!KF9IOL\*V
M\3-VC7[H_4T^ZU34+NQM;&ZNG>SM?^/=3T0$8(K'D^$VYM6=M=;A^SYIW;'B
M%LG_ (!)S71> ;*/QQ\*K[PI)(JW&G3M-:!NVX;E)]@[/7D\FJ7KZ+_9 G9]
M-64SA>RN0?\ &M'PUXEO?"^MQW]HQ";QN0'_ %R[B0I_*E*&C&I:GIFN:1#\
M-?A%=:7.T<FKZQ/Y,C#^[NR2/8( /J17/:PI'[/7A88ZZO,2?3YYQ7+>*O%U
M]XRU>2_N<B!2## 3Q&I #8_$+5"75-2FT*VTF:<_V9!(9(USQN))_P#9S2C%
MV02DM4=U\#[Q(/'DMI)$9(;RPEC<XR%4$-D^V58?B*]4U?X2>&-;N9]0VE9)
ME)!0X49R:\C\%2OHW@'QEXBA3%S'!%80-_<,DF&Q],JU8VD_$/Q/I-Y;7$U]
M)/96S;GB)X=1V_&HFFY,N.B1L>!9I_!'Q92WU)EB2&66SN&/ PXX;_=W*IKT
M.U^$=OIGC^?7)Y8QHD#_ &N*,GE7 4G/MD-7F_QC"#XGZT%D.6C@W>Q\I#_0
M'_@51:K\5M=U7PG'H#;H[B-F^T7.>9$^8%?_ !X?E3<6[,2LM"_X,\5"Z^.4
M>MD^7;ZE<S0\\81PVP'WR%_*NWU?P!;>%?$>N^-B\:V5K!+>6T9ZBY(R/S8\
M?A7@]K,UI-&Z'9Y3*X<?P,.C?AFNN\3?$35?%F@6&CW.Z&&"V"7# Y^TM\H4
MG_@2$_C3E%J6@1DFM39^.L)C^(X8_P#+6PAD4^@W2+_,5)\"[N-/%^HV,Q'E
MWFFR#8?^6C*RX _X"SFO/=2UC4=<N1=ZC<-<RB,0J[=0 2P'_CQI-)U*XT?4
MH=2M93'/;$O&1WZ!A^*DU?*_9V(YOWESVW1/!47PV:35)98Y-0N=0BLK 9SB
M.2:-2/J!FLFR>RLOV@_$&GZJ%\G5(IK57/0&54<?HI7\:XKQ?\0-3\3ZK;WF
M#:K9,LD4(.0D@)(D^N3^E<Y<:M?W>J?VI<3M->!UD$IZY7&W^0K-0;*<DCVS
MPO\ !Z[\/>/(-9N+B%M*LII98DSR%PVS/TR/RKQSQ'J?]L^*=5U(?<N;J61/
M]TMA?_'0*ZJ^^*^MWOA6UT,NT4P<B6]!YD'S @_G^E< G"+Z "KHJTKLFJ]+
M(]+^"VJ16_BJ^T2Z(^RZU;&)@>[KG:/Q5G%=IX;\&CX7P^)?$EY-&R1V\HL>
M>54G.T^YVQC\Z\'MKJXL;J*[MG,<T+AU<=4(!YKJ_%'Q$U/Q58V&GR;H[>"-
M5F7/$[#:58_4BE4@W+U'"7NEKX-%O^%HZ47.7*SEC[F)S_6N6\1#'BK6@>HU
M"YR/^VK55T_4;O2;Q+VQG:"XC!"R+U&1@U'/-+<SRW$QWR3.TCN?XB3DG]:T
M4;2^1FY>[\ST[X+P:=K$OB+PYJ*AO[0LX]I[[4=L@>_S*?\ @-=-I_A.3X8_
M"WQ?<:C.LE]>P-$K(>Q0J@^NYV->,:#K=SX=URSU.R!\ZVE5V /^L3JR_CC'
MXUU/COXEZAXSM+:P>V^R1(V^5%;(D!Q@_AC]:QG%\QM&2Y3J/A/IQ\2_#3Q;
MX:9U_>.KQ _PNR?*3[;HUKJ/!FAQ?#_5- T$,DNKZK)-+?NO.(4CE*_0%O+_
M "->,^#?%U[X/U5;ZU7>KL?-@SQ,-K 9_P!W<#^--U3QIK-WXEGUY;AX;PLR
M)@_ZF++$*/8[C^5*<'S-!&2LCKOA7;R6_A7XBP,N)$TG81[A)Q_2N(\%9;QQ
MX;P,_P#$RMCCT'F)_C5:TUW5+%+V*WO'C%\"DY'_ "U!R!G_ +Z/YU4M9KBS
MNHKFU;R[F!EDB(]0<Y_2MK-)F<FFT>K>&[L6?[2%_P"8P3S[R[B&>^5^7]17
M1:CX-T_P#>>)?&A*$H#)IB'^&5T(;C_?.1]*\.GU+43J[:J\S+J/F^>90>5;
MJ/Y5T7C+Q]J?C*&UM9E-O;P(IDB!R'8'[_ZUG*+;5NQHI'J7B"\CM/VE-!>4
MX5]/6%6[!F\T#\\XHF\ Z?X0\6ZSXTU%T;3;<-<VT1//FL!NS]23C\*\1O-;
MU?4-1AU2ZNF>]C5/*E)Y!0[T/ZUN^+/B/J/C+3[6RGW6]K#&J7"@Y\U@1AC^
M(J>1Z#YDSNO&A>;X]>#Y6^\\-DQ_[^RD_P!:\X\?+CXB>(_4W\F!ZY(_PJC-
MK^KWFJV>HSW#/?VNT02$\X5B0/\ QXU3O+J>]O9KN]8M=SR%I'[C.>:UA&S5
MS.;O<ZCX5W#VOQ/T-MZQB25X6+>A1N/Q(Q^-:?QMO8[KXCSQ '=:6T%NWIG:
M9?\ VHOY&N=\"V\MQ\0/#L0^9O[0A<MZ;&#G]$:I?B+=->_$CQ#,XQMO#$/H
MBA!^BBBUZH7M3.6E_P!4_(^Z?Y&OI?6_AS#XOT3PZTC;4LM/BCC7/^RO^%?-
M6 1@C-=BGQ/\1P0QQ+<.J(@50#V  HJQ;=T*G)(W/B+\-;?P?X>AU*-\O)=+
M#U]5)'_H-=!H6AGXB?![3K&VDC&HZ-</!&[] ,__ !#*/PKS76_&VK^(=.BL
MM2=I(1,LRY/<!A_6K?@7QS?>"[V>2U@\^UN(]CP$X DPIW?D"/QJ'%\MRXR7
M,=G\3+.W\)?"_P ->#E8-=/-]HG*_P 14,6)^KL,?2N@\*>%E\8_!/P]9R,
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M(+DM\WY'%<IVZ5=)-+4SJN[T"BC\**V,P_*C/?\ &C\*/?% !^=%'?K1[9H
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M=PI..:7\:/QI"%^8XVG&?7\OZ4C,78L0 >IQ[T=>]&?>@!5X92.6!!&>G%-
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M(%&]3@';R,T[*C''R@[C]?3Z4E'XTK(+L3ZYSW-*-N0&!V9RW\OZT4?C0"$
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MH]J/PHH .:/>C\** #\J*/PHH /RHH_"B@ _*CM1^%% !11^%% !^5%'X44
M%%'X44 %%'X44 %'O1^%% !11^%% !11^%% !11^%% !WHH_"B@ HH_"B@ H
MH_"B@ HH_"C\* "BC\** "CVH_"C\* "CWH_"C\* "BC\*/PH **/PH_"@ H
MH_"C\* "BBC\* "BC\*/PH **/PH_"@ HH_"C\* "BC\*/PH **/PH_"@ HH
MH_"@ HH_"C\* "BBC\* "BC\*/PH ***/PH **/PH_"@ HHH_"@ HH_"C\*
M"BBC\* "BC\*/PH ***/PH **/PH_"@ HHH_"@ HH_"C\* "BBC\* "BC\*/
MPH */RHH_"@ H_*C\*/PH */RHH_"@ H_*BC\* #VH[]N:*._2@ H[]N**._
M2@ ]J.:*/PH />C\J*/PH */RHH_"@ H_*BC\* #M111^% !1^5%'X4 %%%'
MX4 %%%'X4 %%%'X4 'O111^% !111^% !111^% !1WHH_"@ HHH_"@ HHH_"
M@ HHH_"@ HH_"C\* "BBC\* #VHH_"C\* #WHH_"C\* "BC\*/PH **/PH_"
M@ HH_"B@ HH_"C\* "BC\*/PH **/PH_"@ HH_"C\* "BC\*/PH **/PHH *
M*/PH_"@ HH_"B@ HH_"C\* "BC\** "BC\*/PH **/PHH **/PH_"@ HH_"B
M@ HH_"C\* "BC\** "BC\*/PH **/PHH **/PH_"@ HH_"B@ HH_"C\* "BC
M\** #\J*/PH_"@ _*BC\** '(&WL5"DE=QSTQ_C3$5!( ,X<\ _U_'%+CT'?
M-'X=>M#C<:D*Q8MEMH..W2DI ,<8I:2["8=^W-%'?I13 ._;BCVH[]** #FC
MWH_"B@ _*BC\** #\J*/PHH /RH[4?A10 44?A10 ?E11^%% !11^%% !11^
M%% !1[T?A10 4<@<8R!Q_.C\*.U #MLC2MQ&KL",CH!_CQ2, K$#IU'L#VIN
M 1C!_P \TI)9BQZDDFERV&Y7"BC\**8@[T4?A10 44?A10 44?A10 44?A1^
M% !11^%% !1CM1^%'MB@ H_G1WZT4 'YT4?C1[9]J "BC\:* #\Z*/QH]L^U
M !11^-':@ HH_&CVS[4 %':C\:* "BC\:/QH **/QHH **/QH_&@ HH_&C-
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M1^-'MGVH **/QH[4 %%'XT>V?:@ H[4?C10 44?C1^- !11^-% !11^-'XT
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M4 %'X444 %'X44?A0 >]%%% !1^%%'X4 'O111^% !1^%%'X4 'X4?A11^%
M!VH_"BC\* #_ /71^%%'X4 %'X44?A0 4?A11^% !1WZ44?A0 >]'?ITHH_"
M@ HYSTZT4?A0 >]%%'X4 '^%'X44?A0 444?A0 4?A11^% !_P#KH_"BC\*
M"C\**/PH ***/PH */PHH_"@ HHH_"@ H_"BB@ HHH_"@ H_"BB@ HHH_"@
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M]J* "C\:*/RH */QHHH */QHH_*@ H_&CVHH .U'XT44 %'XT>U% !1^-%%
M!1^-'M10 444?Y_*@ H_&CVHH ***/\ /Y4 %'XT4?E0 9HHH_S^5 !1^-'M
M10 9H_&BB@ _&C\:** #-%%'/^?:@ _&C\:/:B@ HHHYH /QH_&BB@ H_&BB
M@ _&BBB@ S1110 ?C1110 4?C11S0 ?C1^-%% !111S0 ?C1110 444<T 'X
MT444 %%%% !^-%%% !1110 ?C1110 4444 'XT444 %%%% !^-%%% !1110
M?C1110 ?C1110 ?C11^-% !^-%%% !^-%%':@ _&BCFB@ _&BBB@ _&BBB@
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MB@ S[4?A110 >WX49]J** #-&?:BB@ __51GVHHH ,T9]J** #_]5&1Z444
M%&?:BB@ HR/2BB@ S1GVHHH *,^U%% !1GVHHH /:C(]*** "C/M110 49'I
M110 49]J** "C/M110 =Z,^U%% !FC/M110 M)GVHHH ,T9]J** %I,^U%%
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:#\*6BB@8F>^*,T44 %+110 F?:C-%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !] )0# 2(  A$! Q$!_\0
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%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !O Y<# 2(  A$! Q$!_\0
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M_P"$[TK^[=?]^Q_C3]E/L'/$ZVBN2_X3S2?[MW_W['^-)_PGND?W+K_OV/\
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M_*__ !5)_P +D\,_W-1_[\K_ /%4_J]7^5A[6'<]+R*,BO,_^%S>&/[FH_\
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MV*W9@,Y4L0P]B",<\@C!H]G'L',^YK?V78?\^5K_ -^5_P *3^R[#_GRM?\
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MJVJ:G9QOEK>?9%^Z==R>5&Q))&,[G8=N */9Q[!S/N;/]EV'_/E:_P#?E?\
M"C^R[#_GRM?^_*_X52L/$NEWUXMM;W!+R9\IFB=(YL<GRW8!9..?E)XYJ>'6
M]/FO!:PW44MQN="D9W%2I(;=C[O*D<XZ4<D>P<S[DO\ 9=A_SY6O_?E?\*/[
M+L/^?*U_[]+_ (5E^-+N\M;"T&G7"VT]Q>P6WFM&'V*[@$X/&<52>YUC0]2T
MU=0U&WU*UO;C[,0;?R98V*LP9=I(8?+R,9[YXQ1R1["YF=%_9=A_SY6O_?E?
M\*/[+L/^?*U_[\K_ (50NO%&E6MZUM-<,&0[9)%A=HHF]'D"[$/LQ%::WD#7
MDEHDJ-<QQK*\0/S*C%@K$>A*,!_NFCDCV'S/N1_V78?\^5K_ -^E_P */[+L
M/^?*U_[]+_A59_$&F1JS37UO$JW#6I,C[ )54L4R<<A03] :?IVMZ=J,DT=G
M=Q2R0@,Z X90>AP><'!P>AQ1R1[!S/N3?V78?\^5K_WZ7_"C^R[#_GRM?^_2
M_P"%<UX@\7V:VEJ='O[6:>34+.V&"&#I)<QQOM/1OE<\C.*U_%UU<V>@R26,
MHAN&F@A60H'V[Y40G!Z\,:?LX]@YGW+O]EV'_/E:_P#?I?\ "E_LNP_Y\K7_
M +]+_A7,:C<ZWX=-C<76J0:G;SW<%H\#6PBD/FR*FY"K8)7=N((^ZIY%=9;W
M45RLA@D63RW,;[3G:PZ@^XI>SCV#F9%_9=A_SY6O_?I?\*/[+L/^?*U_[]+_
M (54AU2*ZU"Q2WN8&@N[1[J)-IWR*#'AU/3:!(,Y&<LM9^A>(X1X7TW4-:NH
M8IKI.G0NW/"J.3P.@HY(]@YGW-O^R[#_ )\K7_OTO^%']EV'_/E:_P#?I?\
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M?_/K;_\ ?L?X4?V?:?\ /K!_W['^%9UQKKP>)K/27T^=8[I7,=V738Q50Q
M);OW ]LU)#K$K>(#ILVGSP(8I)8IW="LH0H#@*20/W@^]@\'BCD78.9E[[!:
M_P#/M!_W[%'V&U_Y]H/^_8K&NO$%T#?26&EO>VMBYCF=)@'=@ 6$2XPY7.#D
MKR"!DBGWGB+R;G2A!937%EJ#(J7B.@C7<"1QG<3@9Z8YZ]J.1=@YF:_V*V_Y
M]X?^^!2_8[?_ )]X?^^!4W6L&UU1QX@UR"[EC2SL8()0S84(&#EBQ]/E'THY
M5V'=FQ]DM_\ GA%_WP*7[+!_SQB_[X%4--U^PU&;R;=Y5EP659K>2$R*.K)O
M4;QR.5R.14</B?1YX/.@U&VD@\D3F57R@0XP2W09W# ZG-'*NPKFI]FA_P">
M,7_?(H^SQ?\ /*/_ +Y%9VE^(+#4[A[>V>9;A%\PQ7%O) Y7.-P$BJ67/&1D
M4RU\2Z7<WPM8;@EV8HDAB<12,.JI(1L9N#P"3P?2CE07-7R8_P#GFG_?-+Y4
M?]Q?RK*\.WTU\^J^>5(M[Z2"/ Q\H"D?CS6Q3L@N-\M/[J_E2[%_NC\J6B@
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M  JA;^)+6?5+*Q2&Z#7EO]I@E:/$;K@$@'U 8<5M,VU23T'-%V%D4_[)T_\
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MINJ0W45N;H0S6^UY$!Q\HSR<\8HYI=PY8]BU_P (IX>_Z 6D_P#@''_A2?\
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M%50% P !P*7:/2BX6/,9=2;1X-(NK=8VF%YJ4.R59-AC,[$C,:.RD%5(.TC
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MXH\074PM;/48OL]HUQ^[,RK$P0A3SEF9]HZD8/>O06160J5!4C!!'!HVCTI
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MCEQP.>17IY /44;1Z"BX6!>@^E%+12&%12W,$4T,4LT:2S$B)&8!G(&3M'?
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MA:;XBF?7=-MUU&'4K6_\Q1+#:-'$K*NX&.3)5QP1C)/0YX-=;=C-M-_N'^5
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ML"B[-S@^7%M/+!_O YPP(%;FO2V:ZO:IXGU!K33EM08V^T-;P33EB'W.".0
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MLI!P<$$,PQT(Z&BG<#F[S0K[4(+(WU[&9X=0COB%3Y$5>D:]"?\ >/4DG@8
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M6V_, ?3:#D@D]'11<#F(M!U&>\N-0U&[M?MHLWL[5;>)E2%7(+$Y)+$E(_3
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MKX<BB1HAI\EW)/NY617B'EX_W90Q^J^M)>^+[+3[K2+?4+G3X7O@Y9A=KLC
M4G() W D8SQS6%H%B]IXUT.6Y!%[?:7J%Y=;NHD>:S^7Z*NU![**C\/%5L_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJO&&$F.!N!Z_C45II&GV:;+2RM8$Y&V*%5'/7H.^!^57J* (6M8&MA;M#&T
M  C*@J .G'3C JK>:-IM]<+/>V%I<S(-JR30*[*/0$C-:%% $<,*0IMC557)
M.%&.2<D_B234E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #4 70# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG3T54TS5++6+".]L+A)[>0<,IZ>Q'8^QJW3W(E%Q=GHPHHHH$%%%% !1110
M4444 %%%% !117#>*OBIHGA'6FTJ_M-0EG$:R;H$0K@].K _I0!W-%>5_P#"
M_/#'_0.U?_OU%_\ '*/^%^>&/^@=J_\ WZB_^.4 >J45Y7_POSPQ_P! [5_^
M_47_ ,<K6TKXQ^#]3E6)[R:Q=C@?:XMH_P"^AD#\2* .^I"0H))P!UIL4L<\
M22PR+)&XW*Z'(8>H-17&7&T=*38TKLR-0D>ZD[A%^Z*SGA]JVGA]JJO#[5S2
MBV[L[(325D8SP>U5G@]JVWA]JK/![5BX&\:AAO![56D@]JW'@]JK/![5FXF\
M:AA20>U59(/:MYX/:JLD'M4.)T1J&#);^U59+?VK?D@]JQ-=U*WT.T6YN8Y7
M1Y!&!& 3G!/<CTJ5!MV1LJZBKME&2W]JJR6_M6GI]U#JVGI>0(ZQN2 ' !X.
M.V:J:O=PZ3:?:9T=DW!<( 3D_4^U+DE?EZG1'$Q4>>^AF26_M5.6U![5J:?>
M0:M:M<0)(J*Y3#@ YP#V/O3Y+?VI.\79G72Q"DE*+T.<>W9>G-0D$=:WI+?V
MJG+:@]JI3.R%9/<S:*?<I]FB:4Y*J,G%5K>Y2Y5B@88..:U2;7,MAO$4E45)
MR]Y]":K-EJ%[ITIEL;N>VD92I>&0H2/3(JJS!$9CT49J&WN4N=VP,-N,YH2=
MKH)U:2FJ4WJ^G<M22R32-)*[.[')9CDG\:?:W5Q97,=S:S/#/&=R2(V"I^M5
MY'$<;.<X49.*9;W"7"ED#  XYHL[<P2JTE-46]7T\CO)_BQXKFMTB2Y@A95
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M*+)_UZQ?UH ]?M_A3X)>VB=M"C+,@)/GR^G^]4O_  J?P/\ ] &/_O\ R_\
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M@]JX/XG1[/#UN?\ IZ7_ -!:MG2OB5H&J2K#.9;&1C@&<#83_O#I^.*H_%=
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MINF!OW=O;&8C_:=B/Y(/SJ>5%*3,KP-X(N_'E_<:WK=Q,UF)/G<GY[A^X![
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M;LX53G.1_>K=;X/Q#_F,2?\ @./_ (JE4A3<FVRZ5:K&*44;#ZWHAZ:M8_\
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MS\/=?C\1^"M.NU<--'&(+@9Y$B  Y^O!_&NHH @:*O)_CL%3PIIZG[YO@1]
MCY_F*]?KY]^.VOQ7NO66C6[AA8(SS8/_ "T?''U  _[ZI6'<[7X2Q[OAU8G_
M *:2_P#H;5G?&>/9X)C/_3['_P"@O6W\'DW?#6P/_32;_P!&-6=\;TV^!8C_
M -/T?_H+U'+[UR^;W;&5\'(]_@VY/_3\_P#Z E=V\%<?\$DW>"+H_P#40?\
M]%QUZ&\ ]*RG&[-Z<[)&(\/M59X/:MMX*K/![5BX'1&H<)X[AV^#=2/HB_\
MH:UR/PNCWPZI[-%_[-7>?$*+;X'U0_["_P#H:UQOPC3?#J_LT7_L]6H_NFB7
M/_:(O^NIT/B"''A_43Z6TG_H)KAOATF^34?98_\ V:O2O$L./#6J''2UE_\
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M0>?TKT:[LK74+9K:\MH;B!_O1S('4_@:Y6?X5^";B7S'T&$,3G$<LB#\@P%
M'#^(/C>;R/[!X3TVY>\F^1)YD!()_N(,Y/IG\C7)Z_X#O- ^'T^O:X2VL7UW
M'E7;<T2G<3N/]XG&?3'UKW[1_"^AZ #_ &5I=K:L1@NB?.1[L>3^=:%W96E_
M#Y-Y:PW,6=VR:,.N?7!H X?X-?\ ),]/_P"NDW_HQJS_ (Z#_B@83_T_1_\
MH+UZ3:VEM8P+!:6\5O"N2(XD"*,]>!Q27=C::A#Y-[:P7,0.X)-&'7/K@]Z
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MH7L[NWSY-VJ_> !Y5P.2M=97'?$I1;^&H=80?O\ 2KVWNHV'7_6!6'T*L<T
M=C6%XC\31: EO!';27VIWC%+2RA/SRD=23_"H[L>E;M<9X7B_M7QAXDUZ<;G
M@N?[+M=P_P!7'& 7Q_O.<_A0 JZ-XTU4>=J/B2+2E;G[)IMLK[?K(^23]!BE
M/A3Q';C=9>.+_P P=KJUBE4_48!_(UV-% ')Z+XCU.'6E\/^)K:&#4)$+VEU
M;D^3=JO7;GE6 Y*GZUUE<;\2%\G1-/U)!B>PU.VFC;OS($(^A#5V5 !1110
M5R&E?\E4\1?]>%I_.2NOKD-*_P"2J>(O^O"T_G)0!U]%%% !63K7AG1_$$.S
M4;&*5Q]R8#;+&>Q5QR#^-:U% ''^'[_4-&U]O"NLW+W>Z(SZ;?2??GC'#(_J
MZY'/<<T?%'_DGFI?[T'_ *.2D\;_ +G5_"%W'_KUUE( 1UV21N'_ $ I?BC_
M ,D\U+_>@_\ 1R4 :WC"\:P\&:U=1G$D5E*4/HVTX_6G^%K)-.\)Z1:( !%9
MQ*?<[1D_B<U'XQM'OO!6MVT8R\EE*%'J=I(_6IO#%XE_X5TF[0Y66SB;Z':,
MC\Z -6BBB@ KCF'V3XOH4X6_T8[QZO'*,'\FQ78UQSG[5\7XE7E;'1F+GT:2
M48'Y*30!6\9V:7WCWP-%( 52YN)>?5$5A^H%=U7$>+KE;7X@>!W<X5Y[J/\
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M2$DGZG% %;XG:JYT.3P[8-NU#4(79P.?*MU!:1V] 0-H]2:WO!/_ "(GA_\
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M":T]$U#Q'<W)AUG0K>RC6,G[1#>B4.^1P%P" >3SZ4 ;U%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!Q_B/_ )*'X+_WKW_T2*["L34]#DO_ !+H
M6JK,J)IIG+QD<OYB;1CTQ6W0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_
!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
